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Abstract 
The progesterone receptor (PR) gene consists of eight exons and encodes the 
functionally distinct PR-A and B isoforms. PR alternative splicing events involving 
deletion of internal exons or intron retention have been reported, potentially generating 
proteins which lack various internal functional domains or are N-terminally truncated. 
PR status in breast cancer may be predictive of the efficacy of endocrine therapy and is 
measured using N-terminally targeted antibodies which detect both PR-A and B.  
 
In this study PR mRNA expression was assessed in breast cancer (MCF-7, T47-D and 
MDA-MB-231) and non-tumourigenic breast (MCF-10A) cell lines using an RT-PCR 
based gene walking assay. PR mRNA resulting from alternative splicing was detected in 
reportedly PR negative MDA-MB-231 cells using this assay. These mRNA could 
encode the low molecular weight nuclear and cytoplasmic PR proteins which are 
detected in this cell line using the C-terminal PR antibody C19. Ligand blotting, co-
immunoprecipitation and DNA affinity precipitation assays demonstrated the ability of 
these proteins to bind progesterone, interact with the PR nuclear co-factor PSF, dimerise 
and bind DNA; thus potentially to function as ligand activated nuclear transcription 
factors. Validation studies using the gene walking assay demonstrate that alternatively 
spliced PR mRNA was also present in breast tumours originally characterised using N-
terminal antibodies as being both PR+ and PR-. Using a novel non N-terminal PR 
antibody developed in this study, the nuclear PR status differed from the original status 
for 2 of 14 tumours examined, and cytoplasmic PR was detected. The results presented 
in this thesis suggest that PR undergoes extensive alternative splicing, generating 
potentially functional isoforms, and that expression of variant PR isoforms may affect 
the PR status of a tumour as determined using antibodies targeting different epitopes.  
 
PR exons 4 and 6 are flanked by consensus 5′ and 3′ splice sites and contain cryptic 3′ 
splice sites, as well as potential binding sites for a range of RNA binding splicing 
factors. siRNA knockdown of the individual SR proteins SRSF1, SRSF2, SRSF5 and 
SRSF6 identified potentially antagonistic roles for SRSF1 and SRSF2 in influencing the                                                                                                                                           
inclusion/skipping of PR exons 4 and 6, and also for SRSF6 in regulating exon 6 
splicing. 
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1 
1 Introduction 
1.1 Progesterone Receptor 
1.1.1 Progesterone 
Progesterone is a steroid hormone, predominantly released by the corpus luteum in 
response to luteinising hormone prior to ovulation, in order to maintain the environment 
necessary for implantation. If fertilisation, and subsequent implantation, does not occur, 
the regression of the corpus luteum withdraws the progesterone signal. During 
pregnancy, progesterone is involved in regulating uterine proliferation and suppressing 
myometrial contractility (Graham and Clarke, 1997). In the endometrium progesterone 
has a largely anti-proliferative effect, opposing the action of oestrogen. In mammary 
tissue high levels of serum progesterone correlate with periods of extensive epithelial 
proliferation and differentiation to mature secretory structures during pregnancy in 
preparation for lactation (Lydon et al., 1995), whilst also suppressing milk production 
until parturition (Graham and Clarke, 1997). Progesterone signals through the 
progesterone receptor (PR) which exists as two nuclear receptor isoforms PR-B and the 
N-terminally truncated PR-A. PR is a member of the steroid/thyroid hormone receptor 
family of ligand activated nuclear transcription factors (Evans, 1988). The structure and 
function of progesterone receptors will be discussed. 
 
1.1.2 PR gene structure 
The PR gene consists of eight exons punctuated by introns ranging in length from the 
relatively short intron 1 (1275bp) to the long intron 2 (34130bp) (Misrahi et al., 1993). 
The long first exon (2380bp) contains two oestrogen responsive promoter regions which 
initiate transcription of mRNA encoding the nuclear PR isoforms. Transcription of PR-
B is initiated at positions +1 and +15, encoding a 933 amino acid protein. Transcription 
of the N-terminally truncated PR-A isoform is initiated at positions +737 and +842 
encoding a 769 amino acid protein which is truncated of the N-terminal 164 amino 
acids of PR-B (Kastner et al., 1990). The expression of PR protein is responsive to 
oestrogen stimulation, however sequencing of the PR gene revealed that the promoter 
regions do not contain consensus oestrogen response element (ERE) pallindromic 
sequences but do contain an ERE half site in proximity to potential binding sites for the 
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transcription factor specificity protein (Sp)1 (Kastner et al., 1990). It was later 
demonstrated by gel shift assays that the ERE half site in the PR-A promoter is capable 
of binding oestrogen receptor (ER)α,  and oestrogen stimulated transcription of a 
chloramphenicol acetyltransferase (CAT) reporter gene containing the PR-A promoter 
ERE half site and Sp1 sites (Petz et al., 2004). The proximity of the Sp1 sites to the 
ERE half site, and the ability of Sp1 to interact with ERα via the DNA binding domain 
(DBD) and ligand binding domain (LBD) (Petz et al., 2004) demonstrate a potential 
mechanism for combinatorial regulation of PR expression, allowing response to external 
stimuli resulting from changes in the cellular environment. The remainder of the PR 
gene is made up of six short internal exons of 152bp, 117bp, 306bp, 145bp, 131bp and 
158bp. Exon 8, the terminal exon, is 9648bp containing a 153bp coding region and a 
long 3′ untranslated region (UTR) (Misrahi et al., 1993). The structure of the PR gene 
can be seen in Figure 1.1. 
 
1.1.3 Nuclear PR isoforms 
The full length PR-B and N-terminally truncated PR-A isoforms contain distinct 
functional domains characteristic of ligand activated nuclear transcription factors 
(Misrahi et al., 1987) (Figure 1.1). Both isoforms contain a long N-terminal domain 
encoded by exon 1, containing a transactivation domain (AF1) which is common to 
both PR-A and PR-B and responsible for mediating interactions with transcriptional co-
regulators. The N-terminal 164 amino acids of PR-B, the B-upstream segment (BUS), 
which are truncated from PR-A form the PR-B specific AF3. The N-terminal region 
also contains an inhibitory domain (ID), mapping to the first 140 amino acids of PR-A 
(Giangrande et al., 1997). Exons 2 and 3 each encode one zinc finger of the DBD, 
responsible for interacting with progesterone response elements (PREs) of target gene 
promoters. The 5′ part of exon 4 encodes a hinge region responsible for the 
conformational change necessary to expose the DBD and dimerisation domain (DD) 
after ligand binding. Exon 4 also encodes a nuclear location sequence (NLS) and the 3′ 
part of exon 4, along with the rest of exons 5 to 8, encode the LBD, DD and a further 
transactivation domain (AF2) which becomes functional following dimerisation 
(Misrahi et al., 1993; Kastner et al., 1990; Misrahi et al., 1987). At least thirteen 
phosphorylation sites exist within PR, six in the PR-B specific BUS, and seven in 
regions common to both PR-A and PR-B. Some of these are basally phosphorylated, 
exhibiting increased phosphorylation upon ligand binding and others are phosphorylated 
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only after ligand binding (Ward and Weigel, 2009). The functional implications of PR 
phosphorylation will be discussed. The domain structure of PR-A and PR-B are shown 
in Figure 1.1. 
 
 
Figure 1.1: Structure of the PR gene and nuclear PR-A and PR-B isoforms. 
Diagramatic representation of the eight exons of the PR gene, depicted relative to the length in 
bases. Exon 1 contains a long 5′ UTR and exon 8 a long 3′ UTR indicated by the broken lines. 
The eight exons are separated by introns (not depicted by length). The sites of transcriptional 
initiation resultig from promoter B (PR-B) and promoter A (PR-A) are indicated by the arrows. 
The mRNA for each isoform is shown with the structure of the encoded proteins beneath. 
Structural domains are depicted relative to their length in amino acids and position within the 
protein sequence. BUS= B-upstream segment, NTD= N-terminal domain, DBD= DNA binding 
domain, H= Hinge, LBD= Ligand binding domain, ID= Inhibitory domain, AF= Transactivation 
domain, NLS= Nuclear location signal, DD= Dimerisation domain, S= Serine. 
 
 
1.1.4 Mechanism of PR action 
In the absence of ligand PR exists in heteromeric complexes with chaperone proteins 
including the heat shock proteins (Hsp)90, Hsp70 and Hsp40 (Cheung and Smith, 2000). 
Protein complexes containing Hsp90 are required to establish the mature hormone 
binding conformation of PR (Smith, 1993). The chaperone complex also appears to 
provide protection from proteosomal degradation of non ligand bound PR, since 
blocking complex assembly increases the rate of PR degradation (Lange et al., 2000). In 
living cells, non-ligand bound PR localises predominantly in the nucleus but is 
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undergoing constant nucleocytoplasmic shuttling in response to the NLS (Wan et al., 
2001). PR-LBD constructs locate predominantly in the cytoplasm (Kakar et al., 2006), 
presumably since they lack the hinge region constitutive NLS. Cytoplasmic localisation 
of non-ligand bound PR-LBD is mediated by interaction with Hsp90, however Hsp90 is 
also required for nuclear retention of ligand bound PR-LBD, suggesting a role for 
chaperones in regulating transport of PR across the nuclear membrane (Kakar et al., 
2006).  
 
Ligand binding causes specific conformational changes and dissociation from 
chaperones, exposing the DD allowing the formation of PR dimers (Tsai and O'Malley, 
1994). The importance of the hinge region in facilitating this altered conformation and 
thus facilitating dimerisation was indicated by the inability of C-terminal PR constructs 
containing the DD, but lacking the N-terminal and hinge regions, to form dimers 
detectable by co-immunoprecipitation with full length PR, pull down with tagged 
immobilised peptide constructs or by ligand binding assays (Tetel et al., 1997).  
 
Ligand activated, dimerised PR then translocates to the nucleus, largely in response to a 
constitutive NLS located within the hinge region (Kastner et al., 1990). Mutation of this 
sequence leads to cytoplasmic accumulation of PR and delayed translocation in 
response to progesterone (Kakar et al., 2006). Present within the NLS sequence of the 
hinge region is an acetylation domain and ligand induced acetylation of PR has also 
been demonstrated. NLS acetylation domain mutant PR-B, transfected into T47D breast 
cancer cells, displayed delayed ligand induced phosphorylation, nuclear entry and 
transcription of PRE containing target genes (Daniel et al., 2010). A second NLS, 
located within the DBD, can also mediate PR nuclear translocation in response to ligand 
(Guiochon-Mantel et al., 1992). Nuclear PR dimers bind to a PRE sequence within the 
promoter region of target genes and regulate transcription via interaction with co-
activators which help to control chromatin remodelling and assembly of the 
transcriptional machinery (Li et al., 2004). The transcriptional activity of PR is partially 
regulated by phosphorylation; mutation of two key phosphorylation sites, Ser190 and 
Ser294, leads to a reduction in transcriptional activity of ligand activated PR (Takimoto 
et al., 1996) and phosphorylation of Ser400 results in increased transcriptional activity 
of PR in response to progesterone (Pierson-Mullany and Lange, 2004). 
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1.1.5 Transcriptional activity of PR isoforms 
PR-A and PR-B are functionally distinct transcription factors and the gene regulation 
profiles of the two isoforms have been characterised in breast cancer cells which 
express either PR-A or PR-B; PR-B was demonstrated to be a more potent activator of 
transcription, uniquely up-regulating transcription of almost fifteen times as many genes 
as PR-A in these cells (Richer et al., 2002). A subset of genes was up-regulated by both 
isoforms, most of which were preferentially up-regulated by PR-B, and some genes 
were down-regulated by either PR-B only or both PR-A and PR-B (Richer et al., 2002). 
Ten of the genes shown to be regulated by PR-A or PR-B in these experiments have 
known roles in mammary gland morphogenesis or tumourigenesis (Richer et al., 2002). 
Similar patterns of progesterone responsiveness are seen in endometrial stromal cells 
and endometrial carcinoma cells, with PR-A and PR-B demonstrating overlapping but 
largely distinct transcriptional activities, and PR-B being the more potent transcription 
factor (Yudt et al., 2006; Davies et al., 2004). Transfection of T74D breast cancer cells 
which express only PR-B with a PR-A expression vector led to a reduction in PR-B 
mediated transcription, demonstrating the stronger activity of PR-B as a transcriptional 
activator and also the repression of PR-B mediated transcription by PR-A, either 
through competition for co-factor binding or direct repression in heterodimers (Jacobsen 
et al., 2002). 
 
PR-B was demonstrated to be a more potent transcriptional activator of a PRE 
containing reporter gene by transfection of PR negative T74D breast cancer cells with 
either PR-A or PR-B (Vegeto et al., 1993). PR-A also functions as a dominant negative 
regulator of PR-B mediated transcription, an interaction termed transrepression; co-
transfection of PR-A and PR-B with a PRE reporter gene reduced levels of transcription 
compared to expression of PR-B alone. Mutations of the PR-A DBD did not abrogate 
transrepression demonstrating that it is not mediated via competition for PRE binding 
(Vegeto et al., 1993). Transrepression by PR-A of other structurally related members of 
the steroid receptor superfamily, including glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR), androgen receptor (AR) and ER, has also been 
observed, similar to the repression of PR-B (Abdel-Hafiz et al., 2002; Giangrande et al., 
1997; McDonnell et al., 1994; Vegeto et al., 1993). PR dimers were produced in COS-1 
cells by forced dimerisation using PR constructs containing the leucine zipper regions 
of c-fos and c-jun (Mohamed et al., 1994). The transcriptional activity of pure PR-A:B 
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heterodimers was similar to PR-A:A homodimers and significantly lower than PR-B:B 
homodimers demonstrating a role for direct interaction between the dimerised PR 
isoforms in transrepression (Mohamed et al., 1994).  
 
A region responsible for the transrepression of PR-B activity by PR-A was mapped by 
deletion analysis to the extreme N-terminal region in PR-A, and just after the BUS in 
PR-B, termed the inhibitory domain (ID). Deletion of this region removed the 
transrepression of PR-B by PR-A. Furthermore, transrepression could be reversed by 
creating fusion constructs containing the BUS in addition to AF-1 and ID, suggesting a 
role for BUS in the modulation of ID (Giangrande et al., 1997). The ID was later 
demonstrated to also be responsible for autoinhibition, defined as the increase in 
transcription observed by removal of ID, which occurs in PR-A and not PR-B and may 
account, in part, for weaker transcriptional activation by PR-A (Hovland et al., 1998). 
The mechanism controlling transrepression has since been linked to the presence of a 
binding site for small ubiquitin-like modifier (SUMO)-1 within the N-terminal ID, 
encoded by exon 1. Mutation of the SUMO-1 binding sequence abolishes both 
transrepression and autoinhibition, and this sumoylation mediated transrepression and 
autoinhibition requires progesterone binding to the LBD (Abdel-Hafiz et al., 2002), 
demonstrating that coordination between distant regions of the full length receptor are 
necessary for normal function. A putative role in the inhibition of sumoylation was 
proposed for Ser294 phosphorylation since a serine to alanine mutation at this position 
was reported to decrease the transcriptional activity and increase ligand dependent 
sumoylation (Daniel et al., 2007) although the effect of this mutation on sumoylation 
has recently been disputed (Abdel-Hafiz et al., 2009). 
 
1.1.6 Transactivation domains and PR co-regulators 
As well as the autoinhibitory and transrepressive functions assigned above to ID, the 
differing activity of PR-A and PR-B may also in part be due to the different range of 
transcriptional co-regulators which interact with AF1, AF2, AF3 and ID in the two 
isoforms. PR-A and PR-B share two common transactivation domains, AF1 and AF2. 
Mutagenesis studies have mapped the constitutively active AF1 to an N-terminal region 
upstream of the DBD. AF2 was similarly mapped to a C-terminal region of the LBD, 
only becoming active following agonist binding (Meyer et al., 1990). A third 
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transactivation function (AF3) was initially assigned to the BUS region, unique to PR-B, 
since co-transfection of BUS containing constructs with a reporter gene could initiate 
reporter activity independent of the presence AF1 and AF2, but only when constructs 
contained the PR DBD. This transactivation could be enhanced by the presence of AF1 
or AF2, demonstrating the requirement for coordination between distant functional 
domains for proper PR function (Sartorius et al., 1994).  
 
PR co-regulators can be either co-activators, such as the steroid receptor co-activator 
(SRC) family, or co-repressors, such as nuclear receptor co-repressor (N-CoR) and 
silencing mediator for retinoid and thyroid hormone receptor (SMRT). Co-activators 
bind to ligand activated PR and co-repressors bind to non-ligand bound PR or PR which 
is bound by an antagonist. The general functions of steroid receptor co-factors include 
chromatin remodelling, histone acetylation (co-activators)/de-acetylation (co-repressors) 
and recruitment of transcription factors which form part of the transcriptional initiation 
complex (McKenna et al., 1999). SRC-1 was characterised as a general co-factor of all 
steroid hormone receptors, to interact with the C-terminus of PR and to activate 
increased hormone responsive transcription of a PRE containing reporter gene (Onate et 
al., 1995). Transcriptional co-factors of steroid receptors work in a coordinate manner 
as part of multi-protein complexes; CREB-binding protein (CBP) was identified as an 
activator of ER and PR transcription that when co-expressed with SRC-1 could activate 
transcription above the levels predicted by additive effect the two receptors working 
independently (Smith et al., 1996). p300, a structural homologue of CBP, was only 
recruited after SRC-1 binding to PR and exhibited a similar synergistic activation of 
transcription, facilitating the re-initiation of transcription of an activated gene. Mutation 
of the p300 binding site in SRC-1 prevented synergistic activity, demonstrating 
interaction between PR co-factors (Liu et al., 2001). SRC-2 and SRC-3 have also been 
demonstrated to interact with, and enhance transcription by PR (Liu et al., 2001). Jun-
dimerising protein (JDP)-2, interacts with the PR N-terminus and activates transcription 
independently of SRC-1. JDP-2 interacts with other co-activators, demonstrating 
multiple co-activator pathways for regulating PR activated transcription (Wardell et al., 
2002). Additionally to recruitment of co-factors which communicate with other 
transcription factors, PR can interact directly with the transcriptional machinery, 
including transcription factor (TF)IIB which is involved in recruiting RNA polymerase 
to the transcriptional start site (Ing et al., 1992). 
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It has been demonstrated by mammalian two hybrid screening that PR-B interacts more 
strongly with co-activators SRC-1 and GRIP-1, and that PR-A interacts via ID with the 
transcriptional co-repressor SMRT at a much higher affinity than PR-B (Giangrande et 
al., 2000). Because of the competing functions of different co-factors, the ratio of co-
activator/co-repressor expression within a cell modulates the response to ligand, 
providing a potential mechanism for regulating PR function (Liu et al., 2002). Agonist 
bound PR binds to co-activators such as SRC-1, whereas PR bound to antagonist 
RU486 binds both SRC-1 and the co-repressor SMRT (Liu et al., 2001).  
 
For all nuclear steroid receptors distinct classes of co-factors exist, those which bind to 
the constitutive non-conserved N-terminal AF1, and those which interact with the 
highly conserved, ligand induced, AF2. Additionally, co-factors exist which can interact 
with both AF1 and AF2. AF-2 binding co-factors differ from AF1 co-factors in that they 
always possess a leucine rich interaction domain, LXXLL (Warnmark et al., 2003). In 
PR, AF3 has been shown by sequencing and mutation studies to possess two LXXLL 
motifs which are essential for function and may mediate intermolecular interactions by 
binding AF2 (Tung et al., 2001). Direct interaction between PR N-terminal and C-
terminal constructs was demonstrated by in vitro pull down immobilisation assays, and 
higher affinity interactions were demonstrated for PR-B N-terminus (BN) than PR-A N-
terminus (AN) (Tetel et al., 1999) which may in part be due to the LXXLL motifs 
present in AF3. The PR N-C terminal interactions were demonstrated by a mammalian 
two-hybrid assay, using AN/BN and C-terminal constructs, to be enhanced by the PR 
co-activators SRC-1 and CBP which may function as bridging factors between N-
terminal AFs and AF2 (Tetel et al., 1999). Indirect interaction between distant AFs may 
occur via synergistic binding to different domains of the same co-factor, for example 
SRC-1 and TIF2 can act as bridging factors between AF1 and AF2 to enhance the 
activity of both domains (Onate et al., 1998). 
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1.1.7 B-upstream segment (BUS) 
The higher affinity of co-factor binding to PR-B compared to PR-A, and the reverse 
pattern for co-repressor binding, implicated the PR-B specific AF3 in stabilising a 
conformation which masked ID function and facilitated the recruitment of co-activators 
(Giangrande et al., 2000). A role for the conformation of the PR N-terminal regions in 
mediating co-factor interactions was again suggested by assays to investigate the 
structure/function relationship of constitutively active N-terminal (NT) constructs; NT-
A containing AF-1, ID, DBD and hinge, and NT-B containing BUS, AF-1, ID,  DBD 
and hinge (Bain et al., 2001; Bain et al., 2000). It was demonstrated by protease 
digestion and peptide sequencing of the fragments that the presence of DBD conferred 
an organised structure upon AF-1 in both NT-A and NT-B, but that NT-A existed in a 
wider range of conformations than PR-B. It was suggested therefore that the presence of 
BUS may help to stabilize NT-B, and by extension natural PR-B, in transcriptionally 
active conformations, facilitating DNA binding, co-factor interactions with AF-1 and 
perhaps also intramolecular interactions (Bain et al., 2001; Bain et al., 2000). This idea 
gained support from a study which demonstrated that functional AF3 is required for 
interactions with co-factors, intramolecular interactions and transcriptional activation by 
PR-B or BUS containing constructs, but in PR-A these functions map to regions 
common to both receptors. Furthermore, mutation of AF3 does not result in a 
transcriptional activity similar to PR-A, leading to the conclusion that AF3 mediates the 
formation of intramolecular structures that promote more efficient co-factor binding 
leading to stronger transactivation by PR-B (Tung et al., 2006).  
 
PR-B specific phosphorylation within BUS was demonstrated to have no effect on the 
ligand activated transcriptional activity of AF3, or its ability to synergise with AF1 or 
AF2 (Takimoto et al., 1996). However, more recent studies have demonstrated that 
increases the expression of endogenous PR target genes in response to progestin 
stimulation of T47-D breast cancer cells expressing only PR-B could be prevented by 
mutation of Ser81 within BUS. Cells expressing only PR-A, or PR negative cells did 
not exhibit progestin responsive transcription of these genes, indicating the role of BUS 
phosphorylation at Ser81 in regulating gene expression. Mutating Ser81 did not prevent 
recruitment to PRE, and therefore it was hypothesised that Ser81 phosphorylation may 
be required for correct co-activator recruitment and interactions (Hagan et al., 2011). 
Ser294, within the N-terminal region common to both PR-A and PR-B, was 
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demonstrated to be preferentially phosphorylated in response to ligand in PR-B over 
PR-A. Unique PR-B conformations due to BUS could alter the accessibility of Ser294 
and thus the ability of kinases to phosphorylate at this site, contributing to the observed 
functional differences between the isoforms (Clemm et al., 2000). Phosphorylation of 
Ser294 has been linked to transcriptional hyperactivity in response to progesterone, 
which mediates ubiquitinylation and proteosomal degradation of PR, required for 
efficient transcriptional activity (Shen et al., 2001; Lange et al., 2000). Therefore, the 
increased phosphorylation of PR-B Ser294 could mediate hyperactivity of this isoform 
and increased receptor turnover leading to more efficient transcription compared to PR-
A. 
 
1.1.8 Variant PR isoforms 
An N-terminally truncated third PR isoform, termed PR-C, was predicted based on the 
heterogenous nature of the 5′ region of the PR gene, and the abundance of mRNAs 
which arise, some of which are too short to encode PR-B or PR-A. It was predicted that 
translation would initiate at Met595 and encode an N-terminally truncated protein of 
45-50kDa (Wei et al., 1990). Detection in PR positive breast cancer cells of a 60kDa 
protein by a C-terminal PR antibody, but not with N-terminal antibodies, targeted to 
epitopes which would be truncated from the Met595
 
encoded protein, and could bind to 
progesterone, supported the existence of PR-C (Wei and Miner, 1994). Cells transfected 
with PR-C expression vectors, in addition to PR-A/PR-B, were seen to exhibit increased 
transcriptional responses to progestins compared to cells with just PR-A/PR-B. This led 
to the hypothesis that PR-C may be able to dimerise with PR-A/PR-B and preferentially 
recruit co-factors to activate transcription of a PRE reporter gene (Wei et al., 1996). 
However, it was later demonstrated that whilst the protein encoded by PR-C cDNA 
could be co-immunoprecipitated using a PR-B specific antibody, suggestive of 
dimerisation, the presence of PR-C markedly diminished PR-B DNA binding. It was 
therefore suggested that PR-C may promote PR-A/PR-B activity in heterodimers in a 
mechanism independent of PRE binding, perhaps by preferential recruitment of co-
factors which may themselves activate transcription (Wei et al., 1997). A potential 
function for PR-C was more recently suggested in the human myometrium at labour. An 
increase in PR-B is seen in the human myometrial fundus at labour, which is 
paradoxical since most species exhibit a withdrawal of progesterone signal at the onset 
of labour. However, a coinciding rise in cytoplasmic detection of PR-C could provide a 
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mechanism for repressing the function of PR-B in labour, leading to a functional 
progesterone withdrawal (Condon et al., 2006). A 60kDa cytoplasmic protein, 
suggested to be PR-C, was also detected in the human amnion, chorion and placenta, 
suggesting a role in regulating extra-embryonic tissue during pregnancy and parturition 
(Taylor et al., 2009). However, recent studies have demonstrated that the 60kDa protein 
identified as PR-C by Western immunoblotting with a C-terminal PR antibody may not 
be a PR protein (Madsen et al., 2007). The predicted molecular weight and natural 
occurrence of a protein encoded by PR-C mRNA has also been disputed, predicting a 
38kDa protein rather than the previously described 60kDa isoform (Samalecos and 
Gellersen, 2008). 
 
Mechanisms of alternative splicing, its impact on PR and the potential functionality of 
PR spliced variants will be discussed in detail later. Briefly, alternative splicing can 
result in the deletion of one or more exons from PR mRNA, which would either cause a 
change in reading frame or deletion of specific functional domains, altering PR function. 
Alternatively, retention of intronic sequences can result in the use of alternative 
translational initiation sites and generate truncated isoforms which again may display 
functions which differ from PR-A or PR-B, reviewed by (Cork et al., 2008). 
 
1.1.9 Non-genomic PR signalling 
Progesterone signals can be transmitted via PR in a rapid manner that does not involve 
nuclear translocation and PRE binding, typically occurring within minutes of a 
progesterone signal, rather than the much longer time scale required for induction of 
transcription and subsequent protein translation (Gellersen et al., 2009). 
 
The Src/Ras/Raf/MAPK pathway is an important signal transduction pathway involved 
in transmitting signals from membrane receptors to mediate gene activation, and is 
involved in growth factor signalling. Ligand binding to a transmembrane receptor leads 
to Src tyrosine kinase activation, which in turn activates Ras, Raf, MEK and mitogen 
activated protein kinases (MAPKs) including extracellular signal-regulated kinase 
(Erk)-1/2 (Cargnello and Roux, 2011). Progesterone was initially demonstrated to 
activate Erk-1 and Erk-2, and this activation relied on the expression of PR. A similar 
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PR dependent activation of c-Src was observed, and inhibition of c-Src function blocked 
the progestin stimulated Erk-2 function (Migliaccio et al., 1998). This activation was 
demonstrated to be mediated via direct interaction of an N-terminal proline rich region 
of PR with the Src homology (SH)3 domain of the c-Src tyrosine kinase Hck. Mutation 
of this proline rich region inhibited interaction and activation (Boonyaratanakornkit et 
al., 2001). In COS-7 cells transiently transfected with PR-A or PR-B, only PR-B 
interacted with and activated c-Src, and deletion of NLS did not affect this activation 
suggesting an extranuclear interaction. The predominant nuclear localisation of PR-A 
compared to PR-B presumably prevents this cytoplasmic interaction of c-Src with PR-A 
(Boonyaratanakornkit et al., 2007).  
 
Cross talk of PR with c-Src, and subsequent activation of downstream signalling 
cascades, provides a mechanism by which a progesterone signal can activate 
transcription of genes that do not contain a PRE (Boonyaratanakornkit et al., 2007; 
Proietti et al., 2005). Progesterone stimulation of T47D breast cancer cells enhanced the 
expression, phosphorylation and activation of the transcription factor signal transducer 
and activator of transcription (Stat)3. PR interacts directly with Stat3 and the activation 
of Stat3 in response to progesterone is reliant on c-Src function (Boonyaratanakornkit et 
al., 2007; Proietti et al., 2005). Potentially, the direct interaction of ligand bound PR 
with Stat3 mediates the recruitment of c-Src, stimulating Stat3 phosphorylation and 
activating transcription of non-PRE genes.  
 
Progesterone has also been demonstrated to stimulate activation of the MAPK 
dependent transcription factor Elk-1 via the PR/c-Src interaction in a reporter gene 
assay. Progesterone was further able induce PR dependent transcription of the non-PRE 
gene encoding the cell cycle regulator cyclin-D1, leading to cell cycle induction in 
quiescent T47D cells. This activation was reliant on PR interaction with the SH3 
domain of c-Src. Inhibitors of c-Src, MAPK or phosphatidylinositol 3-kinase (PI3K) 
attenuated progesterone responsive cyclin-D1 expression, implicating PR in activating 
multiple signal transduction cascades (Boonyaratanakornkit et al., 2007). Cytoplasmic 
PR can also activate PI3K, a signal transducer involved in activating transcription via 
protein kinase-C or regulating apoptosis via Akt activation. Progestin treatment of 
murine breast cancer cells transfected with PR-B resulted in Akt phosphorylation which 
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was not affected by transfection with a DBD mutant PR, demonstrating non-
transcriptional regulation (Carnevale et al., 2007). 
 
A biphasic pattern of Erk1/2 activation in response to progesterone has been observed in 
T47D cells expressing only PR-B by Western immunoblotting with a phospho-Erk1/2 
antibody. The first phase is due to the rapid interaction of PR and c-Src described above, 
and the second more sustained period of activation involves PR induced transcription of 
Wnt-1, a non-PRE gene, and blocking transcription blocks Erk1/2 activation. Wnt-1 is 
thought to mediate epidermal growth factor receptor (EGFR) activation, which as 
described activates the c-Src/Erk signalling cascade, which stimulates cyclin-D1 
expression. This provides a distinct mechanism for activation of cyclin-D1 transcription 
which does not require direct PR/c-Src interaction, and provides a link between rapid 
cytoplasmic and non-classical genomic PR actions (Faivre and Lange, 2007). 
Progesterone also stimulates a rapid PR-B dependent activation of EGFR in T47-D cells, 
detected by a phospho-specific antibody. This activation stimulates c-Src which 
phosphorylates PR at Ser345 (Faivre et al., 2008). Erk1/2 is also phosphorylated in 
response to c-Src which may account for the first phase of Erk-1 activation described 
above. Phosphorylation of PR Ser345 was demonstrated to be necessary for PR 
interaction with the transcription factor Sp1 which could mediate regulation of non-PRE 
genes via interaction with Sp1 sites within promoter regions (Faivre et al., 2008). This 
transcriptional PR activity, mediated via Sp1 could account for the processes mediating 
the second phase of Erk1/2 activation described previously. The progesterone induced 
cell cycle entry mediated via PR-B in quiescent T47-D breast cancer cells 
(Boonyaratanakornkit et al., 2007), was also seen in MCF-7 breast cancer cells; 
however, this activation of the cell cycle required a functional DBD, and mutation of the 
Src binding domain did not affect transcription of cyclin-D1 in this model suggesting a 
role for genomic PR signalling independent of Src/MAPK activation (McGowan et al., 
2007). 
 
In summary, ligand-bound PR-B is able to bind directly to Stat3 and c-Src. c-Src 
activates Stat3, activating transcription of non-PRE genes in response to progesterone. 
Alternatively PR-B/c-Src can activate Erk1/2 MAPKs, which phosphorylate 
transcription factors to activate non-PRE genes, including cyclin-D1 which promotes 
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cell cycle entry. Activated MAPKs can also phosphorylate PR Ser345, mediating 
binding to Sp1 to activate other non-PRE genes with Sp1 sites within their promoters, 
including EGFR. Wnts, produced in response to progesterone activated transcription of 
non-PRE genes, can activate EGFR to activate MAPK signalling and induce further 
transcription. Cyclin-D1 expression is activated both via rapid PR activation of MAPK 
signalling, and via progesterone induced Wnt activation of EGFR signalling. 
Cytoplasmic PR can also activate PI3K signalling to activate other intracellular 
signalling pathways.  Some of the pathways leading to progesterone induced 
transcription of non-PRE genes are summarised in Figure 1.2. 
 
Figure 1.2: Mechanisms of PR signalling. 
Ligand activated PR can interact with PRE promoters to regulate gene expression. Alternatively, 
PR can directly activate Src/MAPK signalling to promote transcription of non-PRE genes. 
Activated MAPKs can also phosphorylate PR Ser345 to promote interaction with Sp1 and 
transcription from Sp1 promoters (modified from (Faivre et al., 2008). 
 
 
1.1.10 Ligand independent activation of PR 
PR can also regulate gene expression in the absence of ligand; induced expression of 
transfected PR-A or PR-B in PR negative breast cancer cells led to altered gene 
expression without progesterone stimulation. In contrast to progesterone stimulated 
transcription, ligand independent transcription was mainly activated by PR-A (Jacobsen 
et al., 2005). The mechanisms of ligand independent PR activation remain unclear, 
however Ser400 can be phosphorylated by cyclin dependent kinase (CDK)2 in response 
to mitogens such as endothelial growth factor (EGF) and insulin-like growth factor 
(IGF). This phosphorylation stimulates nuclear PR localisation in HeLa cells, and 
increases transcription of a PRE reporter gene independent of progesterone stimulation 
(Pierson-Mullany and Lange, 2004). Therefore it is possible that phosphorylation by 
15 
CDK2, activated by other mitogenic signals, may be sufficient to induce the PR 
conformational changes necessary for transcriptional activation in the absence of ligand. 
This non-classical PR signalling may play a significant role in breast cancer prognosis 
and therapy in post menopausal women with PR positive tumours and low circulating 
hormone levels (Pierson-Mullany and Lange, 2004). 
 
1.2 The mammary gland 
1.2.1 Anatomy 
The adult human breast is made up of 15-25 lobes, consisting of epithelial cell lined 
ducts which branch into secretory lobules to serve the function of lactation. Mammary 
ducts drain into lactiferous sinuses behind the nipple which store the milk until release 
is stimulated. The glandular structures of the breast are surrounded by fatty stromal 
tissue, providing a network of blood vessels, connective tissue and lymphatic vessels to 
support mammary gland function. The anatomy of the adult mammary gland is 
illustrated by the ‘Breast profile’ in Figure 1.3 (Hinck and Silberstein, 2005; Russo and 
Russo, 2004; Elston, 1998). 
 
 
Figure 1.3: Anatomy of the breast and organisation of ductal epithelial cells. 
Figure adapted from (breastcancer.org). 
16 
1.2.2 Cellular organisation of mammary ducts 
At the nipple, the duct consists of squamous epithelial cells which end before the 
lactiferous sinus. Beyond the lactiferous sinus, mammary ducts consist of a layer of 
columnar epithelial cells surrounding the central lumen, enclosed within a layer of 
myoepithelial cells and a collagenous basement membrane. The organisation of luminal 
epithelial cells within a mammary duct can be seen in the ‘Enlargement’ in Figure 1.3. 
These epithelial cells are contained within a layer of delimiting fibroblasts and 
capillaries within the stroma. In the lobuloalveolar structures, the epithelial cells take on 
a cuboidal morphology and the cytoplasm contains a high density of organelles 
associated with the secretory function (Rosen, 2001; Elston, 1998). 
 
1.2.3 Normal mammary gland development 
The newborn breast consists of primitive ductal structures which begin to differentiate 
under the control of steroid hormones at the onset of puberty, forming rounded 
structures termed terminal end buds (TEBs) (Hinck and Silberstein, 2005; Russo and 
Russo, 2004). TEBs branch into smaller rounded structures, alveolar buds, forming 
lobules type 1. Mammary lobular differentiation is illustrated in Figure 1.4. Briefly, the 
adult breast consists of three types of lobule, types 1, 2 and 3, each more differentiated 
than the previous type (i.e. containing more branched structures, termed ductules in 
lobule type 2 and 3). The transition from lobule type 1 to 2 and type 2 to 3 sees an 
increase in lobule size with a decrease in size of individual structures. If no pregnancy 
occurs, lobules de-differentiate to the preceding forms after the age of approximately 23 
years (Russo and Russo, 2004). During pregnancy, a second major period of mammary 
development occurs, with further lobuloalveolar differentiation from lobules type 3 to 
the mature secretory lobules type 4 and the interlobular space is filled by mature 
secretory acini which serve the function of lactation (Russo and Russo, 2004; Elston, 
1998). At the cessation of breast feeding and subsequent termination of lactation, 
lobules type 4 de-differentiate, however parous women retain a higher proportion of 
lobule type 3 and type 2 compared to nulliparous women (Russo and Russo, 2004). 
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Figure 1.4: Ductolobular differentiation of the breast. 
Mammary ducts differentiate at puberty to form terminal end buds (TEB) which branch to form 
alveolar buds (ABs) making up lobules type 1 (lob 1). Further differentiation occurs to lobules 
type 2 (lob 2) and lobules type 3 (lob 3), each larger and containing an increased number of 
more mature ductule structures compared to the preceeding lobule type. Figure taken (Russo 
and Russo, 2004). 
 
 
1.2.4 Steroid hormones in mammary gland development 
The link between mammary gland development and the menstrual cycle, and the role of 
the ovarian steroid hormones oestrogen and progesterone in mammary development are 
well established concepts (Topper and Freeman, 1980; Loeb and Hesselberg, 1917); 
ductal elongation predominates during the follicular phase and alveolar branching 
occurs during the luteal phase, when serum progesterone levels peak (Topper and 
Freeman, 1980).  
 
More recent studies in rodents have provided insight into the differing roles of 
oestrogen and progesterone in mammary development; mice lacking the ERα gene (ER 
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knockout; ERKO) demonstrate impaired ductal elongation, while mice lacking the PR 
gene (PR knockout; PRKO) fail to undergo proper lobuloalveolar differentiation 
(Shyamala et al., 1999; Brisken et al., 1998; Lydon et al., 1995). This suggests that both 
ERα and PR are capable of stimulating epithelial proliferation, but only PR is capable of 
stimulating pregnancy associated lobuloalveolar differentiation. The involvement of PR 
in epithelial differentiation may implicate progesterone signalling in the differentiation 
associated with tumourigenesis (Shyamala et al., 1999).  
 
In the murine mammary gland nuclear PR mRNA and protein were detectable only in a 
subpopulation of undifferentiated luminal epithelial cells. These PR positive cells were 
observed to be intermixed with rapidly dividing PR negative cells in the growing tip of 
an elongating duct (Silberstein et al., 1996). Cytoplasmic PR protein was also detected 
in a further subpopulation of luminal epithelial cells. During development, a switch was 
observed from predominant cytoplasmic expression in pre-pubertal glands, to 
predominant nuclear expression during early pregnancy, with a mixed population of 
cytoplasmic and nuclear PR positive cells in the non-pregnant adult gland. This led to 
the proposition that the cytoplasmic PR positive cells may represent a progenitor 
population for the mature secretory epithelia, or that PR positive cells may release 
paracrine factors to stimulate mitosis in nearby PR negative cells (Silberstein et al., 
1996). This segregation of PR expression and proliferation in the murine mammary 
gland was also demonstrated using a model in which the LacZ reporter gene was 
inserted into PR exon 1.  This model was able to identify where the PR promoter was 
active, demonstrating PR to be expressed only in luminal epithelial cells, and only in a 
subpopulation of cells which are non-proliferative. In the pubertal gland, PR expression 
was seen in ductal side branches and terminal end buds, whereas in the adult gland PR 
was concentrated at distal alveolar structures (Ismail et al., 2002). 
 
The same segregation of PR expressing epithelial cells and proliferating epithelial cells 
exists in the human mammary gland (Russo et al., 1999; Clarke et al., 1997). 
Immunostaining for ERα and PR protein demonstrated that these receptors are 
expressed in a small sub-population of luminal epithelial cells in human mammary 
glands (Clarke et al., 1997) and are expressed at a higher level in the proliferating 
lobules type 1 with progressively decreased expression in the more differentiated 
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lobules type 2 and 3 (Russo et al., 1999). ERα and PR were seen to be co-expressed in 
96% of steroid receptor positive cells and staining for the proliferation marker Ki67 
demonstrated that these steroid receptor expressing cells were non-proliferative, again 
suggesting that hormone receptors signal in a paracrine manner so stimulate 
surrounding cells (Russo et al., 1999; Clarke et al., 1997). The paracrine function of PR 
in murine mammary development was demonstrated by the transplantation of a mixed 
population of PR positive and PR negative epithelial cells into cleared mammary fat 
pads leading to the development of lobuloalveolar structures containing PR negative 
cells. Since PR expression is required for this alveolar differentiation, this demonstrated 
that a paracrine signal from the PR positive cells stimulates the PR negative cells 
(Brisken et al., 1998).  
 
It was later demonstrated that ectopic expression of Wnt-1 in PRKO mice was sufficient 
to rescue lobuloalveolar differentiation and that Wnt-1 released from mammary 
epithelial cells containing a Wnt-1 transgene could activate lobuloalveolar 
differentiation involving surrounding wild-type cells (Brisken et al., 2000). These 
observations implicated Wnt signalling in the paracrine role attributed to PR in 
mammary development. Wnt-1 is not normally expressed in mammary tissue, but other 
Wnt family members are, including Wnt-4 (Brisken et al., 2000). Mammary buds from 
Wnt-4 knockout mice were engrafted into cleared mammary fat pads of wild-type mice 
and failed to undergo normal pregnancy associated lobular differentiation. In wild-type 
animals Wnt-4 expression was observed specifically in PR expressing luminal epithelial 
cells, with increased Wnt-4 expression detected after progesterone treatment of the 
animals. This suggested a role for PR in the release of Wnt-4 and a physiological role 
for Wnt signalling as a paracrine mediator of progesterone stimulated lobuloalveolar 
differentiation (Brisken et al., 2000). As previously described in Section 1.1.9, Wnt-1 is 
a non-PRE gene which can be activated in response to progesterone in a non-classical 
PR signalling dependent manner and leads to sustained Erk signalling to activate cyclin-
D1 expression, promoting cell cycle entry in response to progesterone (Faivre and 
Lange, 2007). This non-classical PR signalling to activate Wnt expression provides a 
potential mechanism by which progesterone releases a PR dependent signal which can 
act on neighbouring cells to induce cell cycle entry leading to proliferation. 
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1.2.5 PR isoforms in mammary gland development 
Transgenic mice overexpressing PR-A exhibit abnormal mammary gland development, 
including increased ductal side branching, hyperplasia and disruption of the basement 
membrane, demonstrating the importance of correct PR isoform balance in mammary 
gland development (Shyamala et al., 1998). Mice selectively lacking PR-A expression, 
PR-A knockout (PRAKO), exhibit normal lobuloalveolar differentiation (Mulac-
Jericevic et al., 2000), whereas PR-B knockout (PRBKO) mice exhibited impaired 
lobuloalveolar differentiation (Mulac-Jericevic et al., 2003). Together these 
observations suggest PR-B is essential for mediating progesterone stimulated 
lobuloalveolar differentiation. Mice deficient for receptor activator of NFκB ligand 
(RANKL) exhibit similar developmental abnormalities to those observed in PRBKO 
mice and mRNA for RANKL was detected to co-localise with PR mRNA in wild-type 
mice and PRAKO mice, and to be segregated from cyclin-D1 mRNA which was present 
in neighbouring cells. Furthermore, RANKL and cyclin-D1 mRNA levels were greatly 
reduced in PRBKO mice suggesting a role for PR-B in paracrine signalling via RANKL 
in the murine mammary gland (Mulac-Jericevic et al., 2003). Induced expression of 
RANKL in ER positive cells from PRKO murine mammary glands was sufficient to 
trigger development of mammary structures analogous to those seen in wild-type mice, 
confirming RANKL as an important mediator of PR induced mammary differentiation 
(Mukherjee et al., 2010). The role of PR-B in lobular development was supported by 
detection of PR-B protein expression specifically in the mammary gland of pregnant 
mice and not virgin adult glands. PR-A and PR-B were rarely detected in the same cell, 
and PR-B co-localised with cyclin-D1 in proliferative cells (Aupperlee et al., 2005). 
Further studies reported that PR-A also co-localised with cyclin-D1 in a subset of 
proliferative cells and mediated ductal side-branching in early pregnancy, whereas PR-
B was again seen to more frequently co-localise with cyclin-D1 and to stimulate 
lobuloalveolar differentiation. These results suggested that progesterone can directly 
stimulate PR expressing cells and can exhibit paracrine control over surrounding PR 
negative cells (Aupperlee and Haslam, 2007). 
 
In contrast to the segregated pattern of PR isoform expression described in the murine 
mammary gland, PR-A and PR-B are expressed at approximately equimolar levels in all 
PR positive human mammary epithelial cells (Mote et al., 2002). In the rat mammary 
gland, a similar pattern to the expression in human was observed, with co-expression of 
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PR-B in the majority of PR-A positive cells and no significant change in expression at 
different developmental stages (Kariagina et al., 2007). However, this study also 
detected a significant subpopulation of PR-B positive cells which did not express PR-A 
and these cells were detected to be the most proliferative of the PR expressing cells, 
particularly during pregnancy. All PR-B positive cells also expressed cyclin-D1, but the 
expression of cyclin dependent kinase inhibitors in cells which also express PR-A is 
likely to restrict cell cycle progression in these non-proliferative cells (Kariagina et al., 
2007). Progesterone can stimulate cyclin-D1 expression via activating transcription of 
Wnt and RANKL which may mediate the paracrine stimulation of PR negative cells. 
However, as described in Section 1.1.9, a second mechanism by which progesterone can 
stimulate cyclin-D1 also exists, via rapid interaction of the PR-B proline rich domain 
with c-Src to activate MAPK signalling (Boonyaratanakornkit et al., 2007). This PR-B 
specific autocrine mechanism for activating cell cycle progression could be responsible 
for cyclin-D1 expression and proliferation of PR-B positive mammary epithelial cells. 
 
The two distinct mechanisms described above for stimulating mammary epithelial cell 
proliferation, rapid activation of cyclin-D1 mediated mitosis in PR positive cells and a 
slower activation of PR negative cells, have recently been demonstrated in the murine 
mammary gland (Beleut et al., 2010). Firstly, it was shown by examining incorporation 
of 5′bromo-2′deoxyuridine (BrdU) into cells that progesterone was required in addition 
to oestrogen to stimulate proliferation in the adult gland. Initial proliferation of 
mammary epithelial cells, within 24 hours of hormone stimulation, showed co-
localisation of BrdU with PR and cyclin-D1, resulting from autocrine activation of 
mitosis in response to progesterone. At later time points, most proliferative cells were 
PR negative and did not express cyclin-D1. This later phase of proliferation was 
dependent on RANKL expression, confirming RANKL as a paracrine mediator of PR 
signalling which functions independently of cyclin-D1 activation of the cell cycle 
(Beleut et al., 2010). 
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1.3 Breast cancer 
1.3.1 Epidemiology 
Breast cancer is now the most commonly diagnosed cancer in the UK with more than 
47,000 new cases diagnosed in 2008 (CRUK). Whilst the incidence of breast cancer has 
risen in the last decade, this is in part attributable to increased awareness and improved 
detection. The overall survival rate for breast cancer patients has improved significantly 
in the last 40 years due to the screening programme and improved access to effective 
treatments. However, breast cancer was still responsible for over 12,000 deaths in 2008 
demonstrating the need for continued research to improve the treatment of breast cancer 
patients (CRUK). The majority of breast cancer deaths occur in women over the age of 
50 years, making age a major risk factor for disease development. Other risk factors 
include a family history of the disease, obesity, alcohol consumption and probably the 
use of exogenous hormones in hormone replacement therapy (HRT) and some forms of 
oral contraceptive (CRUK). 
 
1.3.2 Pathology 
The majority of breast tumours arise from the rapidly dividing epithelial cells lining the 
ductal lumen. Pre-cancerous atypical ductal hyperplasia can occur and if untreated can 
progress to a tumour which is limited to the duct in which it originates; ductal 
carcinoma in situ (DCIS). These tumours can then progress to penetrate the basement 
membrane surrounding the duct and invade the stroma. Such invasive ductal carcinomas 
therefore have the potential to spread via the lymphatic system to axillary lymph nodes 
or other distant sites of metastasis. Ductal carcinomas are classified according to their 
invasive capacity and distinct patterns of growth and cellular morphology; tubular 
carcinomas, papillary carcinomas, medullary carcinomas, metaplastic carcinomas and 
mucinous carcinomas each possess distinct morphological features and are associated 
with differential prognosis. Tumours that possess some but not all of the features of an 
individual type of tumour are termed invasive ductal carcinoma: not otherwise specified 
(NOS). Invasive ductal carcinomas account for around 80% of the total breast cancer 
diagnoses (Bateman, 2006; Rosen, 2001). Malignant transformations of the lobular 
epithelium can also occur and again these tumours can be either restricted to the lobule 
(lobular carcinoma in situ) or invasive (Bateman, 2006; Rosen, 2001). Breast tumours 
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originating from squamous epithelia, myoepithelia or surrounding stroma can occur but 
are relatively rare (Bateman, 2006; Rosen, 2001). 
 
Primary breast tumours usually metastasise first to the axillary lymph nodes following 
invasion from the duct/lobule into the lymphatic system in the breast stroma. Breast 
cancer cells can also invade blood vessels and metastasise via lymph and blood vessels 
to distant sites including the brain, liver, lungs and bone where they can form new 
macroscopic tumours (Bateman, 2006; Rosen, 2001). Breast tumour grading or 
subtyping can be used to assess prognosis independently and as part of a combined 
scoring system. Grading is based in the morphology of the cells; grade 1 are well 
differentiated, grade 2 moderately differentiated and grade 3 are poorly differentiated, 
with increased grade indicating poorer prognosis. The Nottingham Prognostic Index 
(NPI) considers the size of the tumour, number of lymph nodes affected and the grade 
of the tumour and is used to predict the disease prognosis (Bateman, 2006; Galea et al., 
1992). Breast tumours can also be assessed using the TNM staging system. A score is 
given for each of the following disease characteristics: T; the size of the primary tumour, 
N; the presence of lymph node metastasis and M; the presence of breast cancer cells at 
distant metastatic sites. The scores for T, N and M are used to classify the stage of a 
tumour with stage I having the best prognosis and stage IV (the presence of distant 
metastases) having the poorest prognosis (Bateman, 2006; Rosen, 2001). 
 
1.3.3 Cancer aetiology 
Most breast tumours arise from transformation of the rapidly dividing luminal epithelial 
cells (Russo et al., 2005). As described in Section 1.2.3, progression to more 
differentiated structures during mammary gland development is associated with 
decreased cell proliferation. This is thought to contribute to the decreased incidence of 
breast cancer in parous women who possess fewer undifferentiated, proliferative 
structures following pregnancy and lactation (Russo et al., 2005). The development of 
breast cancer from a mammary duct is illustrated in Figure 1.5. 
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Figure 1.5: Development of ductal carcinoma in-situ and invasive ductal carcinoma. 
The anatomical structures of the breast are shown in theleft hand panel. Right hand panel shows 
the organisation of epithelial cells in a mammary duct, developing into invasive ductal 
carcinoma. Figure adapted from (breastcancer.org(b)). 
 
There are several important steps in the transformation of a normal cell into a cancer 
cell which are controlled by activating mutations or amplifications of oncogenes, or loss 
of function mutations in tumour suppressor genes (Lee and Muller, 2010; Croce, 2008). 
These processes were described by Hanahan and Weinberg as the hallmarks of cancer; a 
cell must acquire independence from external growth stimulatory signals, become non-
responsive to normal anti-growth signals, avoid apoptosis and acquire the potential for 
unlimited division. These cells must then be supplied by an independent network of 
blood vessels (angiogenesis) and develop invasive and metastatic capabilities (Hanahan 
and Weinberg, 2000). To permit the acquisition of these hallmarks, changes within the 
cell must occur which prevent the normal monitoring of the genome, and increase 
genomic instability in order to allow the growth and proliferation of cells containing 
mutations and/or amplifications (Hanahan and Weinberg, 2011). 
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A tumour consists not only of the transformed cancer cells, but also a diversity of 
‘normal’ cells which are co-opted by the tumour to support its growth (Hanahan and 
Weinberg, 2011). These include immune inflammatory cells, which may provide 
growth stimulating signals to cancer cells. Endothelial cells within the tumour 
microenvironment form the tumour neo-vasculature, supported by a population of 
pericytes which provide structural support and paracrine stimulation to the endothelial 
cells. Cancer-associated fibroblasts provide a structural foundation for tumour growth 
and promote angiogenesis, invasion and metastasis. As well as the rapidly dividing 
cancer cells, a tumour contains cancer stem cells which exhibit asymmetric division, to 
form either further cancer stem cells or rapidly dividing cancer cells. These cells are 
able to initiate development of new tumours when transplanted in mice and since they 
have mechanisms to evade cancer chemotherapeutic agents, may account for recurrence 
of disease after treatment and apparent clinical cure (Hanahan and Weinberg, 2011). 
 
1.3.4 Breast cancer oncogenes and tumour suppressors 
Somatic activating mutations in the PIK3CA oncogene are observed in approximately 
25% of primary breast tumours (Lai et al., 2008; Bachman et al., 2004). PIK3CA 
encodes the catalytic subunit of PI3K which is a transducer of growth factor signalling. 
Constitutively active PI3K due to activation of PIK3CA would allow cancer cell growth 
independent of external stimulus (Lee and Muller, 2010; Dillon et al., 2007). PI3K 
signalling via Akt kinases has also been demonstrated to be involved in increased cell 
survival (avoidance of apoptosis), stimulating angiogenesis and increasing the invasive 
and metastatic potential of breast cancer cells (Dillon et al., 2007). Thus, the activation 
of the PIK3CA oncogene is likely to be vital in the acquisition of several of the 
hallmarks necessary for initiation and progression of breast cancer. The tumour 
suppressor phosphatase and tensin homologue (PTEN) functions to antagonise PI3K 
signalling, leading to repression of growth factor induced cell division, induction of 
apoptosis and repression of angiogenesis and invasion (Dillon et al., 2007). A high risk 
of breast cancer development is associated with loss of function germ-line mutations in 
the PTEN gene (Lee and Muller, 2010; Dillon et al., 2007). Another tumour suppressor 
gene associated with breast cancer is TP53, encoding p53. p53 controls the expression 
of numerous genes, including those involved in stimulating cell cycle checkpoints and 
response to pro-apoptotic signals. Therefore loss of p53 function would allow 
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uncontrolled cell cycle entry of cells with potentially harmful mutations (Lee and 
Muller, 2010). 
 
Most breast tumours arise from somatic mutations and only approximately 1 in 10 has 
an inherited basis (CRUK). However, in addition to the rare germline mutations 
described above, inherited mutations in the tumour suppressor genes BRCA1 and 
BRCA2 are associated with an increased risk of developing breast cancer in affected 
families (Ford et al., 1998). BRCA1 and BRCA2 mutations account for a majority of the 
familial breast cancer risk (Venkitaraman, 2002; Ford et al., 1998). BRCA1 and 
BRCA2 are involved in maintaining chromosomal stability, and BRCA1 helps control 
cell cycle checkpoints following DNA damage (Venkitaraman, 2002). A loss of BRCA1 
and BRCA2 function would clearly be involved in permitting the cancer associated 
changes described by Hanahan and Weinberg. BRCA1 is also involved in chromatin 
remodelling, transcription-coupled DNA repair and targeting aberrant RNA products for 
degradation, demonstrating the wide range of cellular processes which may be 
misregulated in BRCA1/2 mutation carriers, contributing to cancer development 
(Venkitaraman, 2002).  
 
The breast cancer associated oncogene, ErbB2, encodes the human epidermal growth 
factor receptor (HER)2 which has been seen to be overexpressed in 15-30% of breast 
cancers. HER2 overexpression is linked to an unfavourable prognosis, including 
increased lymph node metastases and increased recurrence (Burstein et al., 2007; 
Slamon et al., 1987). This receptor overexpression potentially makes breast cancer cells 
responsive to normally non-stimulating levels of hormone, thus contributing to their 
apparent autonomy (Slamon et al., 1987). HER2 functions via activation of the PI3K 
and MAPK signalling pathways that promote cell survival and proliferation. However, 
overexpression of HER2 normally stimulates apoptosis. Therefore, earlier genetic 
events that protect cells from apoptosis must be required to permit the effects of HER2 
overexpression (Menard et al., 2003), in accordance with the necessity for enabling 
characteristics to allow the development of cancer hallmarks (Hanahan and Weinberg, 
2011). 
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1.3.5 Ovarian hormones in the aetiology of breast cancer 
Ovarian control of breast cancer development was first hypothesised by George Beatson 
in 1896 based on the known contribution of ovarian stimulus to lactation in animals, and 
observations of the similarities between normal mammary development towards 
lactation and epithelial proliferation in cancer. Surgical removal of the ovaries was 
demonstrated to halt progression and even lead to regression of inoperable breast 
cancers, confirming an element of ovarian control of disease (Beatson, 1983).  
 
HRT is the administration of exogenous steroid hormones to alleviate the symptoms of 
menopause. Compared to women not receiving HRT mammary epithelial cell 
proliferation and density was increased in women receiving oestrogen only HRT. A 
further significant increase in cell proliferation was observed in women receiving 
combined oestrogen plus progestin HRT. These changes in cell growth patterns are 
associated with development of pre-cancerous hyperplasia and are concentrated in areas 
of the breast where most tumours arise (Hofseth et al., 1999). Parallel to these changes 
in cell growth, an increased incidence of breast cancer is seen in women who have 
undergone long term HRT (Beral, 2003); oestrogen only HRT increases breast cancer 
risk and a further increase in risk is associated with combined oestrogen plus progestin 
HRT, implicating both hormones in breast cancer initiation (Beral, 2003; Persson et al., 
1999). Following an apparent initial protection from breast cancer, evidenced by a lower 
rate of disease within the first two years of HRT, combined oestrogen-progestin HRT 
was associated with an increased incidence after longer periods of treatment in a 
randomised, placebo-controlled trial (Rossouw et al., 2002). The risk of breast cancer 
associated with HRT was immediately decreased following treatment withdrawal 
(Chlebowski et al., 2009). Combined oestrogen and progestin HRT was also associated 
with an increased rate of breast cancer mortality in a follow up study of patients from 
this trial (Chlebowski et al., 2010). A recent reduction in use of combined HRT has seen 
a parallel decrease in breast cancer incidence in post-menopausal women (Silverman et 
al., 2011). Together these studies provide strong epidemiological evidence for the 
involvement of both oestrogen and progesterone signalling in breast cancer initiation. 
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1.3.6 ER and PR in breast cancer development 
Evidence for an involvement of ER signalling in breast cancer initiation comes from the 
observation of a disruption in the normal pattern of ER expression in the early stages of 
breast cancer (Clarke et al., 1997). In the normal adult human and rodent mammary 
gland, ER and PR are largely segregated from the proliferative epithelial cells and 
hormone induced proliferation is stimulated in a paracrine manner. However in breast 
cancer a loss of this segregated expression is observed, suggesting a switch from 
paracrine to autocrine stimulation of mammary epithelial cell proliferation (Clarke et al., 
1997). In a model using age matched virgin rats, stimulation with oestrogen and 
progesterone to mimic parity prevents the development of a hormone receptor positive 
proliferating epithelial population in response to a chemical carcinogen, which is 
detected in age control unstimulated animals (Sivaraman et al., 2001b). The protection 
against breast cancer development associated with early parity is linked to a specific 
gene expression profile and the decreased proliferative nature of epithelial cells within 
the structures of the involuted parous gland compared to the proliferative lobules type 1 
and lobules type 2 of the virgin gland (Russo et al., 2005). It is suggested therefore, that 
the proliferative hormone receptor positive population is a target for malignant 
transformation in the virgin gland. The absence of this population in the parous gland 
may contribute to this protection (Sivaraman et al., 2001b). Furthermore, rodent models 
of parity induced breast tumour protection have revealed that several mediators of 
epithelial proliferation are down regulated, and the tumour suppressor p53 is activated 
prior to carcinogenic insult in the parous gland (Blakely et al., 2006; Sivaraman et al., 
2001a). 
 
The role of progesterone/PR signalling in breast cancer development is less well 
established than that assigned to oestrogen/ER. To support the epidemiological data 
suggesting a role for progesterone in breast cancer initiation, described in Section 1.3.4, 
recent experimental evidence implicates PR in breast cancer development. The use of 
murine models to dissect the individual contributions of ER and PR signalling to 
mammary gland development is discussed in Section 1.2. Using the same PRKO mouse 
model, the importance of progesterone signalling in mammary tumourigenesis was 
identified; PRKO mice showed a lower incidence of breast tumour development 
following treatment with a chemical carcinogen, 15% compared to 60% in wild-type 
mice (Lydon et al., 1999). Culturing of isolated mammary glands from wild-type and 
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PRKO mice again demonstrated a lack of response to chemical carcinogenesis in the 
absence of PR, suggesting that the proliferating structures stimulated by progesterone 
signalling may be the targets for carcinogenesis (Chatterton et al., 2002). Treating mice 
with ER+/PR+ tumours with an antisense oligonucleotide targeting PR, which 
decreased both PR-A and PR-B expression, led to decreased proliferation, increased 
apoptosis and regression of the tumour compared to untreated or control treated animals. 
The effect was similar to that seen with antiprogestin treatment, supporting a role for PR 
in the development and progression of breast cancer (Lamb et al., 2005). 
 
1.3.7 Breast cancer therapies 
Localised breast cancer is treated by removal of the tumour mass by surgery. This 
treatment is frequently performed in combination with radiation, adjuvant chemotherapy 
or endocrine therapy to manage the risk of relapse. Systemic therapies such as 
chemotherapy and/or endocrine therapy are also used to treat metastatic disease 
(Makhoul and Kiwan, 2011; Alvarez, 2010; Conzen, 2008). 
 
Chemotherapeutic drugs affect many pathways of cell growth including cell division 
and DNA synthesis, therefore targeting rapidly dividing cancer cells to a greater extent 
than normal mammary epithelial cells (MEC). Breast cancer chemotherapeutics include 
the alkylating agent cyclophosphamide which is often administered in combination with 
the DNA intercalating antineoplastic drug doxorubicin. These drugs are sometimes 
administered along with a taxane such as paclitaxel which blocks mitosis, or the 
antimetabolite fluorouracil which prevents pyrimidine incorporation during DNA 
synthesis (Berry et al., 2006). 
 
Endocrine therapies used in breast cancer include the targeting of oestrogen/ER 
signalling to block its mitogenic effect on breast cancer cells. Oestrogen is secreted 
from the ovaries in pre-menopausal women, in response to luteinising hormone 
releasing hormone (LHRH). Thus LHRH antagonists can effectively block oestrogen 
secretion in pre-menopausal patients. Aromatase inhibitors (AIs) are used in post-
menopausal patients to block the synthesis of oestrogen from adrenal androgens by 
aromatase enzymes in breast tissue and peripheral fat. Selective ER modulators 
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(SERMs), such as the ER antagonist Tamoxifen, are used to block the action of ER in 
both pre- and post-menopausal patients (Conzen, 2008).  
 
1.3.8 Hormone receptors as breast cancer biomarkers 
The assignment of these endocrine therapies is based on the use of ER as a biomarker, 
i.e. ER+ patients are prescribed the treatments. The ER status of a tumour can also be of 
significance in predicting the outcome of chemotherapy. Meta-analysis of data from 
large clinical trials demonstrated that the outcome of a range of adjuvant 
chemotherapeutic regimes was significantly less for ER+ patients; only a 7% increase in 
5 year disease free survival for ER+ patients over patients not receiving chemotherapy 
was seen, compared to a 22.8% increase for ER- patients (Berry et al., 2006).  
 
Further predictive information for the effectiveness of endocrine therapies can be gained 
from measurement of the PR status of a tumour. Analysis of survival data from two 
large patient cohorts, one containing 5427 patients and the other containing 10444 
patients, compared patients not receiving any adjuvant endocrine therapy with patients 
receiving the SERM tamoxifen. A greater relative risk of recurrence was observed in 
patients with ER+/PR- tumours than ER+/PR+ tumours. The predictive value of PR was 
shown to be independent of the quantitated level of ER present in a tumour, suggesting 
that the difference between response in PR+ and PR- patients is not merely due to PR 
being a surrogate indicator of ER function (Bardou et al., 2003). A clinical trial 
comparing the AI anastrazole with tamoxifen or a combination of the two drugs, the 
Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, demonstrated that 7.6% 
of ER+/PR+ patients receiving the combination therapy suffered relapse compared to 
14.8% of ER+/PR- patients. A similar pattern was also evident in the tamoxifen arm of 
the trial, but not the anastrazole arm, suggesting that the reduced effectiveness of 
endocrine therapies in PR- patients was restricted to SERMs (Cui et al., 2005). However, 
analysis of the time to failure of AI treatment for advanced, metastatic breast cancer in 
146 ER+ patients revealed an increased time in patients who were also PR+ indicating a 
potential role for PR status in the assignment of AI therapies and in considering 
combination therapies containing AIs (Anderson et al., 2011). 
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As well as serving as predictive markers for the outcome of endocrine therapies, 
hormone receptor status can also be used in the assessment of disease prognosis. 
Patients with ER+ tumours have better overall survival than ER- patients. Different 
metastatic sites are common in patients with different ER status of the primary tumour; 
bone and soft tissue in ER+, liver and brain in ER-, with the latter associated with worse 
prognosis (Osborne, 1998). ER+/PR- status is associated with increased metastasis in 
post-menopausal patients (Balleine et al., 1999a). PR status has also been shown to be 
inversely associated with tumour stage, i.e. PR expression is a marker for early stage 
breast cancer but expression is not commonly seen in later stage tumours. This could 
indicate a loss of PR expression during tumour development but could also indicate the 
more aggressive nature of PR- primary tumours, making them more likely to 
metastasise (Coyle et al., 2007). Analysis of the gene expression profile of breast 
tumours demonstrates an up-regulation of genes involved in cancer associated cell 
signalling pathways such as the PI3K/Akt pathway in PR- patients compared to PR+, 
providing a potential mechanism for the increased growth and survival of these cancer 
cells and thus the poorer prognosis of PR- tumours (Creighton et al., 2009). In a 
retrospective study, patients with early stage breast tumours which were only positive 
for one hormone receptor, ER+/PR- or ER-/PR+, were seen to be more likely to suffer 
local recurrence following surgery than ER+/PR+ patients, demonstrating the 
prognostic value of both receptors (Albert et al., 2011).  
 
The role of progesterone signalling via PR as a mammary mitogen, discussed in Section 
1.2, and therefore its potential contribution to the growth of breast cancer cells makes 
PR a potential therapeutic target. Mifepristone is a selective PR modulator (SPRM) 
which has been demonstrated to inhibit the growth of PR+ breast cancer cell lines and to 
inhibit tumour growth in animal models. Mifepristone has also been reported to be 
beneficial in preventing tumour progression in patients, especially when administered in 
combination with a SERM (Im and Appleman, 2010). Three small scale clinical trials 
reported a positive response to mifepristone treatment in approximately 10-12% of post-
menopausal breast cancer patients, either before or after other forms of treatment (Im 
and Appleman, 2010). A rat model of breast cancer development following chemical 
carcinogenesis demonstrated a decrease in tumour size and inhibited growth of new 
tumours following treatment with mifepristone. The same study demonstrated an even 
greater decrease in tumour growth following treatment with another antiprogestin CDB-
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4124, with decreased cell proliferation and increased apoptosis compared to 
mifepristone (Wiehle et al., 2007). The experimental and clinical data described above 
point to the potential benefits of SPRMs as breast cancer therapeutics in hormone 
receptor positive disease and SPRMs could improve response when co-administered 
with current therapies such as SERMs (Im and Appleman, 2010). Due to the predictive 
and prognostic value of PR and its potential as a therapeutic target, accurate assessment 
of PR status is vital in the clinical management of breast cancer patients. 
 
The hormone receptor status of breast tumours is usually measured by 
immunohistochemistry using specific monoclonal antibodies. ERα protein expression 
and total PR (PR-A and PR-B) protein expression are both measured using antibodies 
targeted to N-terminal epitopes. The level of protein expression is quantified either 
visually or more usually by an automated process by which the intensity of staining and 
the number of receptor positive cells is accurately quantified to give a score of 0-8 
(Hanley et al., 2009; Payne et al., 2008). Approximately 70% of primary breast tumours 
are reported to be ER+, more than half of which are also PR+. Of the remaining 30%, 
the majority are ER-/PR-, however a subset (<5%) of tumours appear ER-/PR+ 
(Osborne, 1998). Development of new methods to identify biomarker expression in 
breast cancer is ongoing. One such approach is the use of quantitative real-time PCR 
based assays, with the aim of more accurately and more quickly classifying biomarker 
expression (Iverson et al., 2009). Although endocrine therapies typically target ER 
signalling, patients with tumours characterised as ER-/PR+ respond more favourably to 
these therapies than ER-/PR- patients, indicating the importance of PR expression to the 
treatment of breast cancer (Osborne, 1998). A recent retrospective study of 5053 
patients, analysing the occurrence of ER-/PR+ tumours, which represented 
approximately 3% of all tumours examined, reported an increased occurrence in patients 
over 51 years of age. This non-random distribution suggests that this phenotype is not 
an artificial result of false negative ER status measurements and may be clinically 
relevant (Rhodes and Jasani, 2009). 
 
As mentioned above, HER2 is a breast cancer associated oncogene which is 
overexpressed in approximately 20-30% of breast tumours and these tumours tend to 
have a poor prognosis with a high rate of recurrence and mortality (Slamon et al., 1987). 
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HER2+ status has recently been demonstrated to be a associated with microinvasion in 
patients with DCIS, and is therefore of potential importance in the transition from DCIS 
to invasive ductal carcinoma (Liao et al., 2011). The detection of HER2 in breast cancer 
and its role as a biomarker are reviewed by (Payne et al., 2008). Briefly, the 
pathological detection of HER2 in breast cancer is carried out by immunohistochemistry, 
fluorescence in situ hybridisation or chromogenic in situ hybridisation. HER2 is a 
predictive biomarker for the potential use of trastuzumab (Herceptin), a humanized 
monoclonal antibody which targets HER2 protein, preventing its function and 
stimulating a decrease in HER2 expression, improving the outcome of concurrently 
administered chemotherapy compared to chemotherapy alone. A combined 
HER2/EGFR tyrosine kinase inhibitor has also recently been shown to be effective in 
HER2+ breast cancer. HER2+ tumours may also respond more favourably to some 
chemotherapeutics and predict resistance to endocrine therapies (Payne et al., 2008).  
 
1.3.9 Molecular subtypes for breast cancer management 
Traditional molecular biomarkers can distinguish between tumours with different 
characteristics, however the heterogeneity of breast tumours means that biomarker 
expression is not always accurately predictive of prognosis or therapeutic outcome. 
Advances in molecular biological techniques have enabled the analysis of the gene 
expression profiles of breast tumours. This can then be used to classify the tumour 
according to expression of key groups of genes associated with prognosis and response 
to therapy. Expression levels of genes associated with luminal epithelial cells, such as 
ER, PR, cytokeratin 8/18, and ER regulated genes define the Luminal subtypes; 
Luminal A tumours highly express ER/ER regulated genes and have low expression of 
proliferation related genes such as Ki67, whereas Luminal B tumours have much lower 
ER/ER regulated gene levels and higher proliferation associated gene expression. 
Tumours with high HER2 gene expression and low ER/ER regulated gene expression 
are classified into the HER2 subtype, while tumours negative for HER2 and ER but 
enriched in genes associated with basal epithelial/myoepithelial cells and proliferation 
are classified as Basal-like. The Normal-like breast tumour sub-type was defined by a 
gene expression profile resembling non-epithelial normal breast tissue (Sorlie et al., 
2003; Sorlie et al., 2001; Perou et al., 2000). A further subtype, Claudin-low tumours, 
was more recently suggested, defined as distinct subset of basal-like tumours with 
reduced expression of genes associated with cell-cell adhesion, such as claudins, 
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occluding and E-cadherin an increase in genes associated with epithelial-mesenchymal 
transition and stem cell associated genes (Hennessy et al., 2009). Mutations in the TP53 
tumour suppressor gene are detected at a much higher frequency in luminal subtype B, 
HER2 and basal tumours than in luminal subtype A. Additionally, mutations in BRCA1 
were detected specifically in basal tumours, linking BRCA1 mutations to ER- tumours 
and poor disease prognosis (Sorlie, 2004). The molecular subtypes described above are 
summarised in Table 1.1. 
 
Table 1.1: Molecular subtypes of breast cancer 
Gene expression characteristics defining the molecular sub-types of breast cancer. 
 
These molecular subtypes have been linked to prognostic features of breast tumours 
(Dunbier et al., 2011; Calza et al., 2006). Luminal A were typically small, low grade 
tumours which responded favourably to endocrine therapy as expected of ER+ tumours 
with low levels of proliferation. Luminal B had a poorer disease free survival and 
poorer response to endocrine therapies than Luminal A, consistent with the lower ER 
expression predicted from the gene expression profiling. Tumours in the HER2 subtype 
were usually large, high grade tumours which were ER- and consequently showed 
limited response to endocrine therapy and had a poor overall prognosis. Basal-like 
tumours were also high grade and were associated with lymph node metastases, 
however they were associated with better disease free survival than the HER2 subtype. 
Tumours classified in the Normal-like subtype were small, low grade and responded 
well to endocrine therapies (Calza et al., 2006). These observations were supported by a 
recent study which identified a similar initial response to AI therapy between Luminal 
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A and Luminal B, however high residual Ki67 staining in Luminal B tumours after 2 
weeks of treatment were indicative of a poorer response to therapy. HER2 and Basal-
like tumours showed little response to initial AI therapy while Normal-like tumours 
responded well (Dunbier et al., 2011). 
 
As described, the most favourable prognosis is found in tumours which are ER+, PR+ 
and HER2-, since these tumours are the least proliferative and likely to respond well to 
endocrine therapies (Calza et al., 2006). ER+/PR- disease is associated with a worse 
prognosis and poorer response to endocrine therapies (Dowsett et al., 2005; Balleine et 
al., 1999a). HER2+ tumours are associated with a poor prognosis but can be effectively 
treated with Herceptin (Payne et al., 2008). Tumours which are ER-/PR- and HER2-, 
termed ‘triple negative’, mostly characterised in the Basal-like molecular sub-type, have 
been shown by retrospective analysis of breast cancer patients to be associated with 
poor disease free survival, increased lymphatic invasion and more lymph node 
metastasis (Mersin et al., 2008; Calza et al., 2006). Analysis of the molecular phenotype 
of tumours is in its early stages but may play a significant role in the future to accurately 
predict the characteristics of a tumour and assign appropriate therapies, as well as 
revealing potential novel therapeutic targets. However, the prognostic and predictive 
value of ER, PR and HER2 is clearly of great importance. The role of hormone 
receptors in breast cancer development and progression, particularly the role of PR, will 
therefore be addressed and is the focus of this thesis. 
 
1.3.10 PR isoforms in breast cancer 
The ratio of PR isoform expression is altered early in breast cancer development; in the 
normal mammary gland PR-A and PR-B are expressed in the same cells at 
approximately equimolar levels (Graham et al., 1995), whereas in pre-cancerous 
atypical hyperplasia and DCIS, as well as in invasive breast cancers, a loss of this 
homogenous PR isoform expression is observed, with a predominance of PR-A over 
PR-B (Mote et al., 2002), which is due to a reduction in the level of PR-B expression 
(Mote et al., 2002; Graham et al., 1995). Analysis of gene expression in PR positive 
T47D breast cancer cells demonstrated that a number of genes became progestin 
responsive following induced over-expression of PR-A. Many of these genes were 
involved in cell morphology and adhesion, and cells after PR-A induction showed 
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decreased adhesion in mono-layer culture and altered focal adhesion protein expression, 
suggesting an influence on cell mobility (Graham et al., 2005). The altered growth in 
response to a change in PR isoform expression has been demonstrated using transgenic 
mice overexpressing PR-A which exhibit a hyperplastic phenotype similar to the early 
stages of breast cancer development (Shyamala et al., 1998). PR-A transgenic mice 
contain a population of mammary epithelial cells undergoing excessive proliferation 
which express elevated levels of cyclin-D1 and decreased expression of p21, a cyclin 
dependent kinase inhibitor which prevents cyclin-D1 mediated activation of the cell 
cycle (Chou et al., 2003). Transforming growth factor beta-1 (TGF)β1 maintains MEC 
quiescence in the adult gland, and decreased TGFβ1 expression is seen in PR-A 
transgenic mice facilitating the increased proliferation. Increased matrix metalloprotease 
activity is also observed in PR-A transgenic mice and is associated with decreased 
laminin and collagen expression and breakdown of the basement membrane, another 
feature of cancer development (Simian et al., 2009). Inhibiting ER signalling in this 
model using a synthetic antagonist decreased proliferation and hyperplasia, whereas a 
PR antagonist had no effect. Oviarectomy of PR-A transgenic mice, to remove both 
oestrogen and progesterone stimulation, led to decreased proliferation. Co-
administration of oestrogen and progesterone to intact PR-A transgenic mice stimulated 
a much greater incidence of hyperplasia compared to either hormone individually, 
implicating both hormones, and the ratio of PR isoform expression in regulating 
mammary epithelial proliferation (Simian et al., 2009). Post menopausal women treated 
with tamoxifen showed an increased rate of relapse if they exhibited a predominance of 
PR-A over PR-B relative to other PR+ patients. Thus identification of the PR-A:PR-B 
isoform ratio may add value to PR status as a predictive marker for use of endocrine 
therapies in ER+/PR+ breast cancer (Hopp et al., 2004). 
 
1.3.11 PR signalling in breast cancer 
A study using DNA microarray screening of changes in gene expression levels in T47D 
breast cancer cells following progesterone treatment identified several progesterone 
responsive genes encoding proteins associated with the processes of breast cancer 
development or progression (Richer et al., 2002). PR signalling via PR-B has been 
demonstrated in vitro to activate transcription of Wnt-1 which mediates EGFR 
activation, in turn activating the Src/Erk signalling pathway to increase cyclin-D1 
expression. This progesterone induced, PR-B dependent, activation of non-PRE 
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signalling was capable of inducing colony formation of T47D breast cancer cells in 3D 
culture, a feature analogous to tumour formation, and is a potential mechanism for PR+ 
breast tumour growth (Faivre and Lange, 2007). Decreased Erk1 and Erk2 
phosphorylation was observed in mammary tumours of mice following treatment with 
mifepristone or antisense oligonucleotides targeted to knockdown PR expression. Upon 
treatment, regression of the tumours was observed implicating this non-genomic PR 
signalling pathway in the maintenance of mammary tumours (Lamb et al., 2005). Direct 
interaction of PR with c-Src has been demonstrated in vitro (Boonyaratanakornkit et al., 
2001) and this interaction was demonstrated to activate MAPK and PI3K 
(Boonyaratanakornkit et al., 2007; Carnevale et al., 2007). Progestin treatment of mice 
injected with murine breast cancer cells transfected with PR-B resulted in formation of 
lung metastases. However mutation of the N-terminal Src binding domain of the 
transfected PR resulted in a reduction of progestin induced lung metastases, 
demonstrating the importance of PR as a non-genomic signal transducer, rather than as 
a transcription factor, in the development of a metastatic phenotype in PR+ breast 
cancer (Carnevale et al., 2007). 
 
During normal mammary gland development in a rat model, a population of 
proliferating PR-B positive cells was detected during pregnancy, expressing cyclin-D1 
(Kariagina et al., 2007). It is proposed that hormone receptor positive MECs may 
function as a stem cell population, since they are usually quiescent and show the ability 
to differentiate upon the correct stimulus (Clarke, 2005). Therefore, these long living 
cells may be the targets of accumulated mutations necessary for tumourigenesis (Faivre 
and Lange, 2007). Consistent with this hypothesis is the suggestion that parity induces a 
shift from a transformation susceptible stem cell 1, to a transformation refractory stem 
cell 2, meaning that earlier parity would give less time for accumulation of mutations 
which can lead to transformation (Russo et al., 2005). It was therefore suggested that an 
accumulation of transformation inducing mutations in this PR+ MEC population, such 
as a loss of p53, p21 or p27 expression can re-activate proliferation, contributing to 
development of PR positive breast tumours (Faivre and Lange, 2007).  
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1.3.12 PR and growth factor signalling cross-talk in breast cancer 
PR phosphorylation at Ser348 was demonstrated to be dependent on functional EGFR 
and leads to increased PR transcriptional activity at non-PRE promoters (Faivre et al., 
2008). EGFR activation also induced the phosphorylation of PR Ser294 which induced 
hypersensitivity to ligand, increasing ligand dependent down-regulation of PR protein 
levels. PR Ser294 phosphorylation was necessary for efficient cell proliferation 
following EGFR activation by EGF (Daniel et al., 2007). Overactivation of EGFR 
would therefore potentially cause hyperproliferation of PR+ cells. TGF-α is an EGFR 
ligand and TGF-α transgenic mice are susceptible to the formation of ER+/PR+ 
mammary hyperplasia, which develop into ER+/PR- tumours, perhaps due to growth 
factor induced PR hypersensitivity and ligand-dependent PR downregulation (Rose-
Hellekant et al., 2007).  
 
HER2 is closely related to EGFR, and HER2 signalling is mediated in part via the Stat 
family of transcription factors (Yarden, 2001). As previously described, progesterone 
activated PR can interact directly with Stat3, leading to activation of Stat3 regulated 
gene expression (Proietti et al., 2005). Heregulin is a HER2 ligand which transactivates 
PR independent of progesterone by phosphorylation of PR Ser294 through activation of 
downstream MAPKs. Blocking PR activity prevents Stat3 activation by heregulin which 
is required for heregulin induced cell proliferation (Proietti et al., 2009).  
 
Fibroblast growth factor receptors (FGFR) are another family of cell surface receptors 
with tyrosine kinase activity which activate intracellular signal transduction pathways, 
activating transcription by Stat5. Co-immunoprecipitation demonstrated that both 
progestin and fibroblast growth factor (FGF)2 stimulated formation of complexes 
containing PR along with both FGFR2 and Stat5, and immunofluorescent analysis 
showed nuclear co-localisation of these proteins. These complexes were able to interact 
with PRE of endogenous genes and increase gene expression in response to FGF2 and 
PR. Blocking PR activity blocked FGF2 stimulated proliferation of T47D breast cancer 
cells transfected with FGFR2. T47D cells normally require exogenous hormone 
stimulation to form tumours when transplanted into mice, however transfection with 
constitutively active FGFR2 led to hormone independent tumour formation. The nuclear 
co-localisation of PR with FGFR2 and Stat5 was also reported in some human breast 
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tumour samples (Cerliani et al., 2011). This cross talk between PR and growth factor 
signalling could provide a mechanism by which progesterone signalling via PR 
contributes to the development of breast tumours, and also may implicate PR in 
enabling the development of hormone independent tumours which grow in response to 
growth factors secreted by other cells within the tumour microenvironment such as 
cancer associated fibroblasts.  
 
1.3.13 Ligand independent PR signalling in breast cancer 
CDKs contribute to the regulation of cell cycle progression and are frequently activated 
in cancer due to alterations in tumour suppressor and oncogene expression (Caldon et 
al., 2010).  CDK2 is capable of phosphorylating PR Ser400 and activating transcription 
of PRE genes independent of progesterone (Pierson-Mullany and Lange, 2004). Gene 
expression levels were assessed in PR negative T47D-Y cells and compared to T47D 
cells specifically expressing either PR-A or PR-B in either the presence or absence of 
external progesterone stimulation. In this system PR-A was demonstrated to be the 
predominant regulator of transcription in the absence of progesterone treatment 
compared to PR-B (Jacobsen et al., 2005). The genes regulated in the absence of 
progesterone treatment were involved in many aspects of tumour cell biology including 
adhesion, motility, migration, signal transduction, cell cycle progression and apoptosis. 
ER+/PR-A+ T47D cells exhibit increased adhesion to extra cellular matrix when 
cultured on matrigel or collagen, and increased migration towards a chemoattractant 
through transwells coated with collagen compared to ER+/PR-B+ or ER+/PR- T47D 
cells, characteristics indicative of an aggressive tumour phenotype (Jacobsen et al., 
2005). These ligand independent, PR-A mediated effects on cell behaviour may 
contribute to the poorer outcome of tamoxifen therapy in post-menopausal patients with 
an overexpression of PR-A relative to PR-B (Hopp et al., 2004). 
 
Phosphorylation of the PR-B specific Ser81 has been linked to the activation of PR-B 
responsive genes including the breast cancer proliferation associated gene HSD11β2. 
Basal gene activation required Ser81 phosphorylation, as did response to ligand. Ser81 
phosphorylation is mediated by casein-kinase (ck)2, and ck2 is widely upregulated in 
breast cancer. Therefore, this ck2 overexpression could lead to ligand independent 
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Ser81 phosphorylation and activation of transcription, contributing to hormone 
independent growth of receptor positive breast tumours (Hagan et al., 2011). 
 
1.3.14 Interaction of PR with BRCA1/2 
BRCA1/2 mutations are the most common inherited mutations associated with breast 
cancer development, and BRCA1/2 mutations have been shown to disrupt the normal PR 
expression ratio leading to a predominance of PR-A over PR-B (Mote et al., 2004). 
Transfection of BRCA1 into PR+ breast cancer cells reduced progestin induced 
luciferase reporter gene activity and a direct interaction of BRCA1 with both PR-A and 
PR-B was shown by co-immunoprecipitation (Ma et al., 2006). Further studies used gel 
shift assays to demonstrate that BRCA1 inhibits PR action by blocking PR binding to 
PRE, and chromatin immunoprecipitation demonstrated that BRCA1 blocked 
recruitment of PR co-activators and promoted recruitment of co-repressors to PRE 
(Katiyar et al., 2009). Mice containing a BRCA1 mutation encoding a functionally 
deficient protein undergo increased MEC proliferation in response to progesterone 
compared to wild-type mice, demonstrating that mutating BRCA1 removes control over 
PR signalling (Ma et al., 2006). Inactivation of both BRCA1 and p53 in mice, to mimic 
the genetic deficiencies in human BRCA1 mutation associated tumours, resulted in 
increased progesterone induced lobular proliferation and increased tumour formation 
compared to wild-type mice. Treatment with mifepristone completely blocked tumour 
formation, demonstrating the contribution of PR signalling to breast cancer 
development in BRCA1 deficient mice (Poole et al., 2006). These results support the 
use of anti-progestins in BRCA1 mutation carriers as prophylactics in an attempt to 
prevent breast cancer development, or in treating PR+ tumours in pre-menopausal 
BRCA1 mutation carriers (Katiyar et al., 2006). 
 
1.3.15 Potential mechanisms of PR loss in breast cancer 
Since PR is an oestrogen responsive gene (Kastner et al., 1990), it has been suggested 
that loss of PR expression could be due to the low circulating oestrogen levels in post-
menopausal women being insufficient to stimulate PR expression, or that a non-
functional ER may be expressed in breast cancer which may be unable to bind DNA and 
activate transcription. However, ER from fresh tumour biopsies has been demonstrated 
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to bind DNA, making this an inadequate explanation of PR loss (Cui et al., 2005). 
Blocking ER activity with endocrine therapeutics may prevent PR transcription and 
tumours which initially screen PR+ often appear PR- on subsequent analysis following 
tamoxifen treatment (Gross et al., 1984).  
 
PR- primary breast tumours can develop, for example by the mechanisms described in 
the TGF-α transgenic mouse model, via cross talk of PR with overactive growth factor 
signalling pathways hypersensitising PR to progesterone and leading to ligand-
dependent down-regulation (Rose-Hellekant et al., 2007). Indeed HER2 overexpression 
in breast cancer is more common in ER+/PR- tumours than ER+/PR+, so perhaps the 
increased growth factor signalling leads to decreased PR expression, leading to PR- 
tumours (Arpino et al., 2005). Thus the prevalence of growth factor stimulated cell 
growth may provide an explanation for the tamoxifen resistance of PR- tumours since 
they may no longer rely on oestrogen/ER for mitogenic stimulus (Cui et al., 2005). 
Growth factor signalling may also interact with ER and alter its function as a 
transcription factor, potentially affecting PR expression, and promoting non-genomic 
ER signalling. This switch may affect the ability of tamoxifen to function as an ER 
antagonist, again implicating growth factor signalling in both PR loss and tamoxifen 
resistance in PR- tumours (Cui et al., 2005). This interaction of ER and growth factor 
signalling in mediating the loss of PR expression in breast cancer highlights the 
importance of PR as a predictive marker for tamoxifen use; PR- status may reflect ER+ 
tumours in which excessive growth factor signalling alters ER activity or circumvents 
the requirement for ER activation, rendering cells resistant to tamoxifen. 
 
Loss of heterozygosity (LOH) mutations on chromosome 11q, which are observed at an 
increased frequency in breast cancer, may act to prevent high levels of PR expression, 
since the PR gene is located on chromosome 11q22 (Tomlinson et al., 1996). In ovarian 
cancer an aggressive phenotype is also associated with LOH at chromosome 11q22 
(Launonen et al., 1998). Promoter hypermethylation is an epigenetic mechanism of gene 
silencing by which a methyl group is added to cytosine/guanine rich sequences within 
the promoter to either block the assembly of the transcriptional machinery or remodel 
chromatin to stable conformations which cannot be transcribed (Lapidus et al., 1996). 
Hypermethylation of the PR promoter has been frequently observed in breast cancer; 
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40% of PR- breast tumours showed PR promoter methylation which was not seen in 
PR+ tumours or normal breast tissue (Lapidus et al., 1996). PR-B promoter 
hypermethylation was later detected in 76% of breast tumours, and has been 
demonstrated to be linked to PR- tumour status and a number of associated poor 
prognostic features (Mc Cormack et al., 2008). Another study identified 13 breast 
tumours showing full promoter hypermethylation, of which 7 showed a loss of PR-B 
protein, and 19 tumours showing partial methylation, of which 9 showed reduced or lost 
PR-B expression (Mirza et al., 2007).  
 
The use of alternative promoters either within the normal PR mRNA sequence, such as 
PR-C described in Section 1.1.8, or promoters resulting from alternative splicing of PR 
pre-mRNA could lead to the generation of truncated PR isoforms which are not 
detectable by current screening methods which target N-terminal epitopes (Cork et al., 
2008). The alternative splicing of PR pre-mRNA and its potential impact in breast 
cancer will be discussed later in this thesis (Section 1.4.11). 
 
As described in Sections 1.3.5, 1.3.6 and 1.3.10-1.3.13, progesterone signalling via PR 
plays a role in the development of breast cancer. Furthermore, the role of PR as a breast 
cancer biomarker is also described above with PR- tumours associated with poor 
prognosis and poor response to endocrine therapy. Understanding the mechanisms 
involved in the loss of PR expression is therefore vital since, as described in this section, 
PR loss may be a result of cancer associated changes in cell signalling, representing a 
shift in the mitogenic signals stimulating proliferation of cancer cells. Alternatively a 
loss of PR expression may represent a lost mechanism of control over tumour growth in 
PR negative tumours. 
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1.4 Alternative pre-mRNA splicing 
1.4.1 Pre-mRNA splicing 
Splicing is the RNA processing event by which non-coding intragenic sequences, 
introns, are removed from the pre-mRNA transcript and the exons ligated to form the 
mature protein coding mRNA. Pre-mRNA splicing requires recognition of a 5′ splice 
site between the upstream exon and the intron and a 3′ splice site between the intron and 
the downstream exon, followed by cleavage of the splice sites to remove the intron and 
ligation of the exons. Early reports demonstrated that multi-protein complexes 
containing small nuclear RNAs, termed small nuclear ribonucleoprotein particles 
(snRNPs), termed U1, U2, U4, U5 and U6, could be detected in association with RNA 
at each stage of the splicing reaction and that preventing snRNP function prevented 
splicing, suggesting involvement of a multiprotein complex in the splicing reaction 
(reviewed by (Padgett et al., 1986). 
 
Recognition of the 5′ splice site downstream of an exon requires sequence 
complementarity of an AG|GUA/GAGU nucleotide sequence at the upstream 
exon/intron boundary with the U1 snRNP. Recognition of the 3′ splice site requires 
cooperative binding of the large subunit of the U2 auxiliary factor, U2AF65, to a 
pyrimidine rich sequence known as the polypyrimidine tract (PPT) adjacent to the AG 
dinucleotide at the 3′ end of the intron, U2AF35 to the 3′ splice site AG, and splicing 
factor 1 (SF1) with the branch point sequence which contains a conserved adenosine 
and is located approximately 100 nucleotides upstream of the 3′ splice site. The binding 
of U2AF at the 3′ splice site and U1 at the 5′ splice site forms the early (E) complex, 
committing the splice sites to the splicing reaction. U2AF and SF1 recruit U2 snRNP to 
the branch point sequence (BPS), forming the A complex. The U4/U6-U5 tri-snRNP 
then binds to form the B complex and following binding rearrangements U1 is replaced 
at the 5′ splice site by U6 which interacts with U2 and dissociates from U4. Release of 
U1 and U4 forms the catalytically active pre-spliceosomal B* complex which catalyses 
the transesterification of the 5′ splice site G (highlighted in bold above) by the branch 
point adenosine, thus cleaving the upstream exon from the looped intron/downstream 
exon, termed the lariat. The mature spliceosomal C complex is then formed and 
catalyses the second transesterification reaction, of the 3′ splice site G by the 3′ 
hydroxyl group of the upstream exon, excising the intron lariat and ligating the exons 
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(McManus and Graveley, 2011; Jurica et al., 2002; Makarov et al., 2002; Berglund et al., 
1998; Staley and Guthrie, 1998). 
 
Each stage of spliceosome formation and rearrangement subsequent to the E complex is 
ATP dependent and relies on the ATPase activity of spliceosome associated proteins 
(Staley and Guthrie, 1998). Mass spectrometric analysis of spliceosomal complexes 
purified from HeLa cell extract has revealed in excess of three hundred proteins 
associated with the spliceosome. Some of these are core snRNP proteins, some have 
essential functions such as mediating/remodelling snRNA/mRNA interactions or 
ATPase activity and some have as yet unclear roles but associate with spliceosomes in 
vitro (Bessonov et al., 2008; Jurica and Moore, 2003; Makarov et al., 2002; Zhou et al., 
2002).  
 
1.4.2 Splice site selection 
As described above, initial splice site selection involves the binding of U1 to the 5′ 
splice site and U2AF to the PPT and 3′ splice site. This process defines the exon by 
committing the upstream 3′ splice site and downstream 5′ splice sites to spliceosome 
formation (Berget, 1995). Recruitment of U1 and U2AF involves interaction with trans-
acting regulatory RNA binding proteins, termed splicing factors, which bind to cis-
acting regulatory sequences within the pre-mRNA. These regulatory elements either 
enhance or silence splicing, and can be located within exons or introns, thus they are 
referred to as either exon/intron splicing enhancers (ESE/ISE) or exon/intron splicing 
silencers (ESS/ISS), with their function being determined by the range of splicing 
factors which recognise and bind to the sequences and the location within the pre-
mRNA. The presence of competing cis-elements and the balance of expression of 
splicing factors therefore combine to determine splice site selection and the pattern of 
alternative splicing (reviewed by (Hertel, 2008; Matlin et al., 2005). 
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1.4.3 Serine/arginine rich (SR) proteins 
SR proteins are a family of splicing factors which bind to ESEs via N-terminal RNA 
recognition motifs (RRM) and contain a C-terminal arginine/serine rich (RS) domain, 
which mediates protein/protein interactions (Long and Caceres, 2009; Shepard and 
Hertel, 2009). SR protein family members were initially named based on their function 
or approximate molecular weight, and a group of classical SR proteins which were 
detectable by a phospho-specific antibody was identified. Additional SR-proteins were 
also identified and proteins with similar structures were termed SR-related proteins 
(SRrp) (Long and Caceres, 2009; Shepard and Hertel, 2009). The structure of the seven 
classical SR proteins and three SR-related proteins is illustrated in Figure 1.6. A new 
system of nomenclature has recently been proposed, defining SR proteins as containing 
at least one N-terminal RRM or RRM homology (RRMH) domain and a C-terminal RS 
domain of at least 50 nucleotides consisting of at least 40% R/S or S/R dinucleotides. 
Under this new system the classical SR proteins and SR-related proteins depicted in 
Figure 1.6 are renamed, along with two additional SR-related proteins which are re-
classified as SR proteins. The new system terms the proteins, and the genes which 
encode them, as SR splicing factors (SRSF), and the proteins/genes are numbered based 
on the order of discovery (Manley and Krainer, 2010). This new nomenclature will be 
used for the remainder of this thesis and the new protein/gene names are listed, along 
with the traditional terminology for both genes and proteins, in Table 1.2. 
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Figure 1.6: Schematic representation of the domain structure of human SR proteins. 
RRM: RNA recognition motif; RRMH: RRM homology; Z: zinc knuckle; RS: argenine/serine-
rich domain. Figure adapted from (Graveley, 2000). 
 
 
 
 
 
 
Table 1.2: Comparison of old and new nomenclature for SR proteins. 
Table adapted from (Manley and Krainer, 2010). 
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Initial splice site recognition is thought to occur across an exon, in a process termed 
‘exon definition’ in which U2AF binds to the upstream 3′ splice site and U1 to the 
downstream 5′ splice site either side of an exon (Berget, 1995). Addition of individual 
SR proteins (SRSF1, SRSF2 or SRSR6) to a splicing reaction mixture of nuclear extract 
and pre-mRNA was sufficient to commit the substrate to splicing, implicating SR 
proteins in initial splice site selection (Fu, 1993). Yeast two-hybrid screening revealed 
interaction of SRSF1 and SRSF2 with both U2AF35 and the U1 protein U1-70k (Wu 
and Maniatis, 1993) and interaction of the RS domains of SRSF6 or SRSF7 were later 
demonstrated to be required for recruitment of U2AF65 to a weak PPT which was 
dependent on U2AF35 (Graveley et al., 2001). Therefore, a model of SR protein 
involvement in normal splice site recognition is that SR proteins bound to ESEs recruit 
U2AF and U1 to splice sites during E complex formation. Furthermore SR proteins 
interacting with U2AF35 can strengthen a 3′ splice sites with a weak PPT by stabilising 
U2AF65 binding (Graveley et al., 2001). The reported interactions of ESE bound SR 
proteins with U1 and U2AF may also occur across introns after initial splice site 
recognition to bring distant 5′ and 3′ splice sites into proximity for pairing during 
spliceosome assembly in order to ligate upstream and downstream exons (Long and 
Caceres, 2009). 
 
SR proteins have also been reported to be involved in spliceosome formation after 
initial splice site selection. Spliceosome assembly from purified A complex and U4/U6-
U5 tri-snRNP required the addition of SRSF1, SRSF2, SRSF4, SRSF5 or SRSF6. This 
function of SR proteins was reliant on phosphorylation of the RS domain and suggests 
an interaction of the SR proteins with the tri-snRNP components to stabilise tri-snRNP 
binding to the 5′ and 3′ splice site (Roscigno and Garcia-Blanco, 1995). The 
requirement for SRSF1 or SRSF7 to mediate efficient splicing of an mRNA construct 
containing only 1-3 nucleotides of exon indicated that SR proteins could also function 
independent of ESE binding, and the requirement for a functional RRM to mediate this 
splicing suggested interaction with intronic sequences (Hertel and Maniatis, 1999). The 
RS domain of SRSF1 has since been reported to interact with the branch point in the A 
complex and to interact with the 5′ splice site and facilitate U6 binding during 
spliceosome maturation, suggesting a potential mechanism of SR protein dependent tri-
snRNP recruitment and demonstrating the importance of SR proteins in all stages of the 
splicing reaction (Shen and Green, 2004; Shen et al., 2004). 
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1.4.4 Alternative pre-mRNA splicing 
Alternative splicing is the differential removal of exons or retention of introns during 
pre-mRNA splicing, generating different mRNAs which encode structurally and 
functionally distinct protein isoforms. This process allows the generation of protein 
diversity from a relatively compact genome (Nilsen and Graveley, 2010) and it is 
estimated that approximately 95% of multi-exon genes may undergo alternative splicing 
(Pan et al., 2008). This enables the tissue specific or developmentally regulated 
expression of functionally different proteins by alterations in splicing patterns, and 
facilitates response to changes in external stimuli (Moroy and Heyd, 2007; Stamm, 
2002). Changes in the pattern of alternative splicing can also contribute to disease 
development which will be discussed in Section 1.4.7 (reviewed by (Caceres and 
Kornblihtt, 2002). 
 
Spliceosome formation, as described above, requires the interaction of spliceosome 
component snRNPs with splicing factors to direct recruitment to the 5′ and 3′ splice 
sites. In addition to splice sites at constitutive exon/intron boundaries, alternative splice 
sites can exist within exons and introns, or exons may exist with weak splice sites which 
are not normally used (Solis et al., 2008; Kanopka et al., 1996). Silencing of splice sites 
can lead to exon skipping (Figure 1.7b) (Solis et al., 2008). The deletion of an exon 
often causes a change in reading frame and premature termination of translation. 
However a cassette exon is an exon which can be deleted without causing a change in 
reading frame (Richer et al., 1998). Multiple exons can be deleted from a pre-mRNA by 
alternative splicing, allowing further diversity of protein generation (Springwald et al., 
2010). Mutually exclusive exons also exist, whereby one exon is retained and one 
deleted, but never both retained or deleted, generating two different isoforms (Jumaa 
and Nielsen, 1997) (Figure 1.7c). Cassette exonic sequences with weak splice sites can 
also exist within introns and can be retained upon activation of the weak splice sites 
(Pollard et al., 2002) (Figure 1.7d). Silencing of constitutive splice sites either side of an 
intron can lead to retention of the intronic sequence (Figure 1.7e). Weak cryptic splice 
sites can exist within an exon or intron (Balleine et al., 1999b); activation of splicing at 
a cryptic 5′ splice site within an exon would lead to deletion of the 3′ end of the 
upstream exon, and an alternative 3′ splice within an exon would lead to deletion of the 
5′ end of the downstream exon (Figure 1.7f). Cryptic splice sites can also exist within an 
intron leading to retention of parts of the intronic sequence. 
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Figure 1.7: Patterns of constitutive and alternative splicing. 
a) Constitutive splicing; the removal of introns and ligation of exons. b) Exon skipping; 
silencing of constitutive splice sites upestream and downstream of exon 2 leading to removal of 
the exon and ligation of exon 1 to exon 3. c) Exons 2 and 3 are mutually exclusive; either exon 
2 or exon 3 is always removed generating two distinct mRNAs. d) Cryptic exons within intronic 
sequences; exon 2a is normally reomved along with intron 2, activation of the weak splice sites 
flanking exon 2a leads to its inclusion in the mRNA. e) Intron retention; silencing of the 5′ 
splice site downstream of exon 2 and the 3′ splice site upstream of exon 3 leads to the inclusion 
of intron 2 in the mRNA. f) Cryptic splice sites; activation of a weak 5′ splice site within exon 2 
leads to deletion of the 3′ end of the exon. Activation of a weak 3′ splice site within exon 3 leads 
to the deletion of the 5′ end of exon 3.  
 
1.4.5 Non-sense mediated decay 
Deletion of exonic sequences or retention of intronic sequences often disrupts the 
normal reading frame and the mRNA therefore contains a premature translational 
termination codon (PTC) which makes the mRNA a target for degradation by non-sense 
mediated decay (NMD) (Nicholson et al., 2010). An estimated one third of all 
alternatively spliced mRNA are degraded in this way which serves to protect cells from 
the deleterious effects that may be associated with alternatively translated proteins 
(Lewis et al., 2003). NMD is a pathway by which non-sense mRNA resulting from non-
sense mutations which generate a PTC and nucleotide insertions or alternative pre-
mRNA splicing which cause a change in reading frame is degraded. PTCs are 
recognised by a complex of proteins which catalyse mRNA degradation (Nicholson and 
Muhlemann, 2010). During splicing, a multi-protein complex is added approximately 
20-24 nucleotides upstream of the exon/exon junction, termed the exon junction 
complex (EJC). This complex functions in nuclear export of the mRNA and translation. 
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The 5′ end of a nascent mRNA becomes associated with the cap-binding complex (CBC) 
and the 3′ end is polyadenylated. During the initial round of translation ribosomes move 
along the mRNA, displacing the EJCs until they encounter a termination codon, upon 
which they stall and eukaryotic poly-peptide release factor (eRF)3 interacts with the 
poly-A binding protein (PABP) which mediates polypeptide release from the ribosome. 
The CBC is then replaced by eukaryotic initiation factor which appears to protect 
mRNA from NMD (Gardner, 2010). The exact mechanisms by which NMD targeted 
mRNAs are recognised and degraded have not been fully elucidated but current 
understanding is reviewed by (Nicholson et al., 2010); when the ribosome encounters a 
PTC, the interaction of eRF3 with PABP is less efficient due to the increased distance 
from the poly-A sequence allowing distinction to be made between normal and 
premature termination codons. The presence of EJCs downstream of the PTC and the 
long 3′ UTR which is associated with a PTC also appear to promote NMD. The 
interaction of the ribosome with PABP is further inhibited by binding of the essential 
trans-acting NMD factor RENT1 with eRF3. RENT1 is then phosphorylated by RENT2 
and this phosphorylation mediates binding of RENT1 to SMG proteins which stimulate 
mRNA degradation (Nicholson et al., 2010). An example of alternative splicing 
resulting in a PTC and targeting of the mRNA for NMD is the gene encoding murine 
exportin 4 which contains an exon which is alternatively included in adult and 
embryonic tissue, inclusion of which introduces a PTC. Exportin 4 is involved in the 
nuclear import/export of factors essential for embryonic development and the exon is 
preferentially included in adult tissue but excluded in embryonic tissue. The PTC 
introduced by exon inclusion was demonstrated to induce NMD, thereby regulating 
protein expression in different developmental states through coupling of alternative 
splicing and NMD (Barash et al., 2010). The expression and function of NMD factors is 
regulated in response to cellular stresses such as hypoxia and generation of reactive 
oxygen species which are common in cancer and function to inhibit NMD. In the 
absence of NMD, mRNA containing a PTC may be able to encode proteins in cancer 
cells with functions which differ from the normal protein (Gardner, 2010). 
 
1.4.6 Regulation of alternative pre-mRNA splicing 
The binding of SR proteins to ESEs in proximity to weak splice sites can lead to 
selection of the weak splice site; SR proteins can enhance recruitment of U1 to a poor 
consensus 5′ splice site, or stabilise the interaction of U2AF65 to a short PPT at a weak 
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3′ splice site (Graveley et al., 2001). Whilst SR proteins usually function as splicing 
enhancers, this function is dependent on the context of the sequence to which they are 
bound. For example SRSF1, SRSF2 and SRSF6 bind to an ISS sequence close to a 
weak 3′ splice site in an adenovirus mRNA to repress splicing by preventing the binding 
of U2 snRNP. The function of this SR protein binding sequence was switched to a 
splicing activator when moved to an exonic context and similarly an ESE sequence 
became inhibitory when moved to an intron, demonstrating the importance of the 
context in which an SR protein binds to pre-mRNA in determining its function as a 
splicing regulator (Kanopka et al., 1996). Silencing of a proximal 3′ splice site in an 
mRNA construct resulted in suppression of a distal 3′ splice site by downstream ESE 
sequences, and when these sequences were moved to an intronic context, again they 
repressed splicing. This repression of splicing was reliant on SR protein (SRSF2/SRSF7) 
binding, supporting the earlier observation of context dependent SR protein function 
(Ibrahim et al., 2005). As well as demonstrating that SR proteins can function as both 
enhancers or silencers of splicing depending on context, this latter study also reported 
that the binding of SR proteins to ESE sequences prevents exon skipping by both 
activating proximal and silencing distal 3′ splice sites (Ibrahim et al., 2005). 
 
The effect of SR proteins as splice site enhancers is opposed by heterogenous 
ribonucleoprotein (hnRNP) A1, as demonstrated by co-transfection of the adenovirus 
E1A gene into HeLa cells along with either hnRNP A1 or SRSF1 cDNA. hnRNP A1 
overexpression favoured distal 5′ splice site selection whereas SRSF1 overexpression 
favoured proximal 5′ splice site selection (Caceres et al., 1994). hnRNP A1 has been 
demonstrated to bind non-specifically to pre-mRNA and prevent U1 binding to 5′ splice 
sites by competitive inhibition, a role opposing that described above for SR proteins. 
Therefore another mechanism by which SR proteins are required for splice site selection 
and spliceosome formation is by removing the hnRNP block of U1 binding. Prevention 
by hnRNP A1 of U1 recruitment by SR proteins may result in the use of upstream, 
intron distal, 5′ splice sites (Eperon et al., 2000). High affinity binding of hnRNP A1 to 
a specific ESS sequence in exon 3 of HIV-1 tat pre-mRNA enhanced hnRNP binding to 
other exonic sequences and prevented splicing in HeLa cell extracts. Depleting extracts 
of hnRNP A/B proteins activated splicing and addition of SRSF1 but not SRSF2 to 
hnRNP A1 supplemented S100 could restore splicing, demonstrating both that SRSF2 
binding is inhibited by hnRNP A1, and that SRSF1 can out compete hnRNP A1 for 
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binding to the pre-mRNA preventing splicing inhibition, again demonstrating a 
mechanism for the antagonistic properties of hnRNP A1 and SR proteins (Zhu et al., 
2001). This antagonistic function is again demonstrated by the altered inclusion of exon 
3 of the gene encoding the G-protein GαS upon overexpression of SRSF1 or hnRNP A1 
in HeLa or myometrial smooth muscle cells, which promoted proximal or distal 5′ 
splice site selection, respectively (Pollard et al., 2002).  
 
The mechanisms by which individual SR proteins mediate splice site recognition and 
spliceosome formation appear to be similar in the in vitro studies described above and 
there appears to be a degree of functional redundancy among SR family members. 
SRSF2, SRSF4, SRSF5 or SRSF6 could all restore the splicing of human β-globin pre-
mRNA in splicing deficient HeLa cell extract, S100 (Zahler et al., 1993). siRNA 
knockdown of the genes encoding five SR proteins in C. elegans resulted in embryonic 
lethality, whereas knocking down individual SR genes resulted in no developmental 
defects, suggesting the proteins serve similar roles in development and can compensate 
for depletion of individual family members (Kawano et al., 2000). However, when 
alternative splice sites were present in pre-mRNA, addition of different SR proteins to 
S100 extract resulted in different patterns of splicing, demonstrating different roles for 
the individual SR proteins. Analysis of SR protein expression in different calf tissues 
demonstrated tissue specific patterns of expression of SRSF2, SRSF4, SRSF5 and 
SRSF6 (Zahler et al., 1993). Furthermore, tissue specific gene knockdown of SRSF1 or 
SRSF2 in mice had differing effects on cardiac development; SRSF1 ablation resulted 
in lethality at around 6-8 weeks old which was linked to a change in splicing of a 
protein involved in calcium metabolism, CaMKIIδ, whereas SRSF2 deleted mice 
showed no obvious defect until a much later stage and no alteration in splicing of 
CaMKIIδ was observed. SRSF2 deleted mice also demonstrated reduced T-cell 
maturation which was linked to a change in splicing of CD45. These mouse models 
demonstrate critical tissue and developmental state specific roles for individual SR 
proteins in splicing regulation (Moroy and Heyd, 2007). The importance of alternative 
splicing in developmental regulation is also seen in the myometrium during pregnancy. 
The myometrium is the uterine smooth muscle responsible for contractions during 
labour and the upper and lower segments of the myometrium are functionally distinct, 
showing a temporal change in function during pregnancy and labour. Spatial and 
temporal variation in SRSF1 and hnRNP A1 expression in the myometrium are 
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observed during pregnancy (Pollard et al., 2000) and SRSF5 regulates the temporal 
switch in alternative splicing of cyclic AMP-response element modulator (CREM) in 
the myometrium during pregnancy (Tyson-Capper et al., 2005). 
 
Since different SR proteins regulate different splice sites, the ratio of expression of SR 
proteins is important in regulating splicing. For example the ratio of SRSF2 and SRSF4 
simian virus 40 pre-mRNA construct; SRSF2 alone favoured the proximal 3′ splice site, 
whereas SRSF4 alone favoured the distal 3′ splice site, and when added in combination 
an alteration in the ratio of SRSF2 and SRSF4 resulted in a parallel shift in the ratio of 
proximal and distal 3′ splice site mRNA products (Zahler et al., 1993).  
 
SR proteins have also been demonstrated to exhibit antagonistic functions, again 
demonstrating the importance of the expression ratio of different splicing factors in the 
regulation of alternative splicing. The mutually exclusive chicken β-tropomyosin exons 
6A and 6B are retained in mRNA in different tissue types. Recognition of the 5′ splice 
site downstream of exon 6A specifically requires SRSF1 binding to an ISE sequence 
and this activation of splicing by SRSF1 is inhibited by addition of SRSF2 but not 
SRSF7 demonstrating the antagonistic functions of specific SR proteins binding to 
regulatory sequences (Gallego et al., 1997). Antagonism between SRSF1 and SRSF2 
has also been reported in the skipping of exon 3 from human growth hormone pre-
mRNA; SRSF1 binds to an ESE within exon 3 to promote exon inclusion, whereas 
SRSF2 binds to a different sequence to repress splicing and promote exon skipping 
(Solis et al., 2008). Another example of SR proteins exhibiting antagonistic functions is 
the autoregulation of SRSF3. Inclusion of SRSF3 exon 4 alters the reading frame 
encoding a truncated protein lacking the RS domain. SRSF3 binds to an ESE within 
exon 4 and enhances a weak 3′ splice site leading to inclusion of the exon, whereas 
SRSF1 silences the weak 5′ splice site downstream of exon 4 promoting exon skipping 
(Jumaa and Nielsen, 1997). SRSF10 and SRSF12 are described as SR-repressor proteins. 
Neither SRSF10 nor SRSF12 are capable of enhancing splicing in S100 extract and both 
demonstrate a dominant negative regulation over SRSF1 and SRSF2 mediated splicing 
in S100. This antagonism may be via direct competition for binding to ESEs or 
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interaction with specific silencer sequences since the RRM of SRSF10 and SRSF12 
were critical for antagonism (Cowper et al., 2001). 
 
Another inhibitory splicing factor is hnRNP I, also known as PPT binding protein 
(PTB), which binds to the PPT and inhibits the binding of U2AF65 and subsequent 
recruitment of U2 during early pre-spliceosome formation. In the neuronal specific 
alternative splicing of src exon N1, hnRNP I binds to ISS sequences and represses U2 
binding, however a neuronal specific hnRNP I variant promotes binding of hnRNP F, 
hnRNP H and SRSF1 to an ESE, promoting splicing (reviewed by (Matlin et al., 2005). 
As well as alterations in the expression of ubiquitous splicing factors such as hnRNPs 
and SR proteins, tissue specific splicing factors have been described. One such example 
is the Nova family of proteins which function by binding to specific cis-acting 
sequences which can be either exonic or intronic; when bound to exonic sequences 
Nova proteins block U1 binding whereas when bound to intronic sequences they 
enhance U1 binding (Ule et al., 2006). Nova family members are expressed specifically 
in brain and control the neuronal specific splicing of several genes (Buckanovich and 
Darnell, 1997). Other splicing factors which bind to ISE sequences include Fox family 
members and CELF proteins, expression of which is developmentally and spatially 
regulated to differentially regulate alternative splicing (Venables, 2007). Fox proteins 
bind to conserved sequences within introns, and the position of the binding site in 
relation to the exon determines the effect on exon inclusion; Fox binding downstream of 
an exon promotes exon inclusion by activating the 5′ splice site, whereas Fox binding 
upstream of the exon promotes exon skipping by silencing the 3′ splice site (Venables et 
al., 2009). 
 
The differing and antagonistic functions of different splicing factors in 
enhancing/silencing splice site selection which are described above demonstrate that the 
expression ratio of these different splicing factors in a particular tissue, developmental 
state or disease process, as well as the presence and context of the cis-acting regulatory 
elements to which they bind combine to regulate alternative patterns of pre-mRNA 
splicing. It has been reported that ESE and ESS sequences cannot always be considered 
as independent elements with opposing functions, instead positive and negative splicing 
regulators can compete for binding to overlapping sequences, making prediction of 
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splicing patterns difficult. These sequences, termed composite exonic regulatory 
elements of splicing (CERES) were first identified in exon 12 of the CFTR gene, 
encoding the cystic fibrosis transmembrane conductance regulator. It was demonstrated 
by site directed mutagenesis that missense mutations of bases in close proximity within 
two regions of the exon could have differing effects on exon inclusion, and that the 
change in splicing was not predicted by the effect on splicing factor binding sequences. 
It was therefore proposed that these regions represented CERES sequences (Pagani et 
al., 2003b). RNA binding precipitation assays were performed using the RNA sequence 
of a CFTR exon 12 CERES or site directed CERES mutants; both SR proteins and 
hnRNPs were capable of interactions with this region and mutations that altered splicing 
in favour of exon inclusion interacted most strongly with SR proteins. SRSF1 and 
SRSF6 interacted directly with CERES and these SR proteins induced the greatest level 
of exon inclusion compared to SR proteins that did not bind CERES when expression 
vectors were co-transfected into HeLa cells along with a mini-exon 12 CERES 
construct. Similarly, siRNA knockdown of hnRNP A1 which also bound CERES was 
able to rescue exon inclusion in this mini-exon model. Neither SR proteins nor hnRNP 
A1 could affect the splicing of constructs which were deleted for the CERES sequence 
demonstrating that both silencing and enhancing functions are mediated via direct 
interaction with this element (Haque et al., 2010). A similar juxtaposition/overlap of 
ESE and ESS functions has also been observed in CFTR exon 9 (Pagani et al., 2003a), 
survival of motor neuron 1 (SMN1) exon 7 (Vezain et al., 2010) and exon 10 of the gene 
encoding luteinising hormone receptor type 2 (Gromoll et al., 2007). 
 
In order to consider the combined effect of competing splicing regulatory elements 
within pre-mRNA, a splicing code has been formulated using mouse tissue to predict 
tissue specific alternative splicing events. A computer program was developed by 
inputting sequences known to bind trans-acting splicing regulatory proteins, sequences 
overrepresented close to alternatively spliced exons and information on the 
inclusion/exclusion of an exon in a particular tissue type to determine the combinations 
of cis-regulatory sequences which regulate splicing of different pre-mRNA in different 
tissues. This code was then applied to various genes to predict exon inclusion/exclusion 
which was validated by a PCR assay (Barash et al., 2010). The development of this 
code may be the first step in identifying the sequences/features responsible for tissue 
specific alternative splicing regulation. The effect of transcription and RNA secondary 
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structures on alternative splicing must also be considered, and the splicing code is 
predicted to be species specific since there is only an estimated 20% conservation in 
splicing regulation from mouse to human (Tejedor and Valcarcel, 2010). 
 
1.4.7 Alternative pre-mRNA splicing in cancer 
It is estimated that approximately 50% of point mutations that cause genetic disease 
affect alternative splicing, either by silencing a splice site, creating a new splice site, 
strengthening an existing cryptic splice site or altering a cis-regulatory element (Ward 
and Cooper, 2010). Diseases such as cystic fibrosis and spinal muscular atrophy can be 
linked to mutations which affect splicing regulatory elements within CFTR exon 12 and 
SMN exon 7 respectively, which alter the patterns of exon inclusion (Vezain et al., 2010; 
Pagani and Baralle, 2004). Numerous alternatively spliced variants are detected 
specifically in cancer tissue leading to the suggestion of an increase in alternative 
splicing in cancer cells. However, a recent report suggested that there was actually a 
decrease in overall alternative splicing in cancer compared to normal tissue, specifically 
associated with a decrease in exon skipping, whereas an increase in the use of 
alternative splice sites and intron retention was observed in cancer (Kim et al., 2008). 
From these observations it is clear that there is a misregulation of splicing associated 
with cancer development. Whether the observed cancer associated changes in 
alternative splicing are a cause or a consequence of transformation remains to be fully 
elucidated. As will be discussed below, cancer associated changes in alternative splicing 
may provide novel biomarkers and perhaps therapeutic targets in the management of 
cancer patients (reviewed by (Ward and Cooper, 2010; Pajares et al., 2007; Srebrow and 
Kornblihtt, 2006).  
 
The importance of changes in oncogene and tumour suppressor expression in cancer 
development has been described in Section 1.3.4. p53 is a tumour suppressor which 
normally functions to prevent cell cycle entry of cells harbouring mutations, to stimulate 
apoptosis and maintain genetic stability (Lee and Muller, 2010). Nine alternative p53 
isoforms were identified resulting from alternative promoters or alternative pre-mRNA 
splicing including two alternatively spliced variants (ASVs), p53β and p53γ, resulting 
from retention of a cryptic exon within intron 9, termed exon 9b (Bourdon et al., 2005). 
The resulting C-terminally truncated variant proteins lack the tetramerisation domain, 
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and conflicting reports exist over the function of the variant proteins; suggesting that the 
proteins are unable to interact with p53 and are non-functional (Graupner et al., 2009) 
and conversely that p53β was able to enhance the pro-apoptotic effect of p53 when co-
expressed in p53 null cells (Bourdon et al., 2005). p53β but not p53γ has been detected 
in both normal and breast tumour tissue (Bourdon et al., 2005), and expression of p53β 
has recently been linked to poorer recurrence free survival in ovarian cancer (Hofstetter 
et al., 2010). Three further novel p53 ASVs were recently reported resulting from point 
mutations in normal splice sites; p53δ, p53δ, p53ε. All of the p53 ASVs were detected 
in ovarian cancer tissue except p53γ. p53δ expression correlated with poorer disease 
free and overall survival, increased rate of resistance to chemotherapy and an increased 
rate of early recurrence following chemotherapy (Hofstetter et al., 2010). It is therefore 
possible that the expression of these p53 ASVs may modulate normal p53 function or 
represent a loss of p53 function and contribute to disease progression.  
 
The BRCA1 gene encodes a protein with tumour suppressor function, and mutations in 
BRCA1 are associated with a high risk of breast and ovarian cancer as described in 
Section 1.3.4. An analysis of 607 nucleotide variations within BRCA1 which had 
previously been reported in either breast or ovarian cancer patients identified a frequent 
colocalisation of these mutations within predicted ESE sequences identified based on 
the match to consensus SR protein binding sequences. These mutations resulted in the 
weakening or loss of ESE sequences (210/607 mutations studied), as well as 
strengthening or gain of ESEs (131/607 mutations studied) (Pettigrew et al., 2005). The 
G5199T substitution within exon 18 has been previously reported to encode a stop 
codon within exon 18, but to result in skipping of exon 18 which would encode a non-
functional protein (Mazoyer et al., 1998), and was identified to disrupt an ESE binding 
sequence for SRSF1 (Pettigrew et al., 2005). The G231T substitution in BRCA1 causes 
exon 6 skipping by creating an ESS, sequence and varying the levels of SRSF1, SRSF2, 
SRSF7 and hnRNP A1 alters the inclusion or skipping of this exon (Raponi et al., 2011). 
Exon 23 is another BRCA1 exon which shows altered patterns of inclusion as a result of 
a mutation affecting splicing regulation; the C5434G substitution, identified in an 
ovarian cancer patient, resulted in increased exon 23 skipping, encoding a non-
functional protein. The C5434T polymorphism at the same location has limited effect 
on exon inclusion/skipping. Whilst both substitutions disrupt SRSF1 and SRSF6 
binding ESEs, C5434G, which increases exon 23 skipping, creates an hnRNP A1 
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binding ESS (Gaildrat et al., 2010). Mutations which were reported to affect ESEs in 
BRCA1 included previously uncharacterised variants which had no obvious affect on the 
encoded protein sequence (Pettigrew et al., 2005). The loss of function of proteins 
encoded by the exon deleted BRCA1 variants demonstrates the importance of predicting 
the effect of mutations on splicing regulatory elements and the potential role of altered 
BRCA1 splicing in the development of breast and ovarian cancer. 
 
Alternative splicing of oncogenes, generating constitutively active protein isoforms, has 
also been reported in cancer. For example, small deletions have been observed spanning 
the intron 10/exon 11 boundary of the KIT gene which encodes a receptor tyrosine 
kinase which is constitutively active in gastrointestinal stromal tumours (GIST) (Corless 
et al., 2004). This deletion destroys the 3′ splice site upstream of exon 11, resulting in 
the use of an alternative AG within the exon. The resulting deletion of the beginning of 
exon 11 encodes a protein lacking the region targeted by autophosphorylation and 
autoinhibition leading to constitutive KIT activity in mutation carrying GIST patients 
(Chen et al., 2005). 
 
Alternative splicing of the three exon Bcl-x gene encodes an anti-apoptotic long isoform 
(Bcl-xL) and use of a 5′ splice site within exon 2 deletes a coding region present in Bcl-
xL encoding a shorter pro-apoptotic isoform (Bcl-xS) (Boise et al., 1993). 
Overexpression of the antiapoptotic Bcl-xL is common in many cancers including breast 
(Olopade et al., 1997), prostate and lung (Ward and Cooper, 2010). Three cis-regulatory 
elements, B2, B3 and SB1, have been identified within the alternatively spliced exon 2 
of Bcl-x; examining the effect of systematic deletions within the exon identified region 
B2 immediately downstream of the Bcl-xS 5′ splice site which enhanced Bcl-xS splicing 
and region B3 immediately upstream of the Bcl-xL 5′ splice site which enhanced Bcl-xL 
splicing (Garneau et al., 2005). hnRNP F and hnRNP H bind to B2 and siRNA 
knockdown of these hnRNPs reduced Bcl-xS splicing (Garneau et al., 2005). SRSF9 
binds to two regions within B3 to promote Bcl-xL splicing and a third region within B3 
contains two cryptic splice sites which bind U1 and repress splicing at the Bcl-xL 5′ 
splice site (Cloutier et al., 2008). A third exonic sequence upstream of the Bcl-xS 5′ 
splice site, termed SB1, was identified to be responsible for the increased Bcl-xS 
splicing following inhibition of protein kinase C (PKC) (Revil et al., 2007). Therefore 
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PKC signalling has been implicated in activating a splicing repressor which binds to 
SB1 to promote expression of the anti-apoptotic Bcl-xL and promote cell survival. A 
role antagonistic to that of PKC is assigned to DNA damage response pathways which 
promote Bcl-xS expression and apoptosis via either the inactivation of the PKC induced 
repressor or activation of pro-splicing factors (Shkreta et al., 2011). The presence of 
these three cis-elements demonstrates the combinatorial regulation of splice site 
selection and the interplay of cell signalling and splicing regulation which could be 
altered in cancer to provide a survival advantage to cancer cells. 
 
Vascular endothelial growth factor-A (VEGF-A) is involved in the process of 
angiogenesis, vital for tumour growth and survival (Pajares et al., 2007). Alternative 
spicing of the 8 exon VEGFA gene can result in nine angiogenic isoforms, the most 
widely expressed of which are VEGF165 resulting from the skipping of exon 6, VEGF121 
resulting from the skipping of exons 6 and 7 and VEGF189 which contains both exons 6 
and 7. These three VEGF-A isoforms are pro-angiogenic and are widely expressed in 
tumour tissue in response to hypoxia, inducing formation of the tumour neovasculature 
(reviewed by (Pajares et al., 2007). Use of an alternative 3′ splice site within the 3′ UTR 
of exon 8 results in the encoding of an alternative 6 amino acid sequence at the C-
terminus in the VEGF165b isoform. This isoform was demonstrated to be widely 
expressed in normal kidney tissue, to inhibit VEGF-A function in vitro and to be down-
regulated in the majority of kidney tumour samples analysed, suggesting an anti-
angiogenic function which is removed by alternative splicing in cancer (Bates et al., 
2002). Decreased VEGFb isoform expression has since been demonstrated in a range of 
other tumour tissues including lung and pancreatic (Pajares et al., 2007). The ratio of 
VEGF/VEGFb isoforms is regulated by growth factors in primary epithelial cells; 
insulin-like growth factor 1 and tumour necrosis factor-α increased proximal 3′ splice 
site selection, increasing VEGF expression, whereas TGFβ1 induced distal 3′ splice site 
selection via activation of p38 MAPK and the SR protein kinase Clk. SRSF1 and 
SRSF5 overexpression favoured VEGF expression whereas SRSF6 overexpression 
favoured VEGFb isoform. This study implicated growth factor signalling in the 
regulation of splicing factor function in cancer associated alternative splicing events 
(Nowak et al., 2008). 
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CD44 is a cell surface glycoprotein with roles in cell-cell contact, adhesion and 
migration. A complex pattern of alternative splicing involving the differential inclusion 
of ten variable exons has been described for CD44, showing tissue specific variation in 
exon inclusion (reviewed (David and Manley, 2010). CD44 splicing shows cancer 
specific variations, potentially providing therapeutic targets or molecular biomarkers 
(Pajares et al., 2007; Srebrow and Kornblihtt, 2006; Venables, 2004). The Ras/Erk 
signalling pathway has been implicated in inclusion of v6 (Cheng et al., 2006) and v5 
(Matter et al., 2002). v5 inclusion is mediated by the RNA-binding protein Sam68 
binding to an ESE within the exon and Sam68 is phosphorylated by Erk (Matter et al., 
2002). The regulation of CD44 splicing by the Ras/Erk pathway provides a positive 
feedback mechanism for Ras signalling since v6 containing CD44 is a receptor which 
can activate Ras (Cheng et al., 2006). 
 
Altered expression of several splicing factors has also been reported in cancer compared 
to normal tissues (Jia et al., 2010; Piekielko-Witkowska et al., 2010; Karni et al., 2007). 
Genetic amplification was demonstrated to account for increased expression of SRSF1 
(Karni et al., 2007) and SRSF3 (Jia et al., 2010) and the genes encoding these splicing 
factors are within chromosomal regions commonly amplified in cancer. SRSF1 (Karni 
et al., 2007) and SRSF3 (Jia et al., 2010) have recently been described as proto-
oncogenes whilst increased SRSF1 has been linked to poorer disease free survival in 
small cell lung cancer (Ezponda et al., 2010), and increased SRSF3 expression is 
observed from normal ovarian tissue to non-invasive ovarian tumours and to invasive 
ovarian tumours, being associated with increased tumour grade (He et al., 2011). 
Overexpression of SRSF1 in fibroblasts protected cells from apoptosis, and induced 
transformation; increasing anchorage independent growth in soft agar, and promoting 
tumour formation when cells were transplanted into nude mice (Karni et al., 2007). 
SRSF1 overexpression led to decreased expression of the tumour suppressor BIN1 and 
promoted the splicing of oncogenic isoforms of the ribosomal translational regulator S6 
Kinase 1 and of MAPK interacting kinase 2 which constitutively activates eIF4E 
independent of its normal regulation by PI3K signalling (Karni et al., 2007). In lung 
cancer cells, knockdown of SRSF1 led to apoptosis associated with decreased 
expression of survivin and SRSF1 was reported to stabilise survivin mRNA and 
increase translation by inactivating negative regulators of the mTOR complex to 
(Ezponda et al., 2010). Similarly, SRSF3 knockdown with siRNA increases apoptosis 
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(He et al., 2011) and decreases proliferation in a range of cancer cell lines (Jia et al., 
2010). SRSF3 overexpression stimulated anchorage independent growth in culture and 
induced tumour formation when transfected MEF 323 mouse fibroblasts were 
transplanted into nude mice (Jia et al., 2010). 
 
Described above are mutations in tumour suppressors and oncogenes which alter 
splicing patterns and protein functions in cancer and the designation of splicing factors 
as oncogenes due to their capacity to induce transformation, protect against apoptosis 
and alter tumour-suppressor/oncogene expression. These mutations and the altered 
expression of splicing factors early in cancer development suggest that changes in 
alternative splicing may contribute to the initiation of cancer. The examples of Bcl-x, 
VEGF-A, CD44 and fibronectin demonstrate how growth factor and cell signalling 
pathways which, as described in Section 1.3, are misregulated in cancer can contribute 
to splicing. Therefore, changes in cell signalling, which may be a cause or consequence 
of cancer, may result in an altered pattern of alternative splicing. The products of these 
cancer associated changes in splicing can in turn contribute to cell survival, 
angiogenesis or metastasis which are processes required for tumour progression. 
Aberrant and alternative splicing may therefore be considered both a cause and a 
consequence of cancer initiation and a contributor to cancer progression. 
  
1.4.8 Global identification of cancer specific alternative splicing events 
Indentifying the effect of altered splicing of individual genes or of altered expression of 
splicing factors is useful but may not fully reveal the contribution of altered splicing 
patterns to the development of cancer. To more fully determine the changes in splicing, 
global methods to identify cancer associated alternative splicing are being utilised. High 
throughput sequencing has revealed novel potential alternative splicing events (ASEs) 
as well as tissue specific variations in regulated ASEs. This technology could be used to 
compare cancer and normal tissue to identify cancer specific splicing signatures 
(Blencowe et al., 2009; Pan et al., 2008; Wang et al., 2008). Exon junction microarrays 
use probes spanning each putative exon junction to identify alternative patterns of 
splicing, as well as probes located within an exon to measure changes in exon inclusion 
between different tissues. Initial use of these arrays identified tissue specific variations 
in alternative splicing patterns. These methods enable the identification of known as 
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well as novel ASEs which can be validated by quantitative real-time PCR (Johnson et 
al., 2003). The application of exon-junction microarrays to cancer has identified distinct 
patterns of alternative splicing between metastatic and non-metastatic murine breast 
cancer cells following transplantation into immunodeficient mice (Bemmo et al., 2010). 
Distinct patterns of ASEs were also observed which could differentiate between normal 
mammary epithelial cell lines, and breast cancer cell lines of different molecular 
phenotypes (Lapuk et al., 2010). In non-small cell lung cancer 330 genes were identified 
with a different pattern of alternative splicing compared to normal lung tissue (Langer et 
al., 2010) and splicing patterns were observed to differ between early and late stage 
neuroblastoma (Guo et al., 2011). 
 
A compromise between global and functional studies is provided by the layered and 
integrated system for splicing annotation (LISA) platform, in which expression of 600 
cancer associated genes is examined using primers spanning each potential exon 
junction to identify ASEs and calculate a value for the frequency of exon inclusion 
(percent spliced in, PSI) (Klinck et al., 2008). PSI values from LISA identified 48 ASEs 
which were specific for ovarian cancer (Klinck et al., 2008) and 41 ASEs which were 
specific to breast cancer (Venables et al., 2008) compared to normal ovarian or normal 
breast. Cancer specific ASEs could be used to accurately distinguish normal from 
cancer samples in a blinded study illustrating the potential for LISA to be used for 
cancer diagnosis (Klinck et al., 2008; Venables et al., 2008). For breast cancer, ASEs 
were also observed which were specific for ER+ tumours and others which could 
distinguish tumour grade (Venables et al., 2008). Analysis of the PSI profiles for breast 
and ovarian cancer revealed tissue specific differences, however a common signature of 
cancer associated ASEs was observed between the two types of cancer (Venables et al., 
2009).  
 
1.4.9 Therapeutic strategies targeting alternative splicing 
Identification of cancer specific ASEs can provide novel therapeutic targets. Antisense 
oligonucleotides can be used to bind either to splice sites in order to block spliceosome 
formation, or to target cis-regulatory elements and prevent binding of splicing factors. 
Antisense oligonucleotides have been successfully used in the treatment of non-
malignant diseases such as Duchenne’s muscular dystrophy and spinal muscular 
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atrophy (van Alphen et al., 2009) and have been trialled for the blocking of mature 
mRNA translation of protein kinase C in non-small cell lung cancer (Pajares et al., 
2007). Cancer specific exon skipping could potentially be corrected by the 
administration of peptide tagged oligonucleotides which bind ESEs and promote splice 
site selection, thus restoring normal exon inclusion (Cartegni and Krainer, 2003).  
 
Cancer specific protein isoforms which result from ASEs may also provide therapeutic 
targets; if the ASE results in cancer specific exon inclusion, a cancer specific amino 
acid-sequence will be encoded which could be targeted with antibodies. Antibodies 
against cancer specific CD44v6 have been trialled but resulted in toxicity, and a 
tenascin-C antibody, targeting a brain tumour specific ASV has been tested in animals 
(Pajares et al., 2007). These antibodies may directly prevent function of the cancer 
specific protein or could be co-administered with cytotoxic drugs which could be 
targeted to cells expressing the cancer specific isoform (Pajares et al., 2007). An 
antibody targeted to fibronectin extra domain A (EDA) specifically targets tumour 
neovasculature, providing a potential vehicle for cancer targeted therapies (Rybak et al., 
2007). 
 
Administration of alternatively spliced isoforms may also provide a therapeutic strategy. 
As described, VEGF165b is predominantly expressed in normal tissue and inhibits 
VEGF165, but a cancer specific shift to predominant expression of other spliced isoforms 
leads to angiogenesis. Therefore, administration of VEGF165b could inhibit angiogenesis 
(Pajares et al., 2007). SR protein function requires phosphorylation of the serine rich RS 
domains, thus drugs which target the SR proteins kinases (SRPKs) may remove the 
oncogenic effects of these proteins (van Alphen et al., 2009). Inhibition of SRPKs has 
been reported to switch VEGF splicing in favour of the anti-angiogenic VEGF165b 
isoform and reduce angiogenesis in mouse models (Nowak et al., 2010).  
 
Finally, targeting spliceosomal components to prevent functional spliceosome formation 
could again prevent oncogenic ASEs. Inhibiting SF3b, a component of U2 snRNP, has 
been demonstrated to have anti-cancer properties in vitro (van Alphen et al., 2009). 
However, the widespread and essential role of SR proteins and the spliceosome in 
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normal cell processes would make targeting of these latter two strategies to specifically 
affect cancer associated ASEs difficult. 
 
1.4.10 Alternative splicing of breast cancer biomarkers 
As has been described, the identification of cancer specific splicing signatures can be 
used to accurately distinguish normal from cancer tissue, and could therefore provide a 
diagnostic tool in cancer management (Klinck et al., 2008; Venables et al., 2008). The 
identification of cancer specific spliced variants has also been described to be associated 
with prognosis, such as p53δ expression which correlated with poorer survival and 
increased resistance to chemotherapy (Hofstetter et al., 2010). Detection of cancer 
specific protein regions, such as fibronectin EDA can also provide specific biomarkers 
for cancer identification; EDA was detected at high levels in liver metastases 
neovasculature in mice but was undetectable in normal tissue, allowing identification of 
metastatic tumours (Rybak et al., 2007). 
 
The ERα status of a breast tumour is currently used to predict the outcome of endocrine 
therapies. mRNA for several exon deleted ERα spliced variants have been reported in 
breast cancer tissue and examples are described below. Exon 2 deleted ERα (ERΔ2) has 
been observed in both normal and breast tumour but no specific association with breast 
cancer is reported (Herynk and Fuqua, 2004). ERΔ3 which lacks the DNA binding 
domain and is unable to bind DNA is able to activate the VEGF promoter via 
interaction with Sp1 transcription factors (Koduri et al., 2006). Increased ERΔ5 mRNA 
and protein expression was detected in breast cancer tissue compared to normal breast 
(Desai et al., 1997; Leygue et al., 1996b). A similar association of ERΔ5 mRNA with 
cancer is reported by an observed overexpression of ERΔ5 in tumour adjacent prostate 
tissue compared to benign prostate tissue (Taylor et al., 2010). Conflicting reports exist 
regarding ERΔ7 expression, with reports of high expression in breast cancer (Herynk 
and Fuqua, 2004) and reports of decreased expression in breast cancer compared to 
normal breast tissue (van Dijk et al., 2000) and of decreased expression in breast 
tumours with lymph node metastasis compared to non-metastatic tumours (Hsiao et al., 
2006). Increased detection of multi-exon deleted ERα variants and a variant resulting 
from use of a cryptic splice site within exon 7 have been reported in breast cancer 
compared to normal breast tissue (van Dijk et al., 2000). Detection of exon deleted ER 
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variants in breast cancer could provide insight into the likely response to endocrine 
therapy as well as provide novel biomarkers of disease. 
 
ERα antibodies targeting the LBD detect three predominant bands reported to 
correspond to the 66kDa ERα and two spliced variants, a 46kDa protein termed ERα46 
and 36kDa protein termed ERα36. ERα46 results from the splicing of an exon within 
the 5′ UTR onto exon 2 encoding a protein lacking the N-terminal AF1 which is a 
dominant negative regulator of wild-type ER (Flouriot et al., 2000). ERα36 results from 
similar splicing of an exon within the 5′ UTR onto exon 2 resulting in skipping of exon 
1, and the splicing of exon 6 onto a downstream exon within the 3′ UTR. This mRNA 
therefore encodes a unique C-terminal sequence but results in a protein lacking AF2 and 
part of the LBD, as well as AF1 (Wang et al., 2005). Despite the lack of so many 
functional domains, many studies have reported the activation of cytoplasmic ERα 
signalling pathways in cells expressing the membrane associated ERα36 isoform 
(Zhang et al., 2011; Kang et al., 2010; Lin et al., 2010; Wang et al., 2006). Furthermore, 
ERα36 overexpression has been reported in apocrine and adenoid cystic breast 
carcinomas compared to normal tissue (Vranic et al., 2011). The presence of a unique 
C-terminal sequence in ERα36 provides a potential target for specific antibodies for 
detection of this protein and use as a cancer biomarker. 
 
HER2 is commonly overexpressed in breast cancer and provides a therapeutic target for 
the Herceptin antibody (Payne et al., 2008). A natural spliced variant retaining intron 8, 
termed Herstatin is described as a dominant negative regulator of HER2 (Doherty et al., 
1999) and is expressed in both normal breast and breast tumour tissue (Koletsa et al., 
2008). Expression of HER2 was higher in normal tissue and expression in breast tumour 
tissue may prevent therapeutic benefit of HER2 targeted therapies (Koletsa et al., 2008). 
Oligonucleotides to switch HER2 splicing in favour of exon 15 skipping generate the 
Δ15HER2 variant. Treatment of the HER2 overexpressing breast cancer cell line SK-
BR-3 with the splice switching oligonucleotides or with exogenous Δ15HER2 resulted 
in down-regulation of full length HER2 expression, inhibited proliferation and induced 
apoptosis. Therefore it was proposed that these splice switching oligonucleotides or 
administration of HER2 spliced variants may provide novel therapeutics in HER2 
positive breast cancer (Wan et al., 2009). 
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1.4.11 Alternative splicing of progesterone receptor pre-mRNA 
The structure and function of PR-A and PR-B isoforms has been described in detail in 
Section 1.1. The PR status of a breast tumour is reported to have value, independent of 
ERα status, in predicting the outcome of endocrine therapy (Bardou et al., 2003). 
Furthermore, the ratio of PR-A:PR-B detected in a tumour is reported to be of 
prognostic significance (Hopp et al., 2004).  Therefore, the accurate identification of PR 
isoforms, including those resulting from alternative pre-mRNA splicing is important in 
the management of breast cancer patients. 
 
A 78kDa protein was detected by PR antibodies in approximately 26% of breast 
tumours examined (Graham et al., 1996) and this protein was later demonstrated to be 
N-terminally truncated and likely to be a variant of PR-A since it was detected by 
antibodies targeting PR-A and PR-B but not the BUS (Yeates et al., 1998). Whole exon 
deletions of exon 2, exon 3, exon 4, exon 6 and exon 7, and multiple exon deletions 
involving various combinations of internal exons have been previously reported in a 
range of human tissues and cell lines (Springwald et al., 2010; Misao et al., 2000; 
Balleine et al., 1999b; Misao et al., 1998; Richer et al., 1998; Leygue et al., 1996a). 
Exon 4 deleted mRNA (PRΔ4) and exon 6 deleted mRNA (PRΔ6) were detected more 
frequently in breast tumour than normal breast tissue, PRΔ6 was detected more 
frequently in breast tumours characterised as expressing a low level of PR than a high 
level of PR (Nagao et al., 2003) and deletions of exons 3+6 and exons 5+6 were 
detected specifically in breast tumour tissue (Leygue et al., 1996a). PRΔ4 and PRΔ6 
were also detected in vascular smooth muscle, specifically in pre-menopausal women. 
The post menopausal patients examined had all undergone HRT, leading to the 
suggestion that the exogenous oestrogens administered in HRT may affect the 
alternative splicing of PR (Hodges et al., 1999). 
 
PR exons 3, 4 and 6 are cassette exons, therefore deletion of the exon would result in a 
protein lacking just the functional domain encoded by that exon, whereas deletion of 
other exons or multiple exons often changes the reading frame and would prematurely 
truncate the C-terminal end of any encoded protein. A study to examine the function of 
exon deleted PR variants reported that PRΔ2, PRΔ4 and PRΔ5,6 were unable to bind 
DNA, whereas PRΔ6 exhibited constitutive DNA binding in the absence of ligand. 
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Furthermore PRΔ5,6 and PRΔ6 were dominant negative regulators of PR-A and PR-B 
function (Richer et al., 1998). However, the low level of exon deleted PR mRNA 
detected, PRΔ6 was reported at just 8% of wild-type PR mRNA levels, has led to the 
suggestion that any encoded proteins are likely to be expressed at very low levels and 
may not be functionally relevant (Balleine et al., 1999b). 
 
As described in Section 1.4.7, the use of alternative cryptic splice sites is observed more 
frequently in cancer than normal tissue (Kim et al., 2008). Use of two cryptic 3′ splice 
sites have been reported for PR, within exon 6 an exon 4; PRΔ6/2 mRNA with an out of 
frame deletion of 52bp from the start of exon 6 was detected more frequently in breast 
cancer than normal breast tissue and would lead to protein truncation within the DBD. 
PRΔ4/2 mRNA with an in frame deletion of 126bp at the start of exon 4 was detected in 
breast cancer tissue (Balleine et al., 1999b) and normal endometrium (Marshburn et al., 
2005). This mRNA would encode a protein lacking the hinge region and NLS but 
possessing the remaining functional domains. 
 
Another mode of alternative splicing common in cancer is intron retention (Kim et al., 
2008). Several PR isoforms have been reported to result from the retention of intronic 
exons. Sequencing of genomic DNA and screening of the testicular cDNA library 
identified a sequence within intron 3 which was spliced onto the start of exon 4. mRNA 
containing this exon, termed exon S, was detected at a high level in spermatozoa and 
also in the endometrium (Hirata et al., 2000). Further screening of the testicular cDNA 
library identified another retained sequence from intron 3, termed exon T (Hirata et al., 
2002). Neither exon S nor exon T encode protein and these mRNA are predicted to 
generate identical proteins from the first initiation codon within exon 4 (Met692) 
(Hirata et al., 2003). Retention of a 232bp intronic sequence between exons 4 and 5 was 
identified in endometrial tissue by RT-PCR. Sequencing of genomic DNA identified 
two exons termed i45a (123bp) and i45b (109bp). i45a encodes an in frame termination 
codon so would generate a protein truncated within the LBD (Yamanaka et al., 2002). 
Another insertion between exons 3 and 4, termed exon M, was identified by screening 
cDNA libraries and cDNA containing this sequence was later identified in PR+ T47D 
and PR- T47D-Y breast cancer cells. Exon M contains an initiation codon so the PR-M 
protein is predicted to possess 16 unique N-terminal amino acids encoded by exon M 
68 
along with the normal PR hinge region, NLS, LBD, DD and AF2, with a theoretical 
molecular weight of 38kDa. A protein of appropriate molecular weight was detected in 
the membrane fraction of T47D-Y cells by Western immunoblotting with the C-
terminal PR antibody C19 (Saner et al., 2003) and within the cytoplasm of breast cancer 
cells by immunofluorescence using the same antibody (Price et al., 2005). 
 
A recent study using expression vectors containing each initiation codon predicted to 
generate an N-terminally truncated PR protein, i.e. Met692 (PR-S/T), MetPR-M, or 
Met595 (PR-C), reported that none of these lead to translation unless a consensus 
Kozak sequence is added, and suggested that a protein translated from Met595 would be 
38kDa not the previously reported 60kDa PR-C protein (Samalecos and Gellersen, 
2008). This study also suggested that commercial C-terminal PR antibodies are non-
specific, supporting the earlier identification by mass-spectrometry of cytoskeletal 
proteins detected by the C19 antibody, including the protein commonly reported as PR-
C (Madsen et al., 2007). These studies challenge the existence of N-terminally truncated 
PR variant isoforms and the use of current antibodies to identify them. This controversy 
necessitates the study of the expression profile and activity of PR spliced variants in 
breast cancer cell lines and tissue with the aim of improving the understanding of PR 
function. The improved detection of PR proteins with novel antibodies could contribute 
to the identification of variant proteins both in the lab and in clinicopathological breast 
cancer screening, contributing to the value of PR as a clinical biomarker. Furthermore, 
the identification of apparently breast cancer specific PR ASEs such as deletion of 
exons 3+6 or exons 5+6 (Leygue et al., 1996a), and the increased occurrence of other 
ASEs in breast cancer such as deletion of exon 4, exon 6 (Nagao et al., 2003) or usage 
of the exon 6 cryptic splice site (Hisatomi et al., 2003), suggest that a full identification 
of the PR splicing signature may provide molecular markers for breast cancer diagnosis. 
These cancer specific variant PR mRNAs also demonstrate a requirement for 
investigation into the regulation of PR alternative splicing to identify the factors which 
may regulate cancer specific ASEs.  
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1.5 Hypotheses and aims 
1.5.1 Hypotheses 
Breast cancer PR screening uses N-terminal antibodies (Hanley et al., 2009) which may 
detect truncated proteins resulting from exon deletion that are functionally distinct from 
wild type PR, or may fail to detect N-terminally truncated proteins. Evidence exists for 
the detection of truncated PR proteins by C-terminally targeted PR antibodies (Condon 
et al., 2006), however the identity of these truncated proteins and the specificity of 
commercial PR antibodies remains controversial (Samalecos and Gellersen, 2008; 
Madsen et al., 2007). These truncated PR proteins may result from alternative splicing 
of PR pre-mRNA and ASEs involving PR mRNA have been extensively characterised 
in the PR positive MCF-7 and T74D breast cancer cell lines. However, until recently 
(Springwald et al., 2010), no evidence of PR expression had been reported in the MDA-
MB-231 breast cancer cell line which is characterised as PR negative. These ASEs have 
the potential to encode proteins with functions that differ from PR-A and PR-B. 
Therefore the hypotheses of this project are: 
1. The PR negative breast cancer cell line MDA-MB-231 may express alternatively 
spliced PR mRNA which could encode potentially functional PR variant 
proteins. 
2. Variant PR proteins resulting from alternative splicing of PR pre-mRNA may be 
expressed in breast cancer and contribute to misclassification of a breast tumour 
PR status in screening using N-terminally targeted antibodies.  
3. The lack of specificity associated with commercial non N-terminal PR 
antibodies may make them unsuitable for clinical PR screening and necessitates 
the development of novel antibodies. 
4. The use of novel PR screening antibodies which detect truncated PR variant 
proteins may add to the predictive value of PR status for administration of 
endocrine therapies. 
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1.5.2 Aims 
To investigate the hypotheses described above the specific aims of this study are to: 
1. Develop an RT-PCR based gene walking assay using primers directed to each 
exon of the PR gene to identify PR ASEs. PR positive MCF-7 cells will be used 
to validate this assay. 
2. Use the PR gene walking assay and primers directed to previously identified PR 
spliced variants to characterise PR ASEs in MDA-MB-231 cells. 
3. Identify PR proteins detected by commercial PR antibodies by Western 
immunoblotting in breast cancer cell lines. 
4. Validate the specificity of commercial N- and C-terminal PR antibodies using 
siRNA knockdown of total PR expression and Western immunoblotting with 
each PR antibody. 
5. Investigate the potential functionality of PR proteins present in MDA-MB-231 
cells using a range of assays including ligand blotting, co-immunoprecipitation 
with a PR co-factor and DNA affinity precipitation. 
6. Characterise PR ASEs in a small cohort of breast tumour samples using the PR 
gene walking assay. 
7. Develop novel non N-terminal PR antibodies and undertake preliminary 
validation of their specificity for use in Western immunoblotting, co-
immunoprecipitation and immunofluorescent analysis of FFPE breast tumour 
tissue. 
8. Undertake a preliminary investigation into the regulation of PR alternative 
splicing by examining the effect of SR protein knockdown by siRNA on exon 
inclusion. 
71 
2 Materials and Methods 
2.1 Source of tissue 
Frozen breast tumour tissue was obtained from the Newcastle University/Gateshead 
Queen Elizabeth Hospital Breast Cancer Biomarkers tissue bank, and used in 
accordance with Gateshead Local Research Ethics Committee Ref 52/02. Samples were 
taken from consenting patients and snap frozen in liquid nitrogen before storing at -
80°C. Samples from the same tumour were formalin fixed and embedded in paraffin 
wax. Formalin fixed paraffin embedded (FFPE) breast tumour tissue was used on site at 
Gateshead Queen Elizabeth Hospital Histocytopathology Department in accordance 
with local ethics permission. 
 
2.2 Cell culture materials 
2.2.1 Cell lines 
MCF-7 (MD Anderson) and T47-D (American Type Culture Collection, (ATCC)) are 
ER+/PR+ human breast cancer cell lines. MDA-MB-231 (MD Anderson and ATCC) is 
an ER-/PR- human breast cancer cell line. MCF-10A (ATCC) is a non-tumourigenic 
mammary epithelial cell line. Characteristics of these different cell lines can be seen in 
Table 2.1. 
 
2.2.2 Cell culture media 
Dulbecco’s Modified Eagles medium (DMEM) without phenol red (Sigma-Aldrich), 
was supplemented with 10% Foetal Bovine Serum (FBS; Sigma-Aldrich), 20mM L-
Glutamine (Sigma-Aldrich) and 1% penicillin/streptomycin (pen/strep; Sigma-Aldrich,). 
RPMI-1640 without phenol red (Sigma-Aldrich) was supplemented with 10% FBS, 
20mM L-glutamine and 1% pen/strep. DMEM/F12 (Invitrogen, Life Technologies) was 
supplemented with 5% horse serum (Invitrogen, Life Technologies), 20ng/ml EGF 
(Peprotech), 0.5mg/ml hydrocortisone (Sigma-Aldrich), 100ng/ml cholera toxin (Sigma-
Aldrich), 10μg/ml insulin (Sigma-Aldrich) and 1% pen/strep. Cryoprotective media 
consisted of FBS+ 5% dimethyl sulphoxide (DMSO, Sigma-Aldrich; MCF-7, T47-D, 
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MDA-MB-231) or complete DMEM/F12 + 7.5% DMSO (MCF-10A). Details of cell 
culture media can be seen in Table 2.1. 
 
 
Table 2.1: Cell lines and cell culture media used in this study. 
 
2.3 Cell culture methods 
2.3.1 General cell maintenance 
MCF-7 and MDA-MB-231 cells were routinely cultured in complete DMEM without 
phenol red. T47-D cells were cultured in complete RPMI-1640 without phenol red. 
MCF-10A cells were cultured in complete DMEM/F12. All cell lines were routinely 
cultured in 75cm
2 
or 25cm
2
 tissue culture flasks (Greiner) at 37°C in a humidified 
atmosphere containing 5% CO2. Cells were passaged by removing growth media, 
washing with PBS and stripping from the surface of the flask by incubation with 2mM 
trypsin-EDTA (Sigma-Aldrich). Trypsin-EDTA was neutralised by addition of 
complete growth media and cells were pelleted by 5 minutes centrifugation at 1500rpm, 
before resuspending and re-seeding in complete growth media. Cells were passaged at a 
ratio of 1:2-1:4 when they reached approximately 70-80% confluency. 
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2.3.2 Cryo-storage 
For long term storage cells were pelleted as above, and resuspended in an appropriate 
cryoprotective media (Table 2.1). Cells were stored in 2ml cryovials (Simport) in liquid 
nitrogen or at -80°C. 
 
2.3.3 Hormone stimulation of cultured cells  
MCF-7, MDA-MB-231 and MCF-10A cells were seeded at a density of 5x10
4
 cells per 
well in 24 well culture plates and cultured until approximately 60% confluency before 
serum starving by replacing complete growth media with media without FBS. After 24 
hours serum starving, media was replaced with complete media supplemented with a 
range of concentrations of β-oestradiol (Sigma-Aldrich) and cells were cultured for a 
further 24 hours. β-oestradiol was dissolved in absolute ethanol and added to the media 
at a range of concentrations from 0.001-10μM. An ‘ethanol only’ control (labelled 0µM 
was also included for each experiment. Experiments were repeated twice. 
 
2.3.4 Transfecting cultured cells with siRNA to knockdown gene 
expression 
siRNA was purchased from Ambion, Applied Biosystems. Conditions for efficient 
siRNA knockdown were optimised by varying the cell density per well and the 
concentrations of siRNA and transfection reagent within the ranges recommended in the 
Ambion Silencer siRNA Starter Kit manufacturer’s guidelines. For each siRNA, 2.5μl 
siPORT NeoFX Transfection Agent (Ambion, Applied Biosystems) was added to 100μl 
DMEM without FBS and antibiotics, and incubated for 10 minutes to allow 
equilibration of the transfection agent to a working temperature. 2.5μl of 2μM siRNA in 
100μl DMEM without FBS or pen/strep was added to the siRNA and incubated for a 
further 20 minutes to allow formation of siRNA/transfection agent complexes. 
siRNA/siPORT mixes were added to the wells of 12 well culture plates along with 
MCF-7 cells at a density of 1x10
5
 cells per well in DMEM without antibiotics. Media 
was replaced after 24 hours and cells cultured for a further 48hours prior to harvesting.  
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PR siRNA was used to knockdown total PR expression and validate antibody specificity 
by Western immunoblotting and immunofluorescence. siRNA targeted to knockdown 
expression of the RNA-binding proteins SRSF1, SRSF2, SRSF5, and SRSF6 was used 
to examine the effect on PR alternative splicing events (ASEs) by RT-PCR. Cells were 
also transfected with a positive transfection control GAPDH siRNA and a negative 
control scrambled sequence siRNA in each experiment. A transfection agent only 
control was also performed and untreated cells were cultured in parallel for comparison. 
Each siRNA knockdown was performed in duplicate and repeated twice. Details of all 
siRNAs used can be seen in Table 2.2. 
 
 
Table 2.2: Targets and RNA sequences of siRNA used in this study. 
 
2.4 Preparation of protein samples 
Whole cell lysates from MCF-7 and MDA-MB-231 cells were produced by two 
methods depending on the analysis method to be used. SDS Lysis Buffer was used to 
harvest cells for Western immunoblotting. Radioimmunoprecipitation assay (RIPA) 
buffer was used to extract lysates for shrimp alkaline phosphatase (SAP) treatment and 
ELISAs. Both lysis methods and details of how the lysates were used are detailed below. 
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2.4.1 SDS lysis buffer 
0.125M Tris-HCl pH6.8 
2% SDS 
10% glycerol 
10% β-mercaptoethanol 
0.1% bromophenol blue 
 
2.4.2 Preparation of whole cell lysates using SDS lysis buffer 
Growth media was removed and cells washed twice in cold 1 x phosphate buffered 
saline (PBS). Cells in 12 well culture plates were then incubated for 5 minutes at room 
temperature in 100μl SDS lysis buffer before scraping using a P200 pipette tip and 
transferring to a 1.5ml centrifuge tube. Following aspiration of growth media and 
washing in PBS, cells in 75cm
2
 culture flasks were scraped into 1ml 1xPBS using a cell 
scraper and pelleted by 5 minutes centrifugation at 600rpm in a refrigerated centrifuge 
at 4°C. Cell pellets were resuspended in 750μl SDS lysis buffer. 
 
2.4.3 RIPA buffer 
25mM Tris-HCl pH7.6 
150mM NaCl 
1% NP-40 
0.1% sodium deoxycholate 
0.1% SDS 
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2.4.4 Preparation of whole cell lysates using RIPA buffer 
MCF-7 and MDA-MB-231 cells were cultured in 25cm
2
 tissue culture flasks and 
stimulated with 1µg/µl β-oestradiol, with or without subsequent stimulation with 
0.1µg/µl progesterone or an ethanol only control as previously described. Before use, 
cold RIPA buffer was supplemented with 20µl protease inhibitor cocktail (Sigma-
Aldrich) per 1ml of buffer. Control cells were lysed with RIPA buffer without protease 
inhibitors. Cells were washed 3 times in cold 1xPBS before incubation on ice with 
330µl cold RIPA buffer for 5 minutes under gentle agitation. Lysate was collected using 
a cell scraper, transferred to a 1.5 ml microcentrifuge tube and centrifuged for 15 
minutes at 14,000xg to pellet cell debris. Supernatant was removed and stored for 
quantification and further use.  
 
2.4.5 Preparing subcellular fractions: Protocol 1 
Nuclear and cytoplasmic fractions were prepared from cultured MCF-7 and MDA-MB-
231 cells using the Universal Magnetic Co-IP kit (Active Motif) following the 
manufacturer’s protocol. Briefly, cells were washed in PBS containing protease 
inhibitors. Cells were then scraped into 1x complete hypotonic buffer (containing 
protease inhibitors, phosphatise inhibitors and PMSF) and pelleted by centrifugation at 
4°C. The supernatant (cytoplasmic fraction) was removed and stored at -20°C. The 
pellet was resuspended in complete digestion buffer (containing protease inhibitors, 
phosphatase inhibitors, PMSF and detergent) and incubated on ice for 20 minutes. 
Enzymatic shearing cocktail was added and incubated for 10 minutes at 37°C with 
occasional vortexing. EDTA was added to inactivate the enzymatic shearing complex 
and cells pelleted by centrifugation at 4°C. The supernatant (nuclear fraction) was 
removed and stored at -80°C. 
 
2.4.6 Preparation of subcellular fractions: Protocol 2 
Cytosolic, membrane, nuclear and cytoskeletal fractions were prepared from MCF-7 
and MDA-MB-231 cells using the ProteoExtract Subcellular Proteome Extraction Kit 
(Calbiochem) following a modified version of the protocol provided. Briefly, cells in 
25cm
2 
culture flasks treated with 1μM β-oestradiol, 1μM β-oestradiol followed by 
0.1μM progesterone or an ethanol only control were washed twice in cold Wash Buffer. 
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Cells were then gently scraped from the surface of the flask using a cell scraper into 
cold Extraction Buffer I + protease inhibitors, transferred to a pre-cooled 
microcentrifuge tube and incubated at 4°C on a rotary shaker for 10 minutes, before 
pelleting by 10 minutes centrifugation at 4°C, 1000xg. The supernatant (cytosolic 
fraction) was removed and stored at -20°C. The pellet was resuspended in cold 
Extraction Buffer II + protease inhibitors and incubated at 4°C for 30 mins on a rotary 
shaker before pelleting by 10 minute centrifugation at 4°C, 6000xg. The supernatant 
(membrane fraction) was removed and stored at -20°C. The pellet was resuspended in 
cold Extraction Buffer III + protease inhibitors and Benzonase nuclease, incubated for 
10 minutes at 4°C on a rotary shaker, then pelleted by 10 minutes centrifugation at 4°C, 
6800xg. The supernatant (nuclear fraction) was removed and stored at -20°C. The pellet, 
resuspended in room temperature Extraction Buffer IV formed the cytoskeletal fraction 
and was stored at -20°C. 
 
2.4.7 Protein quantification 
Protein concentrations of cell fractions and whole cell lysates in RIPA buffer were 
quantified using the BioRad DC Protein Assay following the manufacturer’s protocol. 
Absorbances were read using a SpectraMax 190 plate reader (Molecular Devices), and 
protein concentrations calculated using SoftMax Pro software (Molecular Devices). 
 
2.4.8 Protein storage 
Whole cell lysates in SDS lysis buffer were stored at -20°C. Following protein 
quantification, RIPA whole cell lysates and nuclear and cytoplasmic fractions from 
protocol 1 (2.4.5) were divided into 100μg aliquots and stored at -20 or -80°C. 
Proteome fractions from protocol 2 (2.4.6) were divided into 10μg aliquots and stored at 
-20°C. 
 
2.5 Shrimp Alkaline Phosphatase treatment 
Whole cell protein lysates in RIPA buffer were prepared as previously described from 
MCF-7 and MDA-MB-231 cells stimulated with 1µg/µl β-oestradiol or an ethanol only 
control. 30µg of protein was used for each 30µl reaction with 10µl shrimp alkaline 
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phosphatase (SAP) and an appropriate volume of 10x SAP reaction buffer. Control 
reactions contained 10µl RIPA buffer instead of SAP. Reactions were incubated for 1 
hour at 37°C before heat inactivation of the enzyme at 65°C for 15 minutes. Samples 
were analysed by Western immunoblotting as described below following addition of 
30µl 2xSDS lysis buffer. 
 
2.6 Co-Immunoprecipitation 
Co-immunoprecipitation (Co-IP) was carried out using the Universal Magnetic Co-IP 
kit (Active Motif), following the manufacturer’s protocol. Briefly, 50μg nuclear or 
cytoplasmic extract was incubated for 4 hours at 4°C on a rotary shaker with a capture 
antibody, or an appropriate IgG control, in a total volume of 250μl of complete Co-IP 
buffer. 12.5μl of Protein G magnetic beads (Active Motif) were added to each tube and 
incubated for 1 hour at 4°C on a rotary shaker. Antibody/protein complexes bound to 
protein G beads were precipitated using a magnetic tube stand, and the beads washed by 
resuspending in complete Co-IP buffer and re-precipitating 4 times. The beads were 
then resuspended in 20μl SDS lysis buffer. Protein/antibody/bead complexes were 
denatured by heating to 95°C for 5 minutes. Proteins in SDS lysis buffer were then 
removed from the beads and stored at -20°C. A list of antibodies used can be seen in 
Table 2.8. 
 
2.7 DNA affinity precipitation assay (DAPA) 
2.7.1 Oligonucleotides 
Biotinylated single strand DNA oligonucleotides were purchased from Invitrogen, Life 
Technologies. Sequences for the sense strands of the consensus PRE, and mutated PRE 
sequence oligonucleotides are shown below. Bases altered in the mutated sequence are 
underlined in bold font: 
Consensus PRE:  GATCCTGTCACGGATGTTCTAGCTACA 
Mutated PRE:  GATCCTCAACAGGATCATCTAGCTACA 
Unbiotinylated (cold) PRE oligonucleotides of the same sequences were purchased 
from Santa Cruz Biotechnology. 
79 
2.7.2 Annealing buffer 
10mM Tris-HCl pH 7.5, 
50mM NaCl 
1mM EDTA 
 
2.7.3 Annealing oligonucleotides 
Complementary oligonucleotides were resuspended to the same molar concentration in 
annealing buffer. Equal volumes of each oligonucleotide were mixed in a 1.5ml 
microcentrifuge tube and placed in a heat block at 95°C. The heat block containing the 
annealing reactions was removed from the apparatus and allowed to cool to room 
temperature on the bench to allow complete annealing of complementary 
oligonucleotides. 
 
2.7.4 DAPA binding buffer 
12mM HEPES pH7.9 
 4mM TRIS-HCl 
 60mM KCl 
 5% glycerol 
 0.5mM EDTA 
 
2.7.5 DAPA protocol 
Nuclear and cytoplasmic fractions were isolated from MCF-7 and MDA-MB-231 cells 
following hormone stimulation using the Universal Magnetic Co-IP kit as described 
previously. 50µg of nuclear or cytoplasmic extract was incubated in 400µl DAPA 
binding buffer for 1 hour on ice with gentle agitation, with 0.25µg synthetic biotinylated 
double stranded oligonucleotide for a consensus PRE sequence or a mutated PRE 
sequence. 40µl streptavidin magnetic beads were equilibrated in DAPA binding buffer 
and added to each reaction before incubation at 4°C for 2 hours on a rotator to prevent 
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settling of the beads and allow formation of protein/PRE/bead complexes. Unbound 
proteins were removed by washing six times in 1ml of DAPA binding buffer. Beads 
were then resuspended in 30µl SDS lysis buffer to dissociate protein/PRE complexes. 
Samples were heated to 95°C for 5 minutes to denature proteins before removing from 
the beads by magnetic separation. Samples were stored at -20°C for future analysis by 
Western immunoblotting. 
 
2.8 SDS-PAGE and Western immunoblotting 
2.8.1 Materials 
2.8.1.1  Polyacrylamide gel 
Stacking gel: 4% acrylamide (BioRad), 125mM Tris-HCl pH6.8, 1% sodium dodecyl 
sulphate (SDS, Sigma-Aldrich), 0.1% TEMED (Sigma-Aldrich) and 0.5% ammonium 
persulphate (APS; Sigma-Aldrich). 
Resolving gel: 10% acrylamide, 375mM Tris-HCl pH8.8, 0.1% SDS, 0.1% TEMED 
and 0.1% ammonium persulphate. 
 
2.8.1.2  Electrode buffer 
1x electrode buffer contained 25nm Tris-HCl, 190mM glycine and 0.1% SDS. 
 
2.8.1.3  Transfer buffer 
1x transfer buffer contained 25nM Tris-HCl, 0.15M glycine and 10% methanol. 
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2.8.1.4  Phosphate buffered saline (PBS) 
137mM NaCl 
 2.7mM KCl 
 8.1mM Na2HPO4.H20 
 1.76mM KH2PO4 
 
2.8.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate proteins for Western immunoblot analysis. Samples 
were loaded into wells in a 4% stacking gel and separated by electrophoresis using a 
10% acrylamide resolving gel. Protein samples were prepared as described previously. 
Proteins in RIPA buffer and cell fractions were denatured by addition of an appropriate 
volume of 2xSDS lysis buffer, and all samples were heated to 95°C for 5 minutes prior 
to loading. PageRuler Prestained Protein Ladder (Fermentas) was used to determine 
protein size and track migration. Electrophoresis was performed in 1x electrode buffer 
at 200V using a BioRad mini-PROTEAN Tetra System. 
 
2.8.3 Protein transfer 
Proteins were transferred onto nitrocellulose membrane (BioRad) by electrophoresis in 
1x transfer buffer at 90V for 2 hours. 
 
2.8.4 Ponceau S staining 
Equal protein loading was assessed by Ponceau S staining (data not shown). Membranes 
were incubated for 1 minute in Ponceau S solution (Sigma-Aldrich) and washed in 
distilled water. Membranes were de-stained by washing in 1xPBS. 
 
2.8.5 Blocking of non-specific proteins 
Unbound sites on membranes were blocked by incubation in a blocking solution of 10% 
non-fat milk powder (Marvel) in 1xPBS for 1 hour at room temperature. 
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2.8.6 Primary antibody incubation 
Primary antibody incubations were performed at an appropriate dilution in a solution of 
non-fat milk powder in 1xPBS or 1xPBS + 0.01% Tween20 (PBST), either for 1 hour at 
room temperature or overnight at 4°C on a rocking platform. Details of primary 
antibody concentrations can be seen in Table 2.8. Membranes were washed twice for 5 
minutes and once for 20 minutes in 1xPBS following primary antibody incubation. The 
membranes were then incubated with a horseradish peroxidise (HRP) conjugated 
secondary antibody (Dako), diluted 1:3000 in 1xPBS, for 1 hour at room temperature. 
Washes were repeated after secondary antibody incubation. The approximate regions of 
the PR protein targeted by each commercial PR antibody can be seen in Figure 2.1. 
 
 
Figure 2.1: Approximate regions targeted by each commercial PR antibody used in this 
study.  
BUS= PR-B specific B-upstream segment, A/B= PR-A and B N-terminal region, C= DBD, D= 
hinge/NLS, E= LBD/DD. 
 
2.8.7 Detection and analysis 
Proteins were detected using ECL Western Blotting Substrate (Pierce), or SuperSignal 
West Femto (Pierce) and exposure to x-ray film (KODAK). Autoradiographs were 
developed using an X-ograph Compact X4 X-ray film processor. Densitometric analysis 
of protein bands detected following Western immunoblotting was performed using 
Intelligent Quantifier (BioImage Systems, Inc). 
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2.9 Ligand blot assay 
2.9.1 Cell fractionation 
Cytosolic, membrane, nuclear and cytoskeletal fractions were prepared using the 
ProteoExtract Subcellular Proteome Extraction Kit as previously described.  
 
2.9.2 Protein separation 
7μg of each fraction was diluted with an appropriate volume of 2xSDS lysis buffer and 
denatured by heating to 95°C. Proteins were separated by SDS-PAGE and transferred to 
nitrocellulose membrane as described previously. 
 
2.9.3 Ligand blotting 
Ligand blotting was carried out following a published protocol (Jang and Yi, 2005). 
Briefly, membranes were incubated for 30 minutes in ligand blot buffer (1x PBS + 3% 
Nonidet-P40), then blocked by incubating for 2 hours in a blocking buffer (1x PBS + 
0.3% bovine serum albumin (BSA) + 0.1% Tween20) and washed for 10 minutes in 1x 
PBS + 0.1% Tween 20. Membranes were then incubated overnight at 4°C in blocking 
buffer + 1μM peroxidase conjugated progesterone (P-POD; Fitzgerald). Membranes 
were washed 3 times in 1xPBS + 0.1% Tween20 before developing using SuperSignal 
West Femto and X-ray film as described above. 
 
2.10 Reverse-transcriptase polymerase chain reaction (RT-
PCR) 
2.10.1 RNA extraction 
RNA was extracted from cultured cells or frozen breast tumour tissue using the SV 
Total RNA Isolation Kit (Promega) following the manufacturer’s Spin Protocol. Briefly, 
cells cultured in a 75cm
2
 culture flask were harvested directly into 700µl RNA Lysis 
Buffer. 175µl cell lysate was used for RNA extraction. Following a DNase I treatment 
step, RNA was eluted in nuclease free water provided with the kit. RNA was extracted 
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from cells in 12 well culture plates after siRNA treatment following the same protocol, 
with cells harvested into 175µl RNA Lysis Buffer per well. Approximately 30mg frozen 
breast tumour tissue was homogenised in liquid nitrogen using a pestle and mortar and 
lysed using 175µl RNA Lysis Buffer. RNA was extracted following the manufacturer’s 
Spin Protocol. RNA concentrations were measured using a NanoDrop ND-1000 
spectrophotometer (ThermoScientific). RNA samples were stored at -80°C. 
 
2.10.2 Reverse transcription 
First strand cDNA was synthesised from total RNA by reverse transcription using 
SuperScript III Reverse Transcriptase (ssRT; Invitrogen, Life Technologies). 1μg total 
RNA was mixed with 10μl 5x First Strand Synthesis Buffer (Invitrogen, Life 
Technologies), 2μl 40mM PCR nucleotides (Promega), 1μl 0.5μg/μl oligo dT20 primers 
(Invitrogen, Life Technologies), 1μl 0.1M DTT (Invitrogen, Life Technologies), 1μl 
RNAse OUT Recombinant Ribonuclease Inhibitor (Invitrogen, Life Technologies) and 
1μl ssRT. Reaction volumes were adjusted to 50µl using nuclease free water (Invitrogen, 
Life Technologies). Reactions were performed at 50°C for 1 hour and cDNA was stored 
at -20°C. A no RT reaction was set up in parallel to each cDNA synthesis reaction as a 
control for genomic DNA contamination; 1µl nuclease free water was added in place of 
ssRT. 
 
2.10.3 Design of the PR gene walking assay 
A PR gene walking assay was developed using primers directed to each of the eight 
exons of the PR gene. Primers were designed based on the PR mRNA sequence (NCBI 
Accession: NM_000926.4) and synthesised by Invitrogen, Life Technologies. Sense 
primers directed to the PR-B and PR-A promoter regions, regions within exon 1 
common to PR-A and B, and to each of the other 7 exons. Antisense primers were 
designed to each of the 8 exons, and 3 within exon 1. Primers were used in combination 
to examine different regions of the PR gene and assess any alternative splicing which 
may be occurring by comparing the size of PCR product to the predicted size base on 
the PR gene sequence (NCBI Accession: NM_000926.4). The predicted sizes of PCR 
products produced using each primer combination in the PR gene walking assay can be 
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seen in table 2.3. PCR reactions were performed using all combinations of primers 
giving products ≤1kb using MCF-7 and MDA-MB-231 cDNA.  
 
Table 2.3: Predicted PCR product size (bp) of each primer combination in the PR gene 
walking assay.  
Combinations with product sizes in the unshaded area (products <1kbp) were used for PCR with 
MCF-7 and MDA-MB-231 cDNA. S=sense primer, A=antisense primer. 
 
 
2.10.4 PCR reactions for gene walking assay 
25µl PCR reaction mixes consisted of 2µl cDNA template, 0.25µl of each primer (sense 
and antisense, 0.5µg/µl), 12.5µl PCR Master Mix (Promega) and 10µl DNase free water 
(Promega). All PR primers were designed to be used at an annealing temperature of 
55°C. 25-30 cycles of PCR were initially performed using RNA from MCF-7, T47-D 
and MDA-MB-231 cells. PCR cycle number was increased to 45 to detect low levels of 
truncated PCR products in MDA-MB-231 cells for cloning and sequencing. PCR 
reaction conditions were as follows: an initial denaturation step of 95°C for 5 minutes, 
followed by 30-45 cycles consisting of denaturation at 95°C for 30 seconds, annealing 
at 55°C for 30 seconds and extension at 72°C for 30-60 seconds depending on the size 
of PCR product to be generated. This was followed by a final extension at 72°C for 5 
minutes and cooling to 4°C for storage. To demonstrate that no contamination was 
present in PCR master mix or primers, a no template control (NTC) was included for 
each primer set. Reaction mixtures contained an extra 2µl DNase free water instead of 
cDNA. As a control for genomic DNA contamination, PCR reactions using GAPDH 
primers were performed using the no RT control template described in Section 2.10.2. 
Primer sequences used in the PR gene walking assay can be seen in Table 2.4. 
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Table 2.4:  Sequences and annealing temperatures of the PCR primers used in the PR 
gene walking assay. 
 
2.10.5 PR intron retention PCR 
To identify the presence of mRNA for previously identified PR isoforms resulting from 
retention of intronic sequences, primers directed to introns M, S, T and i45b were used. 
A sense primer was designed based on the published PR-M intronic sequence (Saner et 
al., 2003) and previously published sense primers were used to detect PR-S and PR-T 
mRNA (Hirata et al., 2002; Hirata et al., 2000). A previously reported antisense primer 
directed to PR-i45 intron b was also used (Yamanaka et al., 2002). Primer sequences 
can be seen in Table 2.5. Primers were synthesised by Invitrogen, Life Technologies. 
PCR was performed using the same reaction conditions described for the PR gene 
walking assay. 
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Table 2.5: Sequences and annealing temperatures of the PCR primers used to examine 
intron retention. 
 
2.10.6 RT-PCR to characterise PR mRNA in frozen breast tumours 
PCR conditions were identical to those used in the PR gene walking assay for breast 
cancer cell lines. 45 cycles of PCR were performed with each 25µl reaction containing 
4µl of tumour cDNA and the volume of water accordingly adjusted to 8µl. Positive 
control reactions used 2µl MCF-7 cell cDNA and no-template controls were included 
for each primer set. 
 
2.10.7 SRSF PCR 
To confirm successful knockdown of splicing factors by siRNA treatment of MCF-7 
cells, PCR was performed using primers directed to each of the targeted splicing factor 
genes. Primers for SRSF1, SRSF2, SRSF5 and SRSF6 were synthesised by Invitrogen, 
Life Technologies and used to examine siRNA knockdown of these splicing factors. 
GAPDH primers were used to ensure equal loading. Semi-quantitative PCR reactions 
were performed using the same reaction conditions described above using the annealing 
temperature and cycle number detailed for each primer set in Table 2.6. 
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Table 2.6: Sequences and annealing temperatures of PCR primers used to assess SRSF 
knockdown. 
 
2.10.8 PCR to investigate the regulation of PR exon 4 and 6 splicing 
Primers from the PR gene walking assay spanning exons 3 to 5 (S7/A4) and exons 5 to 
7 (S9/A2) were used to identify the effect of SRSF knockdown in MCF-7 cells on the 
alternative splicing of exon 4 (S7/A4) or exon 6 (S9/A2). PCR reactions were 
performed following the same conditions as described for the PR gene walking assay. 
To allow semi-quantitative analysis of the levels of PCR products detected, 25 cycles of 
PCR were performed to study full length PCR products and 35 cycles to study exon 
deleted PCR products. 
 
2.10.9 Ethidium bromide/agarose gel electrophoresis 
Orange G DNA loading dye (Sigma-Aldrich) was added to PCR products which were 
then separated by electrophoresis through a 2% agarose gel (Sigma-Aldrich) in TBE 
buffer (Sigma-Aldrich) containing 1.5µl ethidium bromide (10mg/ml; Sigma-Aldrich) 
per 50ml agarose gel. PCR products were visualised under UV light using a 
BioSpectrum Multi Spectral Imager System (UVP). Approximate molecular weight was 
determined using Quick-Load 100bp DNA Ladder (New England Biolabs). 
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2.11 Cloning and sequencing of PCR products 
2.11.1 Excision and purification of PCR products from agarose gels 
Following electrophoresis and visualisation under UV light, PCR products were excised 
from the agarose gel using a sterile scalpel. PCR products were purified from gel slices 
using the Wizard SV DNA Purification Kit (Promega) following the manufacturers 
protocol.  Briefly, excised gel slices were melted by incubation at 60°C in binding 
buffer, added to a spin column and incubated for 1 minute at room temperature to allow 
DNA to bind to the column membrane. The column was then centrifuged and washed 
twice by centrifugation with membrane wash solution. DNA was eluted into 25μl 
nuclease free water provided with the kit. 
 
2.11.2 Ligation into TOPO TA vector 
4μl purified DNA/PCR product was incubated with 1μl pCR4-TOPO plasmid (TOPO 
TA Cloning Kit for Sequencing; Invitrogen, Life Technologies) and 1μl salt solution 
provided with the kit for 30 minutes at room temperature. A map of the pCR4-TOPO 
plasmid can be seen in Figure 2.2. 
 
 
 
 
 
 
 
 
 
 
 
90 
 
Figure 2.2: Map of the pCR4-TOPO plasmid used for cloning PCR products. 
PCR products were ligated into the plasmid in the region indicated. Ligation of the PCR product 
disrupted the LacZα gene preventing production of the toxic gene product, and allowed 
transcription of the ampicillin resistance gene enabling selection for positive clones on LB-agar 
plates containing 100µg/ml ampicillin. EcoR1 restriction sites are located both sides of the PCR 
product insert and were used to digest the plasmid DNA for analysis of the size of DNA insert 
before sequencing. The location of sequencing primer sites are indicated in the sequence and 
M13F was routinely used for sequencing reactions by SourceBiosciences. Figure extracted from 
TOPO TA Cloning Kit for Sequencing User Manual (Invitrogen, Life Technologies). 
 
2.11.3 Transformation of competent E.coli cells 
2μl ligation mix was incubated for 20 minutes on ice in a vial of chemically competent 
E.coli (TOPO TA Cloning Kit for Sequencing; Invitrogen, Life Technologies) before 
heat shocking (42°C, 30 seconds), addition of 250μl room temperature SOC media 
(TOPO TA Cloning Kit for Sequencing; Invitrogen, Life Technologies), and 1 hour 
incubation at 37°C in an orbital shaker at 225rpm. 
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2.11.4 Lysogeny broth (LB)  
10g tryptone 
5g yeast extract 
10g NaCl 
Dissolved in 950ml distilled water, pH adjusted to 7.5 and volume made up to 1L with 
distilled water before autoclaving. 
 
2.11.5 Growth of E.coli colonies on selective agar plates 
Selective 1.5% LB-agar plates containing 100μg/ml ampicillin (Sigma-Aldrich) were 
produced and 125μl transformation mixture was spread onto each plate. The TOPO TA 
vector contains the LacZα gene which can is disrupted by the ligated DNA insert. When 
the vector is circularized, plasmid without an insert will transcribe the LacZ gene, the 
product of which is toxic to the cell. Non-circularized plasmid DNA will be unable to 
transcribe the ampicillin resistance gene, allowing selection of positive clones. Plates 
were incubated overnight at 37°C to allow formation of ampicillin resistant colonies 
containing the plasmid DNA. Isolated colonies were picked from the agar plates, added 
to 4ml LB media containing 100μg/ml ampicillin, and cultured overnight at 37°C in an 
orbital shaker at 225rpm. 
 
2.11.6 Small scale preparation of plasmid DNA 
Plasmid DNA was isolated from overnight cultures of E.coli using the PureYield 
Plasmid DNA Mini Prep Kit (Promega) following the manufacturer’s protocol. Bacteria 
were lysed using alkaline Cell Lysis Buffer, neutralized using Neutralization Solution 
containing acetate and centrifuged to remove cell debris, proteins and bacterial genomic 
DNA. Plasmid DNA in solution was then added to a spin column, incubated for 1 
minute at room temperature to allow DNA binding to the column membrane, before 
centrifugation to remove buffers and washing of the column to remove contaminants 
such as salts and endotoxin. Plasmid DNA was eluted into 25μl nuclease free water 
(Invitrogen, Life Technologies). 
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2.11.7 Restriction analysis 
Restriction digest reactions consisted of 5μl plasmid DNA, 0.2μl BSA, 2μl Buffer H, 
1μl EcoR1 (Promega) and 11.8μl nuclease free water. Reactions were incubated 
overnight at 37°C in a water bath without shaking. Restriction digest fragments were 
analysed by ethidium bromide gel electrophoresis to assess the size of DNA insert in the 
plasmid DNA. Plasmid DNA with the correct size insert was selected for DNA 
sequencing. 
 
2.11.8 DNA sequencing 
Plasmid DNA sequencing was performed using M13F sequencing primers by Source 
BioSciences, Nottingham, UK. 
 
2.11.9 Analysis of DNA sequences 
DNA sequences were compared to the PR mRNA sequence (NCBI Accession: 
NM_000926.4) using the ALIGN program (http://xylian.igh.cnrs.fr/bin/align-guess.cgi) 
to determine the region removed by alternative splicing. The predicted amino acid 
sequence resulting from sequenced mRNA was determined by deleting the appropriate 
region (as identified by ALIGN) from the PR mRNA sequence and inputting the 
truncated sequence into the ExPASy Translate tool (http://web.expasy.org/translate/). 
This predicted amino acid sequence was then used with the ExPASy Compute pI/Mw 
tool (http://web.expasy.org/compute_pi/) to predict the molecular weight of the protein 
produced from each sequenced mRNA. 
 
2.12 Bioinformatic analyses of splicing factor binding sites 
within the PR cDNA sequence 
PR exon 4 and exon 6 mRNA sequences (NCBI Accession: NM_000926.4) were 
entered into the ESEfinder (Cartegni et al., 2003; http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home) and Splicing Rainbow databases 
(http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8) to predict the presence of potential 
binding sites for a range of RNA binding splicing factors. ESEfinder uses a functional 
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SELEX method to predict the presence of binding sites; briefly, potential exon splice 
enhancers (ESEs) were determined by the ability of sequences to enhance splicing in a 
pool of mini-genes. The mini-gene splicing was then carried out in the presence of 
individual SR proteins (SRSF1, SRSF2, SRSF5 and SRSF6), and sequences bound to 
SR proteins were aligned to identify a consensus motif (Liu et al., 1998). The frequency 
of individual nucleotides at particular positions within the sequence was used to create a 
scoring system to identify how likely a sequence is to bind to an SR protein (Cartegni et 
al., 2003). Splicing Rainbow analyses query sequences for the presence of previously 
identified sequences known to be binding sites for a wide range of RNA binding 
proteins (RBP) including those analysed by ESE Finder, and provides a score indicating 
how closely each potential binding site matches the consensus for each RBP (Stamm et 
al., 2006). 
 
2.13 Immunofluorescent staining 
2.13.1 Cultured cells 
To determine the effect of hormone stimulation on PR localisation, MDA-MB-231 cells 
were seeded at a density of 0.3x10
6
 cells per well in 6 well culture plates containing 
glass coverslips (Scientific Laboratory Supplies), cultured to 60% confluency, serum 
starved as previously described, and stimulated with 1μM β-oestradiol, 0.1μM 
progesterone or an ethanol only control. Alternatively MCF-7 cells were seeded at a 
density of 0.3x10
6
 cells per well in the presence of PR targeted siRNA or a negative 
control siRNA and cultured for 72 hours. Cells on coverslips were fixed by immersion 
in cold methanol and incubated at -20°C for 20 minutes. Coverslips were then air dried 
at room temperature before being mounted onto microscope slides (Erie Scientific) 
using clear nail polish.  
 
2.13.2 Tris-buffered saline (TBS) 
0.1M TRIS,  
0.05M NaCl 
Dissolved in distilled water, pH adjusted to 7.6. 
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2.13.3 Blocking of non-specific binding 
Non-specific binding was blocked by the addition of a solution of 10% normal goat 
serum (NGS; Jackson ImmunoResearch Laboratories) in TBS and incubation at room 
temperature for 10 minutes. 
 
2.13.4 Primary antibody Incubation 
Primary antibody C19 was added to the coverslips at a dilution of 1:300 in 1xTBS + 1% 
NGS and incubated at 4°C overnight. Following removal of the primary antibody, cells 
were washed 3 times in TBS. Staining specificity was confirmed by a no-primary 
antibody control (data not shown). Control cells were treated in the same way as 
experimentally stained cells; fixed, blocked and incubated in the absence of primary 
antibody before addition of the secondary antibody. 
 
2.13.5 Secondary antibody incubation 
Rhodamine conjugated goat anti rabbit secondary antibody (Jackson ImmunoResearch 
Laboratories) was added to each slide at a dilution of 1:40 in 1xTBS and incubated at 
room temperature for 30 minutes in the dark. 
 
2.13.6 Analysis of staining by confocal microscopy 
Glass coverslips were mounted over the cells using DAPI Vectashield mounting media 
(Sigma-Aldrich). DAPI provided nuclear staining of the cells. Coverslips were secured 
using clear nail polish. Analysis of immunofluorescent staining was performed using a 
Leica TCS SP2 UV confocal microscope at the Newcastle University Bioimaging 
Facility. 
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2.14 Production of antisera against PR 
2.14.1 Synthesis of internal and C-terminal PR MAPs 
A series of potential peptide sequences were identified within the regions of the full 
length PR protein encoded by exons 2 to 8. These peptides were selected based on their 
specificity for PR and to differ from the regions targeted by commercial PR antibodies. 
Peptide sequences were sent to Alta Bioscience and analysed for potential 
immunogenicity. The two peptide sequences predicted to be the most immunogenic 
were selected and used by Alta Bioscience to synthesise multiple antigenic peptides 
(MAPs) A3 (internal) and A4 (C-terminal). Peptide sequences are detailed in Table 2.7. 
 
 
Table 2.7: Sequences of MAPs used to produce novel PR antibodies. 
MAP A3 and A4 amino acid sequences and locations within the full length PR-B sequence. 
 
2.14.2 Production of antisera 
MAP A3 and MAP A4 were diluted in Freund’s adjuvant and used by PTU/BS Scotland 
to inoculate, by injection, a rabbit and a sheep respectively. Ethical approval for the use 
of animals was obtained by PTU/BS Scotland; PPL 60/3464 in accordance with the 
Home Office Animals (Scientific Procedures) Act. Serum was taken from a bleed pre-
immunisation, and a boost immunisation was administered four weeks after the initial 
immunisation, with the first serum taken from a bleed after five weeks. Further boost 
immunisations were administered after eight and twelve weeks, with serum taken from 
bleeds after nine and thirteen weeks. Serum from the final thirteen week bleed was used 
for antibody purification. 
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2.14.3 Affinity purification of PR antisera 
IgG was purified from 20ml rabbit serum diluted in 20ml 1xPBS pH7 (Sigma-Aldrich) 
using a protein A column (GE Scientific) and sheep serum (20ml diluted in 20 ml 
1xPBS) using a protein G column (GE Scientific). IgG was eluted using glycine pH2.5 
into a neutralising solution of TRIS-HCl pH8. Rabbit IgG was concentrated and 
rediluted into 1xPBS using a 6ml Vivaspin centrifuge tube (Sartorius Stedim Biotech). 
Sheep IgG was dialysed into 1xPBS using a Slide-A-Lyzer Dialysis Cassette (Thermo 
Scientific). 
 
Affinity columns containing MAPs A3 and A4 were provided by Alta Biosciences and 
affinity purification was performed according to the protocol provided. Purified IgG in 
1xPBS was added to the appropriate column (rabbit to A3 and sheep to A4) and the 
eluate was again added to the column to ensure maximum binding of specific IgG. Final 
eluate was stored at -20°C. Purified A3 or A4 IgG was eluted into 5 aliquots using 
glycine pH2.5 into a neutralising solution of 10xPBS pH7. The aliquots were combined 
and the concentration of IgG determined using the BioRad DC protein assay. The novel 
PR antisera will hereon in this thesis be termed Rabbit PRA3 and Sheep PRA4. 
 
2.15 Validation of PR antisera by Western immunoblotting 
Initial Western immunoblotting experiments were performed using whole cell lysates in 
SDS Lysis Buffer from MCF-7 and MDA-MB-231 cells and conditions were optimised 
using a range of concentrations of each novel primary antibody; PRA3 1:2000-1:500 
and PRA4 1:250-1:100. The conditions for incubation with the anti-sheep secondary 
antibody were optimised by varying the antibody concentration (1:5000 and 1:3000), 
dilution in the presence or absence of 0.1% Tween20 and diluting the secondary 
antibody in solutions of either milk or BSA. Western immunoblotting was also 
performed using whole cell lysates in SDS lysis buffer from MCF-7 cells treated with 
PR siRNA (and controls as described above), for each of the novel antibodies to 
validate specificity to PR using the optimised Western immunoblotting conditions. 
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2.16 Validation of PR antisera by Co-Immunoprecipitation 
Co-IPs were performed as described earlier using commercial PR antibodies, A3 and 
A4 as capture antibodies, and A3 and A4 as detection antibodies in Western 
immunoblotting. Details of antibodies used can be seen in Table 2.8. 
 
2.17 Validation of PR antisera by enzyme linked 
immunosorbant assay (ELISA) 
2.17.1 ELISA coating buffer 
35mM NaHCO3,  
15mM Na2CO3  
Dissolved in distilled water, pH adjusted to 9.6 
 
2.17.2 ELISA developing solution 
0.43mg/ml o-phenylenediamine (OPD) in 0.1M citrate buffer (pH5.0) + 0.012% H2O2 
 
2.17.3 ELISA protocol 
Immulon ELISA plates (ThermoFisher Scientific) were coated with 1µg/µl or 10µg/µl 
of primary antibody diluted in ELISA coating buffer. 100µl diluted antibody was added 
per well, with ELISA coating buffer used in blank wells. Plates were incubated at 4°C 
overnight to allow antibody binding to the plate. Details of the antibodies used can be 
seen in Table 2.8. Plates were then washed 5 times using 1xPBST and blocked by 2 
hours incubation at room temperature with a 5% solution of non-fat milk powder in 
1xPBST. Plates were again washed in 1xPBST and then incubated for 2 hours at room 
temperature with HRP conjugated secondary antibodies (Dako), diluted 1:3000 in 5% 
non-fat milk in 1xPBST. The wash steps were repeated before addition of ELISA 
developing solution. After sufficient colour development 2M H2SO4 was added to each 
well as a stop solution. Absorbances were read at 490nm using a plate reader. 
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2.18 Clinicopathological analysis of breast tumour tissue 
sections 
2.18.1 Optimisation of immunohistochemistry 
Epitope retrieval was optimised by the Histocytopathology Department, Gateshead 
Queen Elizabeth Hospital; high and low pH retrieval solutions were used with varying 
incubation times. Antibodies PRA3 and PRA4 were optimised for use in staining of 
FFPE breast tumour sections by the Histocytopathology Department, Gateshead Queen 
Elizabeth Hospital. 4µm sections were cut from three FFPE blocks of tumour samples 
previously characterised as strongly PR positive, weakly PR positive or PR negative, 
deparaffinised in xylene and rehydrated in graded alcohol and water. A range of 
dilutions of each antibody, from 1:500-1:50, was used for immunohistochemical 
staining in an automated two step polymer method using the EnVision Flex detection 
system (Dako) on an Autostainer Plus Link (Dako) to determine optimal conditions.  
 
2.18.2 Analysis of tumour PR expression by immunohistochemistry 
Following optimisation of conditions, staining was performed using PRA3 and PRA4 
on 4µm sections from fifteen FFPE breast tumour blocks matched to the frozen samples 
used for RT-PCR analysis of PR expression. One sample used for RT-PCR was a core 
biopsy and therefore matched FFPE tissue was not available. Sections were initially 
analysed by haematoxylin and eosin staining to confirm the presence of tumour tissue 
(data not shown). The optimised antibody dilutions used for immunohistochemical 
staining are detailed in Table 2.8. Sections were incubated for 40 minutes with primary 
antibody and analysed using the Autostainer Plus Link. Sections were counterstained 
with haematoxylin (EnVision Flex, Dako) to highlight cell architecture and identify 
nuclear staining. 
 
2.18.3 Scoring of tumour PR status 
Tumour PR status was scored depending on the clarity, intensity and proportion of 
nuclear staining observed during microscopic analysis using a modification of the 
Quickscore method for hormone receptors. The Quickscore method assigns a score of 0-
3 for intensity of staining, and 0-6 for the proportion of nuclei stained. The two scores 
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are multiplied to give a maximum score of 18. The modified scoring system was 
developed by the Histocytopathology Department, Gateshead Queen Elizabeth Hospital. 
Tumours were scored negative if ≤10% of nuclei stained positive (Quickscore 0-2), and 
positive if >10% of nuclei stained positive (Quickscore 3-6). PRA3 staining intensity 
was not as strong as commercial antibodies and was therefore not considered in the 
modified Quickscore method. 
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2.19 Antibodies 
 
Table 2.8: Details of the antibodies used in this study.
1
0
0
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3 Characterisation of PR expression in breast cancer 
cell lines 
3.1 Introduction 
ASEs involving deletion of various internal PR exons have been described (Balleine et 
al., 1999b; Hodges et al., 1999; Misao et al., 1998; Leygue et al., 1996a). In addition, 
retention of intronic sequences in PR mRNA has also been reported (Saner et al., 2003; 
Hirata et al., 2002; Yamanaka et al., 2002; Hirata et al., 2000). The previously reported 
alternative splicing of PR is described in depth in Section 1.4.11 of this thesis, and 
could give rise to mRNA which would encode truncated proteins which may impact on 
PR screening in breast cancer. PR screening in breast cancer has traditionally used 
antibodies targeted to N-terminal epitopes (Hanley et al., 2009). N-terminally truncated 
PR variants may result from alternative splicing or alternative promoter usage and 
would not be detected by PR screening. Alternatively, exon deleted PR mRNA may 
encode functionally different PR proteins with N-terminal regions identical to full 
length PR, making them indistinguishable from full length PR using current screening 
antibodies. Therefore, a breast cancer cell line characterised as PR negative, MDA-MB-
231, was assessed for the presence of PR spliced variants and to predict the structures of 
the potential proteins which may be encoded. The potential functionality of the putative 
variant proteins and the impact of variant protein expression on breast cancer screening 
were then predicted. Expression of previously reported N-terminally truncated PR 
spliced variants was also assessed in this cell line. Recent controversy over the 
specificity of non N-terminal commercial PR antibodies (Pang and Thomas, 2011; 
Madsen et al., 2007), and over the existence of truncated PR isoforms (Samalecos and 
Gellersen, 2008) has necessitated firstly the characterisation of proteins detected by 
commercial PR antibodies, and secondly validation of the specificity of these antibodies. 
 
Small interfering RNAs (siRNAs) are short, non-coding, double stranded, antisense 
RNA molecules which are produced by the cleavage of longer RNAs (Elbashir et al., 
2001; Hamilton and Baulcombe, 1999). siRNA reduces gene expression through the 
RNA interference pathway; the two siRNA strands separate and one of the strands is 
integrated into the RNA induced silencing complex (RISC). RISC binds via the siRNA 
strand to a complementary sequence of mRNA and the active component of RISC, 
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Argonaute, then cleaves the mRNA preventing translation (Liu et al., 2004). siRNA 
molecules are designed to be complementary for a specific gene. Therefore transfection 
of siRNA into cultured cells prevents translation of a specific mRNA. This reduced 
protein expression was used to validate the specificity of antibodies by observing 
knockdown of proteins detected by the antibody. 
 
3.2 Aims 
The aims of this chapter were to: 
1. Develop a PR gene walking assay and use this to identify ASEs and 
characterise PR mRNA expression in a range or breast cancer cell lines 
with different phenotypes. 
2. Characterise PR protein expression in MCF-7 and MDA-MB-231 breast 
cancer cell lines and select which commercially available antibodies to use 
for further experimentation. 
3. Determine the effect of β-oestradiol stimulation on the expression of PR in 
breast cancer and normal mammary epithelial cell lines. 
4. Examine the subcellular localisation of PR in breast cancer cell lines and 
the effect of hormone stimulation on subcellular localisation. 
5. Validate the specificity of commercial PR antibodies. 
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3.3 Results 
3.3.1 Characterising PR mRNA expression in breast cancer cell lines 
3.3.1.1 Development of an RT-PCR based PR gene walking assay 
An RT-PCR based PR gene walking assay was developed using sense and antisense 
primers targeted to each of the 8 exons of the PR gene. This assay was used to 
characterise PR mRNA expression in the breast cancer cell lines MCF-7, T47-D and 
MDA-MB-231. Details of these cell lines can be seen in Table 2.1. The size of PCR 
product detected was compared to the predicted size based on the PR gene sequence 
(NCBI Accession: NM_000926.4) to determine potential regions which may undergo 
alternative splicing (see Table 2.4 for predicted PCR product size). This assay was 
initially validated using cDNA from MCF-7 cells. Each pair of primers predicted to give 
a PCR product size less than 1kbp was used for PCR. The gene walking assay is 
illustrated in Figure 3.1; sense primers directed to exon 3 (S7), exon 4 (S8), exon 5 (S9), 
exon 6 (S10) and exon 7 (S11) were used for PCR in combination with antisense 
primers directed to exon 5 (A4), exon 6 (A3), exon 7 (A2) and exon 8 (A1). As the 
distance between the two exons to which the sense and antisense primers are directed is 
increased, an increased size of PCR product was detected. For example S7/A2 (exon 3 
to 7) gives a larger PCR product than S7/A3 (exon 3 to 6) (Figure 3.1). 
 
 
Figure 3.1: Validation of the PR gene walking assay using MCF-7 cDNA. 
RT-PCR was carried out for 30 cycles using MCF-7 cDNA and a range of primers from the PR 
gene walking assay. M=100bp DNA ladder; S=sense: S7=exon 3, S8=exon 4, S9=exon 5, 
S10=exon 6, S10=exon 7; A=antisense: A1=exon 8, A2=exon 7, A3= exon 6, A4=exon 5. 
Correct molecular weight of PCR product was confirmed by comparison to the size predicted by 
analysis of the PR mRNA sequence (NCBI Accession: NM_000926.4). 
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3.3.1.2  PR mRNA is detected in breast cancer cell lines using a gene walking assay 
After initial validation, the PR gene walking assay was then used to characterise PR 
mRNA expression in the PR+ breast cancer cell lines MCF-7 and T47-D, and the 
reportedly PR- breast cancer cell line MDA-MB-231. PR mRNA was detected in all 
three cell lines. Figure 3.2 shows an example of the PCR products detected using this 
gene walking assay. Primers spanning exons 3 to 4 and 3 to 5 detected PR mRNA in 
MCF-7 and T47-D cells. Additionally, primers spanning exons 3 to 6 also detected PR 
mRNA in MDA-MB-231 cells which are characterised as PR- (Figure 3.2a). The gene 
walking assay further detected truncated PCR products in MCF-7 and  T47-D cells 
which may be indicative of ASEs occurring in breast cancer cell lines (Figure 3.2b). 
Primers spanning exons 3 to 4 detect only the full length PCR product, whereas primers 
spanning longer regions also detect the truncated product, suggesting alternative 
splicing of exon 4 may be occurring. 
 
Figure 3.2: PR mRNA expression in breast cancer cell lines. 
RT-PCR carried out for 35 cycles using MCF-7 (lane 1), T47-D (lane 2) and MDA-MB-231 
(lane 3) cDNA detects PR mRNA in each of these cell lines using primers from the gene 
walking assay. A no template control PCR reaction (NTC, lane 4) was also performed. 
Molecular weights were approximated using a 100bp DNA ladder (M). a) PR mRNA is 
detected by the PR gene walking assay in MCF-7 and T47-D cells using a sense primer in exon 
3 (S7) with antisense primers in either exon 4 (A5) or exon 5 (A4) after 30 cycles of PCR. 
Primers spanning exon 3 (S7) to exon 6 (A3) also detect PR mRNA in MDA-MB-231 cells. b) 
A longer exposure of the same gel additionally reveals PR mRNA detected by primers spanning 
exon 3 (S7) to exon 5 (A4) in MDA-MB-231 cells, and reveals the presence of additional PCR 
products  in MCF-7 and T47-D cells. 
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3.3.1.3  Detection of alternatively spliced PR mRNA in MDA-MB-231 cells 
To enable increased detection of low levels of PR mRNA in MDA-MB-231 cells, the 
PCR cycle number was increased from 35 to 45 cycles. In addition to the predicted full 
length band, the gene walking assay detected a range of PCR products in MDA-MB-231 
cells ranging from 100bp to almost 700bp smaller than the predicted full length size 
(Figure 3.3). This suggests that not only do reportedly PR- MDA-MB-231 cells express 
PR, but that PR may be undergoing ASEs in this breast cancer cell line. Comparison of 
the size of PCR product with the predicted size based on the PR gene sequence suggests 
both whole and partial exon deletion may be occurring. 
 
Figure 3.3: Truncated PR mRNA is detected in MDA-MB-231 cells using the gene walking 
assay. 
PCR performed for 45 cycles using MDA-MB-231 cDNA generates the predicted full length 
product and a range of products from 100bp-700bp below the predicted size, e.g. the upper 
arrow highlights the full length product of S7/A4 (446bp), and the lower arrow indicates a 
truncated PCR product approximately 300bp smaller than full length. PCR product size can be 
compared to the full length size to predict the regions which may be deleted. PCR was 
performed with sense primers: A (exon 1), 6 (exon 2) and 7 (exon 3); in combination with 
antisense primers: A2 (exon 7), A3 (exon 6) and A4 (exon 5). Molecular weights were 
approximated using a 100bp DNA ladder (M). 
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3.3.1.4  PR intron retention in breast cancer cell lines 
As discussed in the introduction to this thesis, and in Section 3.1, previous studies have 
demonstrated the retention of intronic sequences in PR mRNA. These include intronic 
exons S, T and M between exons 3 and 4 (Saner et al., 2003; Hirata et al., 2002; Hirata 
et al., 2000), and intronic exons i45a and b between exons 4 and 5 (Yamanaka et al., 
2002). The locations of the intronic primers and the PR gene walking assay primers 
used to detect intron retained PR mRNA are shown in Figure 3.4.  
 
Figure 3.4: Location of PCR primers used to investigate intron retention in breast cancer 
cell lines. 
Sense primers directed to intronic exons S, T and M were used in combination with an antisense 
primer directed to exon 5 (A5). An antisense primer to the intronic exon i45b was used in 
combination with a sense primer directed to exon 4 (S8). 
 
 
Expression of intron retained PR mRNA was compared between the PR+ MCF-7 cell 
line which was predicted to express these isoforms, and the reportedly PR- MDA-MB-
231 cell line, which has been demonstrated by the gene walking assay in Section 3.3.1.3 
to potentially express PR mRNA which may undergo ASEs. PR-T, PR-S and PR-i45 
mRNA was detected specifically in PR+ MCF-7 cells. However, PCR products 
representing mRNA for the PR-M isoform was also detected in MDA-MB-231 cells 
(Figure 3.5). 
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Figure 3.5: Intron retention in breast cancer cell lines. 
RT-PCR was undertaken using sense primers directed to the previously described intronic exons 
T, S and M in combination with an antisense primer directed to exon 4, and an i45a antisense 
primer with an exon 4 sense primer. PCR products are detected for all isoforms in MCF-7 cells 
(lane 2). PR-M is also detected in MDA-MB-231 cells (lane 1). M=100bp DNA ladder, 
1=MDA-MB-231, 2=MCF-7, 3=NTC. 
 
 
3.3.1.5  Alternative splicing of PR in MDA-MB-231 breast cancer cells 
All combinations of primers in the PR gene walking assay were used for PCR with 
MDA-MB-231 and MCF-7 cDNA. Cloning and sequencing of PCR products focused 
on reportedly PR- MDA-MB-231 cells which have been previously demonstrated in this 
chapter to express PR mRNA which undergoes ASEs (Figures 3.3 and 3.5). 
Computational analysis of DNA sequences obtained from cloning and sequencing of 
MDA-MB-231 PCR products was performed using ALIGN and ExPASy Translate as 
described in Section 2.11.9. This analysis revealed several modes of ASE that may be 
affecting PR mRNA in MDA-MB-231 cells. Figure 3.6 is a diagrammatic 
representation of the regions removed/retained by the alternative splicing of PR in 
MDA-MB-231 cells, and the potential structures of putative protein products of these 
alternatively spliced mRNAs. Examples of DNA sequencing analysis using ALIGN can 
be seen in Appendix 1.  
 
Firstly, several partial exon deletions were detected, potentially resulting from the use of 
cryptic splice sites within the exons (Figure 3.6b). Deletions of large regions within 
exon 1 and the start of exon 2 usually cause a change in reading frame and truncation 
within the DBD, so are unlikely to generate functional PR proteins and may be targeted 
for NMD (Figure 3.6b). However, one of the observed deletions, designated Δp1c 
would remain in the original reading frame, potentially generating a protein with a 
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truncated N-terminal domain lacking the constitutive AF1, but retaining the other 
functional domains including DBD, NLS, hinge region and LBD (Figure 3.6b). 
 
Whole exon deletions of exon 2 (Δ2) and the cassette exons 3 (Δ3) and 4 (Δ4) were also 
observed in MDA-MB-231 cells (Figure 3.6c). Deletion of exon 2 predicts a change in 
reading frame, leading to a truncated protein which would be unlikely to function. The 
predicted protein product of the PRΔ3 mRNA would lack the second zinc finger of the 
DBD encoded by this cassette exon, but since the mRNA would remain in the original 
reading frame, would possess the normal C-terminal regions so could potentially be 
functional either non-genomically or by competition with wild-type PR for ligand 
binding or dimerisation, thereby modulating PR function. Deletion of the cassette exon 
4 would generate a protein lacking, the hinge region and NLS, but possessing the other 
functional domains. Therefore PRΔ4 protein may be structurally distinct from wild-type 
PR and segregated from the nucleus, but again may be able to function either non-
genomically or through modulation of wild-type PR function (Figure 3.6c). Several 
partial exon deletions within the region of exon 4 to 6 would generate proteins lacking 
parts of the LBD, DD ligand dependent AF2 (Figure 3.6d). 
 
Intron retention was demonstrated in this cell line by presence of mRNA specific for the 
intronic exon M. As previously reported (Saner et al., 2003), PR-M mRNA would 
encode an N-terminally truncated protein also lacking a DBD. This protein would 
contain a functional LBD and a short N-terminal sequence of hydrophobic amino acids 
encoded by exon M (Figure 3.6e). 
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Figure 3.6: Predicted structures of alternatively spliced PR variants detected in MDA-
MB-231 cells. 
Computational analysis of sequenced PCR products from MDA-MB-231 cells was used to 
analyse the regions spliced out of the mRNA and predict the structures of proteins produced. 
ALIGN was used to identify the region spliced out of the mRNA by comparison with the 
published PR gene sequence (NCBI Accession: NM_000926.4), and ExPASy Translate, to 
determine where a STOP codon would be inserted. a) Diagram of the 8 exon PR gene sequence 
showing the ASEs detected in MDA-MB-231 using the gene walking assay. Dashed lines 
indicate the regions deleted/retained by each ASE. The domain structure of the full length PR-B 
protein is shown, indicating the domains encoded by each exon. PR variants have been named Δ 
for deletion and the number of the exon deleted (e.g. Δ4 for exon 4 deleted). Where partial 
exons have been deleted this is indicated by p before the exon number (e.g. Δp4). When 
multiple deletions within an exon are observed, a letter is assigned to each deletion e.g. (Δp1a). 
b) Predicted proteins produced from mRNAs with deletions of parts of exon 1 and exon 2. c) 
Predicted proteins produced from mRNAs with whole exon deletions of exons 2, 3 or 4. d) 
Predicted proteins produced from mRNAs with partial or multiple exon deletions in the region 
exon 4 to 6. e) Potential protein produced from mRNA retaining the intronic exon M. 
 
3.3.2 Characterisation of PR protein expression in breast cancer cell 
lines 
PR protein expression was compared in breast cancer cell lines with different reported 
PR statuses, MCF-7 (PR+) and MDA-MB-231 (PR-). PR expression in these cell lines 
was determined by Western immunoblotting using whole cell lysates and a range of 
commercially available PR antibodies, targeted to epitopes in different regions of full 
length PR protein, as detailed in Figure 2.1 and Table 2.8.  
 
Using N-terminally targeted PR antibodies, proteins corresponding to the full length 
nuclear PR isoforms PR-B (~120kDa) and PR-A (~80kDa) were detected specifically in 
the MCF-7 cell line (Figure 3.7a and b). However, N-terminally targeted PR antibodies 
did not detect protein in the reportedly PR negative MDA-MB-231 cells (Figure 3.7c).  
The C-terminally targeted PR antibody C19 detected a range of low molecular weight 
proteins, between 30 and 50kDa, in addition to a protein of approximately 80kDa in 
MDA-MB-231 and MCF-7 cells. A 60kDa protein, previously described as PR-C, was 
also detected by this antibody, though the identity of PR-C remains controversial as will 
be discussed. The presence of these low molecular weight proteins could indicate that 
alternatively spliced PR proteins are expressed in this cell line, as predicted from the 
mRNA expression previously described. 
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Figure 3.7: Characterising PR protein expression in MCF-7 and MDA-MB-231 cells. 
SDS-PAGE and Western immunoblotting was carried out using whole cell lysates from cultured 
breast cancer cell lines and a range of commercially available PR antibodies. a) Proteins are 
detected at 120kDa (PR-B) and 80kDa in MCF-7 cells using NCL-PgR-B targeted to the B 
upstream segment. No protein is detected in MDA-MB-231 cell lysates. b) N-terminal 
antibodies NCL-PgR-AB and NCL-PgR-312 detect protein at 120kDa (PR-B) and 80kDa (PR-
A) in MCF-7 cells. No protein is detected in MDA-MB-231 cells. NCL-PgR-AB52 failed to 
adequately detect PR proteins in either cell line. c) C20, targeted to an internal epitope, and C19, 
targeted to a C-terminal epitope detect low molecular weight proteins in MCF-7 and MDA-MB-
231 cells. Another internal PR antibody PR-AT 4.14 failed to adequately detect PR proteins. 
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3.3.3 Selection of antibodies for use in future studies 
N-terminal antibodies NCL-PgR-B and NCL-PgR-AB were selected for use in future 
studies as they appeared to demonstrate the greatest specificity of binding to PR-A and 
PR-B in MCF-7 cells. Since C19 was able to detect low molecular weight proteins with 
minimal background in the MDA-MB-231 cells, this C terminal antibody was selected 
for use in assays to determine the effect of β-oestradiol and progesterone stimulation on 
PR expression in breast cancer cell lines. The specificity of all of these antibodies will 
be further analysed in Section 3.3.6. 
 
3.3.4 Hormone responsive PR expression in breast cancer cell lines 
Since the PR gene is oestrogen responsive, containing a partial ERE sequence in both 
the PR-A and PR-B promoters (Kastner et al., 1990), and β-oestradiol has previously 
been reported to influence alternative splicing (Zhang et al., 2007; Zhu et al., 2005), a 
hormone response assay was developed to determine if β-oestradiol had an effect on PR 
expression in breast cancer cell lines. Cells were cultured in the presence of a range of 
concentrations of β-oestradiol (0-10μM) for 24 hours prior to harvesting. The antibodies 
selected from PR characterisation experiments were used for Western immunoblotting 
to assess the effect of β-oestradiol on PR expression. 
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3.3.4.1  Effect of β-oestradiol on PR-A and B expression 
As previously described (Section 3.3.2) the N-terminal antibodies, NCL-PgR-B and 
NCL-PgR-AB, detect protein specifically in the MCF-7 (PR+) cell line. As expected of 
products of oestrogen responsive genes, low doses of β-oestradiol stimulate an 
increased expression of both PR-B (~120kDa) (Figure 3.8a and b) and PR-A (~80kDa) 
detected by these N-terminal PR antibodies (Figure 3.8b). Figure 3.8 provides further 
validation that these N-terminal PR antibodies do not detect PR protein in MDA-MB-
231 and also in the MCF-10A non-tumorigenic MEC line. 
 
Figure 3.8: β-oestradiol stimulates increased expression of PR- B and PR-A in MCF-7 cells. 
MDA-MB-231, MCF-7 and MCF-10A cells were cultured in the presence of a range of 
concentrations of β-oestradiol (0-10μM, 0μM=ethanol only control) for 24 hours prior to lysing 
for SDS-PAGE and Western immunoblotting. All experiments were replicable and carried out 
at least twice. a) Western immunoblotting using NCL-PgR-B detects increased PR-B expression 
at low doses of β-oestradiol. b) Western immunoblotting using  NCL-PgR-AB detects increased 
expression of PR-A and PR-B at low doses of β-oestradiol. No protein was detected by either 
antibody in MDA-MB-231 or MCF-10A cells. 
[β-oestradiol] 
[β-oestradiol] 
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3.3.4.2  β-oestradiol stimulates cell line specific changes in PR expression 
The C-terminal PR antibody C19 detected a range of low molecular weight proteins in 
breast cancer and non-tumourigenic MEC lines. Distinct changes in the patterns of PR 
expression were observed between the cell lines in response to changing concentrations 
of β-oestradiol (Figure 3.9). 
 
In MCF-7 cells low doses of β-oestradiol (0.01µM) appear to stimulate an increased 
expression of proteins in the range 70-90kDa, possibly including PR-A, supporting the 
observations made with N-terminal PR antibodies (Figure 3.9). However, in MDA-MB-
231 cells no effect on the approximately 80kDa protein was observed, and an increased 
expression of several low molecular weight proteins, between 30-60kDa was seen 
(Figure 3.9). In contrast to this metastatic breast cancer cell line, the non-tumorigenic 
mammary epithelial MCF-10A cell line exhibits decreased expression of the low 
molecular weight proteins around 30-40kDa and 60kDa, and an increased expression of 
the 80kDa protein in response to increasing β-oestradiol concentration (Figure 3.9).This 
demonstrates that not only may β-oestradiol be having a cell line specific effect on the 
level of PR expression, but also on the ASEs affecting PR in these cell lines. 
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Figure 3.9: β-oestradiol stimulates cell line specific changes in PR expression in breast 
cancer and non-tumourigenic mammary epithelial cells. 
Lysates from MCF-7, MDA-MB-231 and MCF-10A cells stimulated for 24 hours with a range 
of concentrations of β-oestradiol (0-10μM, 0μM=ethanol only control) were used for SDS-
PAGE and Western immunoblotting using the C-terminal PR antibody C19. Cell line specific 
effects on PR expression were observed. Experiments were reproducable and repeated twice. 
 
 
 
3.3.5 Effect of hormone stimulation on subcellular localisation of PR 
in MDA-MB-231 cells 
β-oestradiol was demonstrated to increase PR expression in MDA-MB-231 cells in the 
hormone response assay (Section 3.3.4). The β-oestradiol concentration which 
stimulated the greatest effect on PR expression in MDA-MB-231 cells was selected to 
stimulate cells to examine the subcellular distribution of PR. MDA-MB-231 cells were 
cultured in the presence of 1μM β-oestradiol for 24 hours. Alternatively, MDA-MB-231 
cells were stimulated with 0.1μM progesterone to examine the effect of ligand binding 
on the translocation of PR in this cell line. Immunofluorescent staining was performed 
using the C-terminal PR antibody C19 to localise PR within the cells. Treated cells were 
compared to a vehicle only control (ethanol) and untreated cells. Untreated and ethanol 
treated cells exhibit a similar distribution of both cytoplasmic and nuclear PR (Figure 
3.10). 
 
 
 
[β-oestradiol] 
C19 
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The classical mechanism of PR action is discussed in Section 1.1; ligand binding causes 
receptor dimerisation phosphorylation, leading to nuclear translocation. Increased 
nuclear and perinuclear staining for PR in MDA-MB-231 cells following progesterone 
treatment suggests PR is translocating in response to progesterone signal (Figure 3.10), 
indicating that PR is potentially functional in these cells. β-oestradiol stimulation 
increased expression of both nuclear and cytoplasmic PR (Figure 3.10). This supports 
the observed β-oestradiol induced increase in PR expression detected by Western 
immunoblotting using C19. 
 
Figure 3.10: Hormone responsive subcellular localisation of PR in MDA-MB-231 cells. 
MDA-MB-231 cells were cultured on glass coverslips in the presence of either 1μM β-
oestradiol or 0.1μM progesterone for 24 hours prior to fixing. Cells were also treated with an 
ethanol only control. Nuclear staining was performed using DAPI and PR staining using the C-
terminal antibody, C19. Untreated cells were also stained for comparison. All staining was 
analysed by confocal microscopy using identical settings. 
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3.3.6 Validation of commercial PR antibodies 
As discussed in Section 1.4.11, recent publications since the start of this study have 
questioned the existence of truncated PR variants, and controversy persists over the 
specificity of commercial non N-terminal PR antibodies (Samalecos and Gellersen, 
2008; Madsen et al., 2007). Since the commercially available PR antibodies have been 
shown in this thesis to detect a range of proteins (Sections 3.3.2 and 3.3.4), validation of 
the specificity of these antibodies was necessary to confirm the identity of the PR 
proteins detected. 
 
3.3.6.1  Knockdown of PR expression demonstrates the specificity of NCL-PgR-B, 
NCL-PgR-AB and C19 
siRNA knockdown of total PR expression was performed in MCF-7 cells, and analysed 
by Western immunoblotting using the N-terminal PR antibodies NCL-PgR-B and NCL-
PgR-AB and the C-terminal PR antibody, C19. Using the PR-B specific antibody NCL-
PgR-B a significant knockdown of the approximately 120kDa PR-B protein was 
observed (Figure 3.11a and b). However, no knockdown was seen of the second band at 
approximately 80kDa (Figure 3.11a). Since the epitope for this antibody is within the 
PR-B specific B-upstream segment, detection of PR-A is not expected. Therefore, while 
NCL-PgR-B does detect PR-B, this data also suggests it detects a smaller non-PR 
protein. MCF-7 cells were also treated with a GAPDH siRNA as a positive transfection 
control and reduced GAPDH levels can be observed in these cells compared to 
untreated, vehicle, negative control siRNA or PR siRNA treated cells (Figure 3.11a). 
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Figure 3.11: Validation of PR binding by NCL-PgR-B. 
a) MCF-7 cells in culture were treated with siRNA for 72 hours prior to lysing for SDS-PAGE 
and Western immunoblotting using NCL-PgR-B. PR= PR targeted siRNA, G= GAPDH targeted 
siRNA (positive transfection control), N= negative control (untargeted) siRNA, V= transfection 
reagent (vehicle) only control, U= untreated cells. GAPDH knockdown is highlighted in the 
blue box. b) Histogram showing levels of PR knockdown relative to the negative control siRNA 
treated cells. Pixel density of the 120kDa band was measured using Intelligent Quantifier, and 
values normalised to the negative control siRNA bands which were always assigned a value of 1. 
Data represents average PR expression relative to N for three experiments. Statistical 
significance of PR knockdown was calculated using a student’s t-test. * = p<0.0001. 
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Knockdown was observed of both the approximately 120kDa (PR-B) and the 
approximately 80kDa (PR-A) proteins using the N-terminal antibody NCL-PgR-AB 
(Figure 3.12a and b). However, this antibody also detected another protein band close to 
the molecular weight of PR-A and no knockdown of this protein was observed (Figure 
3.12a). NCL-PgR-AB is a cocktail of an antibody with an epitope common to PR-A and 
PR-B, and an antibody targeted to the same epitope as NCL-PgR-B, therefore this band 
could result from detection of the same non-specific protein detected by NCL-PgR-B 
(Figure 3.12a). MCF-7 cells were again treated with the positive transfection control 
GAPDH siRNA and reduced GAPDH levels can be observed in these cells compared to 
untreated, vehicle, negative control siRNA or PR siRNA treated cells (Figure 3.12a). 
 
 
Figure 3.12: Validation of PR binding by NCL-PgR-AB. 
a) MCF-7 cells in culture were treated with siRNA for 72 hours prior to lysing for SDS-PAGE 
and Western immunoblotting using NCL-PgR-AB. PR= PR targeted siRNA, G= GAPDH 
targeted siRNA positive transfection control, N= negative control untargeted siRNA, V= 
transfection reagent (vehicle) only control, U= untreated cells. PR-B knockdown is highlighted 
in the red box, PR-A knockdown in the green box and GAPDH knockdown is highlighted in the 
blue box. b) Histogram showing levels of PR knockdown relative to the negative control siRNA 
treated cells. Pixel density of the 120kDa bands was measured using Intelligent Quantifier, and 
values normalised to the negative control siRNA bands which were always assigned a value of 1. 
Data represents average PR expression relative to N for two experiments. 
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Using the C-terminal PR antibody C19, knockdown of an approximately 80kDa protein 
(highlighted red), potentially PR-A, and several low molecular weight proteins between 
30-50kDa (highlighted green) is observed, confirming that these are PR proteins. 
However, no knockdown of the abundant 60kDa protein is seen (Figure 3.13). 
 
Figure 3.13: Validation of PR binding by C19. 
a) MCF-7 cells in culture were treated with siRNA for 72 hours prior to lysing for SDS-PAGE 
and Western immunoblotting using C19. PR= PR targeted siRNA, G= GAPDH targeted siRNA 
positive transfection control, N= negative control untargeted siRNA, V= transfection reagent 
(vehicle) only control, U= untreated cells. PR-A knockdown is highlighted in the red box, low 
molecular weight PR knockdown in the green boxes and GAPDH knockdown is highlighted in 
the blue box. b) Histogram showing levels of PR knockdown relative to the negative control 
siRNA treated cells. Pixel density of the 80kDa bands was measured using Interligent Quantifier, 
and values normalised to the negative control siRNA bands which were always assigned a value 
of 1. Data represents average PR expression relative to N for two experiments. 
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3.3.6.2  Validation of the C-terminal PR antibody C19 for use in immunofluoresent 
staining 
An abundant non-specific protein at approximately 60kDa was detected by the C-
terminal PR antibody C19 by Western immunoblotting after PR knockdown using 
siRNA. Therefore siRNA treatment of MCF-7 cells was repeated, culturing the cells on 
glass coverslips in 6 well culture plates in the presence of PR or negative control siRNA 
for 72 hours before fixing. These cells were used for validation of the C-terminal 
antibody C19 for immunofluorescent detection of PR. Immunofluorescent staining of 
PR siRNA treated cells was performed with C19 and compared to cells which were 
untreated or treated with negative control siRNA. Little reduction of overall staining 
was observed with C19 after treatment with PR siRNA compared to untreated or 
negative control siRNA treated cells (Figure 3.14a). Successful PR knockdown in these 
cells was confirmed by Western immunoblotting with the N-terminal PR antibody 
NCL-PgR-B, using lysates of residual cells from the well in which the coverslips were 
cultured (Figure 3.14b). 
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Figure 3.14: Immunofluorescent analysis of PR knockdown in MCF-7 cells. 
MCF-7 cells were cultured on glass cover slips in 6 well plats and treated with PR or untargeted 
(negative control) siRNA for 72 hours prior to fixing. a) Cells on coverslips were stained using 
DAPI (nuclear staining) and C19 (PR staining). Untreated cells were also stained for 
comparison. All staining was analysed by confocal microscopy using identical settings. b) Cells 
from the culture plate around the periphery of the coverslips were lysed after 72 hours for use in 
SDS-PAGE and Western immunoblotting using NCL-PgR-B to confirm efficiency of PR 
knockdown. PR= PR targeted siRNA, N= negative control untargeted siRNA, U= untreated 
cells. 
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3.3.6.3  Analysis of PR proteins detected after treatment with protease inhibitors 
To validate that the low molecular weight proteins detected by the PR antibodies were 
not the products of protein degradation, cells were lysed in RIPA buffer with or without 
protease inhibitors. When cell lysates were treated with protease inhibitors, no change 
was observed in the overall pattern of proteins detected with NCL-PgR-B (Figure 3.15a), 
NCL-PgR-AB (Figure 3.15b) or the C-terminal PR antibody C19 (Figure 3.15c). This 
confirms that the low molecular weight proteins detected are not the products of 
degradation of full length PR in either MCF-7 or MDA-MB-231 cells. Hormone 
stimulation experiments were repeated, stimulating cells with 1μM β-oestradiol or an 
ethanol only control. PR expression was compared to untreated cells, and no effect of 
hormone stimulation on protein degradation was seen compared to previous 
experiments (Figure 3.15d).  
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Figure 3.15: Expression of low molecular weight PR proteins detected by commercial PR 
antibodies is not due to protein degradation. 
MCF-7 and MDA-MB-231 cells were lysed in RIPA buffer in the presence or absence of a 
protease inhibitor cocktail. Paired lysates were then used for SDS-PAGE and Western 
immunoblotting. a) PR proteins detected by NCL-PgR-B in MCF-7 cell lysates with or without 
protease inhibitors. b) PR proteins detected by NCL-PgR-AB in MCF-7 cell lysates with or 
without protease inhibitors. c) PR proteins detected by C19 in MCF-7 and MDA-MB-231 cell 
lysates with or without protease inhibitors. d) PR proteins detected by C19 in lysates, with 
protease inhibitors, from MCF-7 and MDA-MB-231 cells after stimulation with ethanol (V), 
1μM β-oestradiol (E). Untreated cells (U) were used for comparison. 
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3.3.6.4  Analysis of the phosphorylation of proteins detected by C19 
As discussed previously in Section 1.1, PR can be phosphorylated at a number of 
different sites (Figure 1.1) and this phosphorylation is important for all mechanisms of 
PR action. Therefore, the effect of phosphorylation on the range of proteins detected by 
the C-terminal PR antibody C19, and the effect of hormone stimulation on PR 
phosphorylation was assessed. Western immunoblotting was carried out using cell 
lysates treated with SAP following stimulation of MCF-7 and MDA-MB-231 cells with 
1μM β-oestradiol or an ethanol only control. The pattern of proteins detected was 
compared to lysates without SAP treatment; a change in molecular weight post SAP 
treatment would indicate a change in phosphorylation status. Whilst the level of 
expression of some low molecular weight proteins seemed to differ after SAP treatment, 
the overall pattern of protein expression remained similar in both cell lines (Figure 3.16). 
In MDA-MB-231, whilst most protein bands remained the same size +/- SAP treatment, 
there was an apparent shift in molecular weight of one protein after dephosphorylation 
with SAP (Figure 3.16). However, this protein, highlighted by red arrows, may be the 
non-specific 60kDa protein previously described. This experiment demonstrates that 
although low molecular weight PR proteins do undergo phosphorylation, the detection 
of a range low molecular weight proteins in MDA-MB-231 and MCF-7 breast cancer 
cells is not due to differential phosphorylation of a single protein isoform. 
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Figure 3.16: Low molecular weight PR proteins are not the products of differential 
phosphorylation. 
MCF-7 and MDA-MB-231 cells were treated with 1μM β-oestradiol (E) or an ethanol control 
(V) for 24 hours prior to lysing in RIPA buffer containing protease inhibitors. Lysates were 
incubated in the presence or absence of Shrimp Alkaline Phosphatase (SAP) to dephosphorylate 
proteins. SAP +/- lysates were used for SDS-PAGE and Western immunoblotting using the C-
terminal PR antibody C19. 
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3.4 Discussion 
This chapter uses breast cancer cell lines as a model to characterise PR expression and 
identify PR ASEs which may have an impact on PR detection in breast cancer. Breast 
cancer cell lines were selected for the reported hormone receptor status. MCF-7 and 
T47-D are both reported to be ER+/PR+. Both cell lines were initially used and 
provided similar results allowing use of just one of the cell lines, MCF-7, in further 
experiments. MDA-MB-231 cells are a commonly used ER-/PR- breast cancer cell line, 
so were selected for analysis of potential PR expression in a PR- cell line. Use of this 
cell line for analysis of PR expression is supported by recent controversy over the 
detection of PR mRNA in this cell line, described in publications since the start of this 
study (Pang and Thomas, 2011; Springwald et al., 2010). MDA-MB-231 and MCF-7 
were both isolated from metastatic breast cancer. In order to compare these cell lines 
representing advanced stages of breast cancer with PR expression in normal mammary 
cells, a non-tumourigenic mammary epithelial cell line MCF-10A was used. A second 
ER-/PR- breast cancer cell line (SK-BR-3) and another non-tumourigenic mammary 
epithelial cell line (184A1) were also used for some studies (data not shown), providing 
similar results to MDA-MB-231 and MCF-10A respectively, supporting use of the 
selected cell lines. 
 
Normal PR signalling, as discussed in Section 1.1, involves ligand binding, dimerisation, 
nuclear localisation, interaction with PRE and transcriptional co-regulators to modulate 
gene expression. Alternatively, the N-terminus of ligand activated PR can rapidly 
interact with cytoplasmic signal transduction molecules such as c-Src 
(Boonyaratanakornkit et al., 2007) or PI3K (Carnevale et al., 2007) to activate 
signalling cascades and regulate non-PRE containing genes. Ligand activated PR can 
also interact with Stat transcription factors to mediate their activation (Proietti et al., 
2005). Activated MAPKs can phosphorylate PR, leading to tethering of PR with Sp1 
transcription factors and transcription of Sp1 regulated genes (Faivre et al., 2008). 
 
An RT-PCR based PR gene walking assay detected truncated PR variant mRNA in the 
MDA-MB-231 breast cancer cell line (Figure 3.3). None of the PR mRNA variants 
detected by this assay have been previously reported in this cell line. However, exon 7 
and exon 6+7 deleted PR mRNA was recently detected in this cell line using primers 
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spanning distal exon/exon boundaries (Springwald et al., 2010). Furthermore, 
alternatively spliced PR mRNA has been reported in the PR negative T47D-Y breast 
cancer cell line (Saner et al., 2003), and PR mRNA was detected using primers to the 
exons encoding the LBD in PR negative MDA-MB-468 breast cancer cells (Pang and 
Thomas, 2011). Whilst this observation was not discussed in the report by (Pang and 
Thomas, 2011), a low level of PR mRNA is clearly visible in MDA-MB-468 cells in the 
results presented. Together with these previous studies the results presented in this 
chapter support the existence of PR variants which are not detected by common 
screening methods leading to characterisation as PR negative. 
 
Sequencing of the PCR products generated by the PR gene walking assay identified 
several modes of alternative splicing occurring in MDA-MB-231 cells to generate 
truncated PR mRNA including; whole, partial and multiple exon deletions, and intron 
retention (Figure 3.6). Examples of sequencing analysis can be seen in Appendix 1. 
Each of the ASEs identified by sequencing could affect either PR-B or PR-A pre-
mRNA so potentially generate two distinct variants which would not be distinguished 
by the gene walking assay. The structures of the potential proteins resulting from the 
identified ASEs in PR-B are shown in Figure 3.6.  Proteins encoded by spliced variants 
of PR-A mRNA would be identical except for the absence of the BUS. Table 3.1 details 
the region deleted from the PR-A or PR-B mRNA, the number of amino-acids each 
mRNA would encode and the theoretical molecular weight of the protein before post-
translational modifications. 
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Table 3.1: Predicted structures of alternatively spliced PR variants detected in MDA-MB-
231 cells. 
Computational analysis of sequenced PCR products from MDA-MB-231 cells reveals the 
potential structure and molecular weight of putative PR proteins resulting from alternative 
splicing in this cell line. ALIGN was used to determine the region removed by the ASE, 
ExPASy Translate to determine the presence of a premature termination codon (STOP) and 
ExPASy Compute pI/Mw was used to predict the molecular weight of the unmodified protein 
predicted based on the amino acid sequence encoded from each alternatively spliced mRNA. 
Full length PR-B and PR-A molecular weights were calculated by the same means and variant 
sizes resulting from alternative splicing of both full length mRNAs were predicted. 
 
Δp1a and Δp1b mRNAs are the result of deletions of different regions within exon 1, 
and Δp1,p2 mRNA results from deletion of the 3′ end of exon 1 and the 5′ end of exon 2. 
These variant mRNAs would cause a change in reading frame and if translated would 
encode a protein lacking a varying portion of exon 1, in each case disrupting AF1, and 
Δp1,p2 would also lack the start of exon 2. The altered reading frame of each mRNA 
would encode a PTC within either exon 1 or exon 2. Therefore none of these proteins 
would be likely to function as a progesterone receptor. The PTC encoded by these 
deletions makes the mRNA likely targets for NMD. Deletion of exon 2 (Δ2 mRNA) has 
been previously reported in MCF-7 and T47-D breast cancer cells (Richer et al., 1998). 
This deletion would again cause a change in reading frame encoding a PTC within exon 
3, so the mRNA may be targeted for NMD. A potential protein encoded by this mRNA 
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would however contain the full sequence of the N-terminal domain and therefore may 
still be capable of interactions with PR co-regulators and cytoplasmic signalling 
molecules. C-terminally truncated AR variants have been reported to be constitutively 
active (Hu et al., 2009; Dehm et al., 2008). These variants contained at least the first 
zinc finger of the DNA binding domain and were functional as nuclear transcription 
factors, an unlikely function for PRΔ2 based on the functional domains it contains. 
However, these reports do demonstrate the potential for expression of C-terminally 
truncated hormone receptor proteins. However, analysis of the structure of N-terminal 
PR constructs containing the N-terminal AFs and DBD, and which similar to the 
truncated AR variants were constitutively active, demonstrated that in the absence of 
DBD the NTD is not stabilised in a functional conformation (Bain et al., 2001; Bain et 
al., 2000). Therefore, Δ2 mRNA, similarly to the partial exon 1 deleted mRNAs, is 
unlikely to encode a functional protein. 
 
The previously unreported Δp1c mRNA results from an in-frame deletion of 469bp 
within exon 1 which would encode a protein lacking 223 amino acids including AF1. 
This protein would however retain the DBD, hinge, LBD and DD, as well as the ligand 
inducible AF2 and the PR-B specific AF3 in PR-BΔp1c. Therefore this protein may be 
able to function through classical PR signalling mechanisms similarly to wild-type PR-
A and PR-B. Additionally, PR-AΔp1c would also posses ID, so may be capable of 
regulating the function of full length PR. The N-terminal cystine rich domain involved 
in interaction of PR with c-Src (Boonyaratanakornkit et al., 2001) would also be intact, 
suggesting a possible role for PR-BΔp1c in activating rapid PR signalling. 
 
PR Δ3 mRNA was previously detected at low levels in breast cancer tissue (Balleine et 
al., 1999b). PR exon 3 encodes the second zinc finger of the DNA binding domain, so 
the protein encoded by Δ3 mRNA is unlikely to function through the classical 
mechanism of PRE gene regulation. However, the presence of the other functional 
domains suggest PR-BΔ3 may be able to function through rapid PR signalling pathways, 
and that PR-AΔ3 may be able to regulate PR function in a similar manner to full length 
PR-B and PR-A respectively. Exon 4 of the PR gene encodes the hinge region, 
containing a nuclear location signal and phosphorylation and acetylation domains which 
are vital for normal nuclear localisation and gene activation (Daniel et al., 2010), and 
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exon 4 also encodes the N-terminal part of the LBD (Misrahi et al., 1993; Misrahi et al., 
1987). Therefore, deletion of exon 4 in the Δ4 ASV makes normal genomic PR function 
unlikely. However, it is possible that the delayed nuclear entry and delayed gene 
activation observed upon mutation of the hinge region acetylation domain (Daniel et al., 
2010) may still occur in the absence of this region. Furthermore, this variant may still be 
functional through other previously described rapid PR signalling pathways. PRΔ4 
mRNA has been reported previously in a range of human tissues and cell lines (Misao et 
al., 2000; Hodges et al., 1999; Misao et al., 1998; Richer et al., 1998; Leygue et al., 
1996a). A previous report of the function of PRΔ4 protein translated from a cDNA 
expression vector suggested that this variant is non-functional as either a transcriptional 
activator or a regulator of wild-type PR function (Richer et al., 1998). However this 
study was conducted before recent extensive characterisation of the non-genomic 
mechanisms of PR signalling and therefore focussed only on classical PR signalling. 
The expected structure of the PRΔ4 protein predicts that this variant would most likely 
function through non-genomic pathways. 
 
Previously unreported out of frame deletions were observed within exon 4 (Δp4), 
spanning the 3′ end of exon 4, exon 5 and the 5′ end of exon 6 (Δp4,5,p6) and spanning 
the 3′ end of exon 5 and the 5′ end of exon 6 (Δp5,p6). Δp4 lacks the hinge region and 
generates a PTC within exon 4 encoding a protein also lacking the LBD. Both Δp4,5,p6 
and Δp5,p6 contain PTC within exon 6, encoding a protein with a truncated LBD. The 
presence of the PTC may target these mRNA for NMD. If a protein were encoded, the 
lack of a functional LBD would make function as a ligand activated transcription factor 
unlikely. However, ligand independent PR functions have been reported, regulating 
genes in the absence of ligand stimulation (Jacobsen et al., 2005) via activation by 
cross-talk with other signalling pathways (Proietti et al., 2009; Pierson-Mullany and 
Lange, 2004), and these functions may be particularly important in breast cancer 
development (Cerliani et al., 2011; Hagan et al., 2011). Furthermore, C-terminally 
truncated ER proteins encoded from mRNAs containing an insertion between exons 4 
and 5 are truncated after exon 4, thus lacking the LBD. These proteins were reported in 
the mouse to be constitutively transcriptionally active nuclear proteins (Ishii et al., 
2011), demonstrating the potential functionality of hormone receptor proteins lacking 
LBD, suggesting that if encoded PRΔp4, Δp4,5,p6 or Δp5,p6 proteins may be able to 
function independent of ligand activation and contribute to breast cancer development. 
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A novel in-frame deletion of 96bp was observed within exon 6, generating a protein 
lacking just 32 amino acids from within the LBD. Therefore the encoded protein may 
lack a functional LBD and function through other PR signalling mechanisms as 
discussed for other variants, or the small deletion may leave the LBD functional and 
thus the protein may function in a similar manner to wild-type PR. 
 
Retention of intronic sequences within PR mRNA has previously been reported as 
described in Section 1.4.11. Exons S and T from intron 3 are spliced onto exon 4 and 
may encode a protein from the first initiation codon within exon 4 (Hirata et al., 2002; 
Hirata et al., 2000). Exon M which contains a consensus Kozak translation initiation site 
is also located within intron 3 and spliced onto exon 4 (Saner et al., 2003). These 
mRNA would therefore encode N-terminally truncated proteins containing the normal 
hinge and C-terminal domains. Exons i45a and i45b are located within intron 4 and are 
spliced onto the end of exon 4 (Yamanaka et al., 2002). i45a contains an in-frame 
termination codon so this mRNA would encode a protein similar in structure to those 
discussed for Δp4, Δp4,5,p6 and Δp5,p6, containing a short i45a specific sequence of 
amino acids. PCR primers directed to these intronic exons detected mRNA for each 
isoform in the PR positive MCF-7 breast cancer cell line, and mRNA for PR-M was 
also detected and sequenced in the reportedly PR negative MDA-MB-231 cell line 
(Figure 3.5). The presence of mRNA encoding an N-terminally truncated PR protein 
supports the initial hypothesis that expression of such proteins may lead to 
misclassification as PR negative. Exon M would encode a unique N-terminal sequence 
of 16 hydrophobic amino acids and therefore the function of PR-M was initially 
suggested to be as a membrane associated receptor (Saner et al., 2003). However, later 
analysis of the expression of green fluorescent protein (GFP) tagged PR-M identified 
the protein to be expressed predominantly in the cytoplasm (Price et al., 2005). This 
suggests a potential mechanism of PR-M protein function through interaction with other 
cytoplasmic signalling pathways. However, the absence of the N-terminal domain 
which has been implicated in interactions with Src and other signalling molecules 
suggests other domains my mediate these interactions for PR-M. The expression and 
function of N-terminally truncated ER variants was recently examined in the mouse 
(Ishii et al., 2011), with a cytoplasmic expression and an inability to activate ERE being 
observed. The observation that both N-terminally truncated PR and ER proteins are 
expressed in the cytoplasm suggests that the PR-M mRNA detected in the MDA-MB-
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231 cell line may encode a protein which could function cytoplasmically via non-
genomic signalling pathways. 
 
Analysis of the potential splice sites associated with each deletion reveals that none of 
the partial exon deletions (Δp1a, Δp1b, Δp1c, Δp1,p2, Δp4, Δp4,5,p6, Δp5,p6 or Δ6) 
were associated with a classical GT 5′ splice site or AG 3′ splice site. Further analysis of 
the sequences is necessary to identify potential ESE sequences which could serve to 
strengthen weak non-consensus splice sites within the exons and silencer elements 
which may inactivate the normal splice sites. Skipping of exons 2 and 3 are possible 
through silencing of the 3′ splice sites at the end of the preceding intron, although again 
further analysis of the sequences is required to identify silencer elements which may 
mediate this mechanism of splicing. Exon 4 is 306bp long, longer than the ideal length 
of <300bp necessary for efficient exon definition (Berget, 1995). At the 5′ end of exon 4 
is a GT dinucleotide, although the rest of the 5′ sequence differs from the splice site 
consensus. The 3′ end of exon 4 is an AG dinucleotide, with a short PPT located just 
upstream, and a consensus BPS approximately 100bp upstream of the 3′ AG. Whilst the 
weak 5′ splice site and short PPT mean that utilisation of these splice sites may require 
enhancer sequences, the presence of the 5′ and 3′ splice sites together with the length of 
the exon suggest that exon 4 is likely to undergo enhancer dependent alternative 
splicing. Preliminary investigation of the regulation of PR exon 4 splicing and analysis 
for the presence of enhancer elements within the sequence will be undertaken in 
Chapter 6. 
 
The PR gene walking assay, using RT-PCR, agarose gel electrophoresis and DNA 
sequencing, enabled the identification of novel ASEs which would not have been 
possible by real-time quantitative (q)RT-PCR which would be unable to distinguish 
between full length and exon deleted mRNA when quantifying expression. Exon 
deletion ASEs can be assessed by qRT-PCR using splice specific primers (as described 
by Springwald et al (Springwald et al., 2010). This method however requires prediction 
of ASEs and design of primers for each predicted ASE whereas the conventional RT-
PCR and agarose gel electrophoresis method employed in this study removes this 
requirement. And does not allow comparison of the levels of expression of exon deleted 
and full length mRNA. The relative costs of the two methods for application to a 
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discovery screen such as the gene walking assay further support the use of conventional 
RT-PCR. Capillary electrophoresis is a method of separating differently sized PCR 
products by which product size is analysed by UV absorbance. This method allows 
quantification of the relative expression levels of differently sized PCR products within 
a sample and is an alternative to the agarose gel electrophoresis used in this study. 
However, PCR products separated by agarose gel electrophoresis can be purified, 
cloned and sequenced to identify the regions deleted. Thus, despite strengths of 
individual alternative methods, the RT-PCR and agarose gel electrophoresis method 
used in this study is the most appropriate for a gene walking discovery assay.  
 
Clinicopathological screening of PR status in breast tumour tissue uses antibodies 
targeted to N-terminal epitopes common to both PR-A and PR-B (Hanley et al., 2009). 
These epitopes would also be present in the proteins produced from the exon deleted PR 
mRNA detected by the gene walking assay, so this screening would be unable to 
distinguish between differently functional PR isoforms. Additionally, these antibodies 
would be unable to detect N-terminally truncated proteins such as PR-M. Using N-
terminal antibodies similar to those used clinically, PR protein was detected specifically 
in PR positive MCF-7 cells (Figure 3.7a) and the specificity of these antibodies was 
confirmed by siRNA knockdown of PR expression (Figures 3.11 and 3.12). However, 
oestrogen inducible expression of low molecular weight PR proteins was also detected 
in MDA-MB-231 cells using the C-terminally targeted C19 antibody (Figure 3.9). PR is 
an oestrogen responsive gene containing a partial ERE sequence within the promoters 
for both PR-A and PR-B (Kastner et al., 1990) so the increase in PR expression 
following β-oestradiol stimulation observed in Figure 3.8 was expected. Oestrogen has 
also been shown to influence alternative splicing; β-oestradiol treatment decreased 
inclusion of an alternatively spliced exon in the rat Slo channel mRNA (Zhu et al., 
2005), and increased exon 11 skipping in the liver scavenger receptor B (SR-B) (Zhang 
et al., 2007). Liver SR-B exon 11 skipping was regulated by SRSF1, and the SR-related 
proteins Tra2α and Tra2β, with the expression of Tra2β regulated by β-oestradiol 
suggesting that β-oestradiol may regulate exon skipping by regulating SR-related 
protein expression (Zhang et al., 2007). The increase in expression of low molecular 
weight proteins following β-oestradiol stimulation of MDA-MB-231 breast cancer cells 
(Figure 3.9), and the apparent switch in isoform expression observed in MCF-10A non-
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tumourigenic MECs (Figure 3.9) following stimulation may indicate a similar effect of 
β-oestradiol on PR alternative splicing to that previously reported for Slo and SR-B. 
 
siRNA knockdown of total PR expression in MCF-7 cells confirmed that low molecular 
weight proteins detected by C19 are PR proteins, although non-specific proteins were 
also detected (Figure 3.13). Expression of proteins of approximately 80kDa, 50kDa and 
a doublet between 30kDa and 40kDa was knocked down by PR siRNA, expression of 
which was not due to protease degradation of full length PR (Figure 3.15) or differential 
phosphorylation (Figure 3.16). A truncated PR protein has previously been reported 
with molecular weights of 60kDa resulting from use of an alternative promoter and 
initiation of translation at Met595 (Wei and Miner, 1994). Expression of this protein has 
since been reported using the C19 antibody in human tissue (Condon et al., 2006). 
However, recent reports suggest that the 60kDa protein detected by C19 is in fact a 
cytoskeletal protein (Madsen et al., 2007), and that the PR-C cDNA is likely to give rise 
to a protein smaller than originally predicted, around 38kDa (Samalecos and Gellersen, 
2008). These reports are supported by the results presented in this chapter 
demonstrating that expression of the 60kDa protein detected by C19 is not reduced by 
siRNA targeting PR (Figure 3.13). This validation of the specificity of the C19 antibody 
was performed in MCF-7 cells whereas analysis of PR alternative splicing was 
performed predominantly in MDA-MB-231 cells. Transfection of MDA-MB-231 cells 
with siRNA was attempted; the transfection conditions used in MCF-7 cells did not 
produce knockdown of PR or GAPDH and extensive optimisation using three different 
transfection reagents at a range of concentrations with a range of siRNA concentrations 
failed to achieve efficient knockdown. Transfection of MDA-MB-231 cells cultured on 
glass coverslips with GFP labelled GAPDH siRNA and analysis by confocal 
microscopy did not demonstrate any uptake of the siRNA or any reduction in the level 
of GAPDH when cell lysates were analysed by Western immunoblotting (data not 
shown). Since both MCF-7 and MDA-MB-231 cells express a similar range of proteins 
detected by C19 (Figures 3.7c, 3.15 and 3.16) and PR appears to undergo a similar 
pattern of alternative splicing in the two cell lines, validation of the antibody was 
performed in just the MCF-7 cells and the PR proteins identified  in this cell line can be 
compared to the proteins predicted from the ASEs identified in MDA-MB-231 cells. 
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Table 3.1 shows the predicted molecular weight of proteins resulting from each of the 
detected ASEs affecting either PR-B or PR-A. From these predicted molecular weights 
several potential identities for each of the knocked down PR proteins can be determined 
based on the pattern of splicing detected by the PR gene walking assay. Full length PR-
A (82kDa), PR-AΔ3 (78kDa), PR-AΔp6 (78kDa), PR-BΔp1c (77kDa), PR-BΔ4 (87kDa) 
or PR-BΔp5,p6 (81kDa) could all account for the PR protein detected at approximately 
80kDa although the latter is unlikely to be a functional PR protein. A truncated PR 
isoform of 78kDa has previously been reported to be detected in approximately 26% of 
breast tumours (Graham et al., 1996). This protein could be detected by an antibody 
targeting both PR-A and PR-B, but not by an antibody targeting the B-upstream 
segment, and it was therefore suggested that the protein was N-terminally truncated, 
perhaps resulting from alternative splicing of PR-A pre-mRNA. This 78kDa PR protein 
was also demonstrated to bind ligand (Yeates et al., 1998). If the approximately 80kDa 
protein knocked down by PR siRNA in this study is the previously identified 78kDa 
protein then the PR-AΔ3 mRNA is most likely to give rise to an appropriately sized 
protein with ligand binding potential.  
 
An approximately 50kDa PR protein was also identified by siRNA knockdown and 
Western immunoblotting using C19. PR-AΔp4 (50kDa), PR-AΔp4,5,p6 (54kDa), PR-
BΔp1b (47kDa) or PR-BΔ2 (57kDa) mRNAs could give rise to appropriately sized 
proteins. PR-AΔ2 (40kDa) or the more likely functional PR-M (39kDa) could give rise 
to proteins represented by the 40kDa band. Alternatively, as suggested previously 
(Samalecos and Gellersen, 2008), PR-C cDNA may encode a 38kDa protein which 
could be the protein detected by C19 at approximately 40kDa. The lower band of the 
doublet could be the protein product of either PR-AΔp1b, PR-BΔp1a or PR-BΔp1,p2 
mRNAs, again none of which are predicted to give rise to functional PR proteins. The 
low molecular weight PR proteins detected by C19 undergo extensive phosphorylation; 
dephosphorylating the proteins increased the intensity of the 50kDa band (Figure 3.16). 
This phosphorylation could provide a mechanism by which non-ligand binding proteins 
which may be produced from the ASV mRNAs could be activated. However, the 
detection of these proteins by C19 in MDA-MB-231 cells which appear PR negative 
when analysed using N-terminal antibodies suggests that the proteins are unlikely to be 
exon deleted variants of either PR-A or PR-B. Furthermore, as previously suggested, 
(Samalecos and Gellersen, 2008; Yeates et al., 1998), the levels of exon deleted mRNAs 
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detected by RT-PCR relative to wild-type mRNA are unlikely to give rise to highly 
expressed proteins. Therefore, it is more likely that the truncated proteins detected in 
MDA-MB-231 and MCF-7 cells, and knocked down by siRNA targeting PR in MCF-7 
cells, are N-terminally truncated, resulting from alternative promoters or intron retention. 
 
Expression of non-functional exon deleted PR variant proteins which would be detected 
by PR screening and not distinguished from PR-A or PR-B could lead to patients being 
characterised as PR positive but lacking PR function. Alternatively, variant PR proteins 
such as PRΔ3 or PRΔ4 may function differently to wild-type PR and could alter the 
progesterone response of a tissue without altering the overall appearance as PR positive 
since they would be detected by N-terminal antibodies in PR screening. N-terminally 
truncated proteins such as PR-M or PR-C would not be detected by N-terminal 
antibodies, but would be able to bind progesterone and therefore may function as PR in 
tissues described as PR negative. 
 
The C19 antibody was demonstrated by Western immunoblotting following siRNA 
knockdown of PR expression in MCF-7 cells to detect PR proteins in addition to some 
non-specific proteins. When used for immunofluorescent analysis of PR expression in 
MDA-MB-231 cells, C19 detects abundant nuclear and cytoplasmic proteins and detects 
increased nuclear staining following progesterone stimulation of the cells (Figure 3.10). 
However, upon siRNA knockdown of total PR expression in MCF-7 cells, which was 
confirmed by Western immunoblotting, C19 still detects protein by 
immunofluorescence (Figure 3.14). Therefore, it can be concluded that the non-specific 
binding observed using C19 for Western immunoblotting makes this antibody 
unsuitable for detecting PR by immunofluorescence, by which different proteins cannot 
be distinguished by size. C19 has previously been used to detect PR-C in human tissue 
(Condon et al., 2006) and to detect the PR-M protein in PR negative T47D-Y breast 
cancer cells (Price et al., 2005). The observation that C19 detects protein in cells 
following PR knockdown suggests that these immunofluorescent studies may not be 
identifying PR protein. This is supported by the predominant membrane staining 
observed using C19 in T47D-Y cells, suggested to be PR-M, but a cytoplasmic 
localisation of GFP tagged PR-M (Price et al., 2005), suggesting that the antibody is not 
detecting the protein that was expected. Therefore the development of novel, more 
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specific, non N-terminal PR antibodies could improve both laboratory investigation of 
PR expression and function, as well as clinicopathological detection of PR in breast 
cancer. 
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4 Validating the functionality of truncated PR 
isoforms in MDA-MB-231 cells 
4.1 Introduction  
MDA-MB-231 cells are described as a PR- breast cancer cell line (Neve et al., 2006) 
and it has been demonstrated in this thesis that Western immunoblot analysis using PR 
specific N-terminal antibodies, similar to those used in breast cancer screening, does not 
detect PR protein in lysates from these cells (Section 3.3.2). It was also demonstrated by 
the PR gene walking assay in Section 3.3.1 of this thesis that alternatively spliced PR 
mRNA is present in MDA-MB-231 cells which may encode truncated, potentially 
functional proteins. Further to this, Western immunoblotting and hormone response 
assays have demonstrated that truncated PR proteins can be detected using the C-
terminal PR antibody C19 in MDA-MB-231 cells (Sections 3.3.2 and 3.3.4). A similar 
range of protein bands was observed in Western immunoblotting of MCF-7 and MDA-
MB-231 whole cell lysates by C19 and siRNA knockdown of total PR expression in 
MCF-7 cells identified 80kDa, 55kDa and 30-40kDa PR proteins detected by this 
antibody (Section 3.6). An analysis of the potential for the proteins detected by C19 to 
function as classical ligand activated nuclear transcription factor PR isoforms in MDA-
MB-231 cells was therefore undertaken to examine ligand binding, dimerisation, co-
factor binding and DNA binding. 
 
Nuclear progesterone receptor isoforms PR-A and PR-B function as ligand activated 
nuclear transcription factors. The first stage of the classical mechanism of PR action is 
the binding of progesterone to the LBD of PR in the cytoplasm. Progesterone binding 
has previously been assessed using a ligand blot assay (Jang and Yi, 2005). Proteins are 
separated by SDS-PAGE and transferred to a nitrocellulose membrane. Membranes are 
then incubated with P-POD which binds to any progesterone binding proteins present 
and can be detected by developing using ECL and x-ray film. Rapid non-genomic 
progesterone responses can be mediated through cytoplasmic PR-B 
(Boonyaratanakornkit et al., 2007) and potentially through other truncated variant PR 
isoforms which result from alternative splicing (Price et al., 2005) or the use of 
alternative promoters (Taylor et al., 2009; Condon et al., 2006). Membrane bound 
progesterone receptors (mPRs) are the products of different genes to the 8 exon gene 
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encoding PR-A and PR-B. Interaction of the intracellular domain of ligand activated 
mPRs with other signalling pathways can activate cellular responses to progesterone 
that are independent of DNA binding (Thomas, 2008). Response to cell-impermeable 
progesterone has been reported in the PR negative T47D-Y breast cancer cell line 
suggesting that membrane associated PR proteins, potentially mPR, are expressed in 
this cell line which is characterised as nuclear PR negative (Lee and Muller, 2010). In 
this chapter, the presence of non-genomic progesterone binding proteins in MDA-MB-
231 cells was assessed by ligand blotting using fractionated lysates from breast cancer 
cells. 
 
Following ligand binding, nuclear receptors undergo dimerisation and nuclear 
translocation. PR homo- or heterodimers then interact with transcriptional co-regulators. 
The interaction of PR with other proteins can be examined by Co-IP using highly 
specific antibodies. If PR proteins are in complex with the targeted proteins they can 
then be detected by Western immunoblotting (Tyson-Capper et al., 2009). PPT-binding 
protein associated splicing factor (PSF) is a multi-functional nuclear protein possessing 
both RNA and DNA binding domains. PSF was first characterised bound to the PPT in 
intronic RNA and associates with spliceosome components involved in the second 
catalytic step of splicing, with a role in 3′ splice site selection. PSF has also been 
demonstrated to bind to the DBD of thyroid hormone and retinoid X receptors and 
prevent their DNA binding in the absence of ligand. The DNA binding capacity of PSF 
was demonstrated by binding to insulin-like growth factor response elements (IGFRE) 
and preventing transcription of the porcine P450scc gene (Shav-Tal and Zipori, 2002). 
In human cells, murine (m)VL30 induces the transcription of the human homologue of 
P450scc and other IGFRE containing genes, including the oncogene 24p3. PSF was 
demonstrated to complex with the PSF binding tracts (pbt) of mVL30 and ptb was 
demonstrated to prevent the binding of PSF to IGFRE, thus preventing the repression of 
gene expression by PSF (Song et al., 2004). This indicates a potential role for PSF in the 
repression of cancer associated gene expression. Furthermore, repression of PSF by 
interaction with pbt induced progesterone synthesis in mice, demonstrating a role for 
PSF in regulating steroidogenesis (Song et al., 2004). Due to these established roles of 
PSF in cancer, hormone synthesis and splicing, in addition to a previously demonstrated 
interaction of PSF with PR-A and PR-B in myometrial cells (Tyson-Capper et al., 2009), 
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PSF was chosen as a candidate PR co-factor to investigate the potential functionality of 
truncated PR proteins by Co-IP. 
 
Activated PR dimers then bind to PREs in promoter regions of progesterone controlled 
genes to regulate gene expression. A biotinylated synthetic PRE oligonucleotide 
sequence was used to bind to any PR proteins which possess DNA binding capacity 
present in cell lysates. These protein/PRE complexes can then be precipitated using 
streptavidin magnetic beads and the PR proteins present can be analysed by Western 
immunoblotting (Tyson-Capper et al., 2009). 
 
4.2 Aims 
The aims of this chapter are to: 
1. Identify the proteins detected by the C-terminal PR antibody C19 in 
different cell fractions from MDA-MB-231 breast cancer cells by Western 
immunoblotting. 
2. Determine the progesterone binding capacity of proteins in MDA-MB-231 
cells using a ligand blot assay. 
3. Assess the detection of PR proteins in MDA-MB-231 cells by two 
commercial non N-terminal PR antibodies by Co-IP using C20 and 
detection of proteins by Western immunoblotting with C19, and to use this 
assay to assess the potential presence of PR dimers in MDA-MB-231 cells. 
4. Identify interactions of proteins detected by C19 in MDA-MB-231 cells 
with the nuclear PR co-factor PSF by Co-IP. 
5. Determine if truncated PR proteins detected by C19 in MDA-MB-231 
cells can interact with PREs by DAPA using biotinylated PRE. 
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4.3 Results 
4.3.1 Low molecular weight progesterone binding proteins exist in 
MDA-MB-231 cells 
The C-terminal PR antibody C19 detects a range of proteins in breast cancer cells, some 
of which have been demonstrated in this thesis to be PR proteins by siRNA knockdown 
of total PR expression in MCF-7 breast cancer cells (Section 3.3.6). To establish the 
potential for the proteins detected by C19 to function as progesterone receptors, their 
ability to bind progesterone was examined. MDA-MB-231 cells were stimulated with 
1µM β-oestradiol, the optimal concentration for stimulating low molecular weight PR 
protein expression (Section 3.3.4) or an ethanol control and cultured for 24 hours to 
allow the effects of stimulation on protein expression to develop. Following β-oestradiol 
stimulation some cells were stimulated with 0.1µM progesterone (a concentration 
optimised to stimulate PR expression) and cultured for a further 24 hours. Following 
hormone stimulation cells were fractionated to isolate cytosolic, membrane, nuclear and 
cytoskeletal proteins. Proteins in the four cell fractions were then separated by SDS-
PAGE and transferred to nitrocellulose membranes. Membranes were used for either 
Western immunoblotting with C19, or ligand blotting using P-POD.  
 
Western immunoblotting using C19 detected a range of proteins in each of the cell 
fractions of both hormone stimulated and unstimulated cells (Figure 4.1a). A similar 
pattern of proteins was observed with β-oestradiol or progesterone treatments, and in the 
control ethanol treated cells. However, an apparent decrease in expression of some low 
molecular weight proteins was observed in the cytosolic fraction following β-oestradiol 
stimulation (Figure 4.1a, lanes 5 and 9, indicated with red arrows). An increased 
detection of nuclear proteins by C19 can be observed following progesterone 
stimulation suggesting nuclear translocation (Figure 4.1a, lane 11).  
 
The proteins detected by C19 were compared to proteins present in the MDA-MB-231 
cell fractions which bound to peroxidase conjugated progesterone in the ligand blot 
assay (Figure 4.1b). Proteins of approximately 100kDa in the cytosolic fraction (orange 
box), 55kDa in the cytosolic and nuclear fractions (black box), two proteins between 42 
and 50kDa in the cytosolic fraction (red box), a protein in the membrane fraction just 
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under 42kDa (blue box), and two different proteins of approximately 35kDa in the 
cytosolic and nuclear fractions were all detected by both assays. Progesterone binding 
proteins were not detected in the cytoskeletal fraction of MDA-MB-231 cells.  
 
The purity of the individual fractions was confirmed by detection of α-tubulin 
specifically in the cytosolic fraction, c-jun in the nuclear fraction and vimentin in the 
cytoskeletal fraction (Figure 4.1c). Purity of the membrane fraction was concluded 
based on the purity of the other three fractions and the unique pattern of proteins 
detected in this fraction by Western immunoblotting and ligand blotting. 
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Figure 4.1: Detection of progesterone binding proteins in MDA-MB-231 cells. 
MDA-MB-231 cells were stimulated with 1µM β-oestradiol (E), 1µM β-oestradiol followed by 
0.1µM progesterone (P) or an ethanol only control (V). Cells were then fractionated to separate 
cytosolic (Cso), membrane (M), nuclear (N) and cytoskeletal (Csk) fractions. Proteins within 
the fractions were separated by SDS-PAGE and transferred to nitrocellulose membranes. a) 
Western immunoblotting using the C-terminal PR antibody C19. The blue arrow indicates an 
80kDa nuclear protein detected by C19 in nuclear fractions (lanes 3, 7 and 11). b) Ligand 
blotting using peroxidase conjugated progesterone (P-POD). Coloured boxes in a and b 
highlight where proteins of similar molecular weight are detected by C19 and P-POD, 
representing progesterone binding PR proteins as discussed above. c) Purity of the fractions was 
confirmed by Western immunoblotting using antibodies against α-tubulin (Cso), c-jun (N) and 
vimentin (Csk). 
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4.3.2 Identifying proteins detected by the C-terminal PR antibody C19 
in MDA-MB-231 cells 
MDA-MB-231 cells were fractionated to separate nuclear and cytoplasmic proteins 
following stimulation with 1µM β-oestradiol, 1µM β-oestradiol followed by 0.1µM 
progesterone or an ethanol only control. These fractions were initially used for Western 
immunoblotting using the C-terminal PR antibody C19 to identify the proteins detected 
by this antibody in each fraction prior to using C19 as the detection antibody in future 
Co-IP and DAPA experiments. C19 detected a range of different molecular weight 
proteins in both nuclear and cytoplasmic fractions of MDA-MB-231 cells (Figure 4.2a). 
Proteins of approximately 100kDa and 80kDa were detected specifically in the nuclear 
fraction along with a doublet of proteins detected at 35kDa (Figure 4.2a, lanes 1-3). A 
55kDa protein was detected in the nuclear and cytoplasmic fractions (Figure 4.2a). In 
the cytoplasmic fraction, a protein of 42kDa was also detected and expression of the 
42kDa and 55kDa cytoplasmic proteins was induced by β-oestradiol stimulation (Figure 
4.2, lane 5). The purity of the fractions was confirmed by the detection of c-jun 
specifically in the nuclear fractions and ERK-1 in the cytoplasmic fractions (Figure 
4.2b). 
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Figure 4.2: Detection of PR proteins in MDA-MB-231 nuclear and cytoplasmic fractions 
using C19. 
MDA-MB-231 cells were stimulated with 1µM β-oestradiol (E), 1µM β-oestradiol followed by 
0.1µM progesterone (P) or an ethanol only control (V) and cultured for 24 hours before 
harvesting and fractionating to separate nuclear and cytoplasmic proteins. a) Western 
immunoblotting of MDA-MB-231 nuclear and cytoplamic fractions using C19 to. b) Western 
immunoblotting of MDA-MB-231 nuclear and cytoplasmic fractions to confirm the purity of 
the fractions using c-jun (nuclear) and ERK-1 (cytoplasmic). 
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4.3.3 PR proteins can form heterodimers in MDA-MB-231 cells 
As described, C19 detects a range of potential PR proteins in MDA-MB-231 cells. To 
identify whether these proteins, which are not detected by N-terminal antibodies, can 
also be detected by another non N-terminal antibody and to identify the ability of the 
proteins detected by C19 to dimerise, co-immunoprecipitation experiments were 
performed using nuclear and cytoplasmic fractions from hormone stimulated and 
unstimulated MDA-MB-231 cells. The PR antibody C20, targeted to an epitope within 
the DBD, was used as the capture antibody and proteins bound to this antibody were 
precipitated using Protein G magnetic beads. Immunoprecipitated proteins were 
separated by SDS-PAGE and used for Western immunoblotting with C19 as the 
detection antibody. 
 
Immunoprecipitated proteins were detected by C19 in both nuclear and cytoplasmic 
fractions at approximately 100kDa, 80kDa, 55kDa and 35kDa (Figure 4.3a, lanes 1-3 
and 7-9, indicated by red arrows), demonstrating that the proteins detected by C19 are 
also bound by the other PR antibody. These proteins were not detected in IgG control 
experiments. In addition to this, Western immunoblotting using C19 following Co-IP 
with C20 detects protein bands in excess of 170kDa, suggesting that proteins detected 
by C19 may be in complex with other PR proteins detected by C20, and that these 
heteromeric complexes may be resistant to denaturation during sample preparation 
(Figure 4.3b lanes 1-3 and 7-9, indicated by red arrow). 
 
 
 
148 
. 
Figure 4.3: C19 detects proteins that are immunoprecipitated using C20, including high 
molecular weight heterodimers. 
Nuclear and cytoplasmic fractions of MDA-MB-231 cells stimulated with 1µM β-oestradiol (E), 
1µM β-oestradiol followed by 0.1µM progesterone (P) or an ethanol only control (V) were used 
for Co-IP using the PR antibody C20 as the capture (lanes 1-3 and 7-9) and a rabbit IgG as 
control (lanes 4-6 and 10-12). a) Western immunoblotting of immunoprecipitated proteins using 
C19 detects PR proteins in MDA-MB-231 nuclear and cytoplasmic fractions. b) Western 
immunoblotting with C19 detects potential high molecular weight heterodimers in MDA-MB-
231 cells. 
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4.3.4 Nuclear and cytoplasmic PR proteins interact with the PR co-
regulator PSF 
As described in Section 4.1, PSF is a nuclear receptor co-factor with previously 
described roles in alternative splicing, hormone synthesis and cancer which has 
previously been demonstrated to interact with PR-A and PR-B. These roles relating to 
the subject of this thesis therefore make PSF an ideal co-factor for preliminary analysis 
of the functionality of low molecular weight PR proteins. To identify interaction of the 
low molecular weight PR proteins detected by C19 in MDA-MB-231 cells with the 
nuclear PR co-factor PSF, Co-IP experiments were performed using MDA-MB-231 
nuclear and cytoplasmic fractions and a highly specific PSF monoclonal antibody, 
which has previously been validated for use in Co-IP experiments (Tyson-Capper et al., 
2009), as the capture antibody. C19 was used for Western immunoblotting to detect PR 
proteins which were precipitated with PSF and identify whether any truncated PR 
isoforms can interact with this PR co-factor in a similar manner to wild-type PR. 
Western immunoblotting with C19 detected a protein at approximately 80kDa 
predominantly in the nuclear fraction which was not detected in IgG control 
experiments (Figure 4.4a, upper red arrow). C19 also detected a predominantly 
cytoplasmic doublet of proteins at around 35-40kDa which was co-immunoprecipitated 
with PSF (Figure 4.4a, lower red arrows). In MCF-7 breast cancer cells, a similar 
protein doublet was also detected at relatively high levels in the nuclear fraction by the 
N-terminal PR antibody NCL-PgR-AB (Figure 4.4b). The purity of MCF-7 fractions 
was confirmed by the detection of ERK-1 specifically in cytoplasmic fractions and c-jun 
predominantly in nuclear fractions (Figure 4.4c). 
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Figure 4.4: Low molecular weight PR proteins can form complexes with PSF in MDA-
MB-231 and MCF-7 breast cancer cells. 
MDA-MB-231 and MCF-7 breast cancer cells were stimulated in culture with 1µM β-oestradiol 
(E), 1µM β-oestradiol followed by 0.1µM progesterone (P) or an ethanol only control (V). 
Nuclear and cytoplasmic fractions from these cells were used for Co-IP using an anti-PSF 
antibody. a) Western immunoblotting of co-immunoprecipitated proteins from MDA-MB-231 
cells using C19. Red arrows indicate proteins co-immunoprecipitated specifically with PSF 
(lanes 1-3 and 7-9) and not the IgG controls (lanes 4-6 and 10-12).b) Western immunoblotting 
of co-immunoprecipitated proteins in MCF-7 cells using NCL-PgR-AB. c) Western 
immunoblotting of MCF-7 nuclear and cytoplasmic fractions using fraction controls c-jun 
(nuclear) and ERK-1 (cytoplasmic).  
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4.3.5 PRE binding proteins are present in MDA-MB-231 cells 
To assess the interaction of proteins detected by C19 in MDA-MB-231 cells with PRE, 
nuclear and cytoplasmic extracts were incubated with double stranded biotinylated 
oligonucleotides. These oligonucleotides were either a consensus PRE or a mutated 
sequence (detailed in Section 2.7.2). PRE binding proteins were precipitated using 
streptavidin magnetic beads and analysed by Western immunoblotting with C19 (Figure 
4.5). In MCF-7 cells, a PRE binding nuclear protein which migrated slightly faster than 
the 100kDa molecular weight marker was assumed to be PR-A, and a larger protein 
nearer to the 130kDa marker was assumed to be PR-B (Figure 4.5a, lane 1). In MDA-
MB-231 cells, a PRE binding protein was detected specifically in the nuclear fraction 
(Figure 4.5a, lanes 3-8) and did not migrate to the same size as either of the PR-A or 
PR-B proteins detected in MCF-7 cells. However, perhaps due to insufficient mutation 
of the consensus PRE sequence, PR-A, PR-B (Figure 4.5a, lane 2), and the MDA-MB-
231 specific 100kDa protein (Figure 4.5a, lanes 9-11) could also bind PREmut. In MDA-
MB-231 cells, a nuclear protein which migrated slightly faster than the 35kDa 
molecular weight marker bound to PRE with a higher affinity than PREmut (Figure 4.5b, 
lanes 1-3 and 7-9). 
 
In addition to these nuclear PRE binding proteins present in MDA-MB-231 cells, under 
these artificial conditions, where PRE is accessible to cytoplasmic proteins, a protein 
that migrated slightly faster than the 55kDa marker was detected specifically in the 
cytoplasmic fraction (Figure 4.5c, lane 2). This protein did not bind to PREmut (Figure 
4.5c, lane 4), and the binding to biotinylated PRE could be successfully prevented by 
incubation of the cell extract with an unlabelled PRE prior to incubation with the 
biotinylated PRE (Figure 4.5c, lane 5). 
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Figure 4.5: MDA-MB-231 cells express proteins capable of binging PRE. 
MDA-MB-231 and MCF-7 breast cancer cells were stimulated in culture by 1µM β-oestradiol 
(E), 1µM β-oestradiol followed by 0.1µM progesterone (P) or an ethanol only control (V). 
Nuclear and cytoplasmic fractions from these cells were used for DAPA reactions using a 
biotinylated synthetic PRE oligonucleotide or a biotinylated mutated sequence PRE (PREmut). 
Biotinylated oligonuleotides, and any proteins which bind them, were precipitated using 
streptavidin magnetic beads. Precipitated proteins were analysed by Western immunoblotting 
using C19.  a) Oligonucleotide binding proteins in vehicle treated MCF-7 nuclear extract and 
MDA-MB-231 nuclear and cytoplasmic fractions. b) Oligonucleotide binding proteins in 
nuclear and cytoplasmic fractions of oestrogen stimulated MDA-MB-231 cells. Cytoplasmic 
extract was also pre-incubated with unbiotinylated PRE (cold PRE). c) Oligonucleotide binding 
proteins in MDA-MB-231 nuclear and cytoplasmic fractions. 
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4.4 Discussion 
The C-terminal PR antibody C19 detects a range of proteins in cytosolic, membrane and 
nuclear fractions of MDA-MB-231 cells. Expression of these proteins appears to be 
responsive to β-oestradiol; low molecular weight proteins of around 37kDa and 40-
45kDa in the cytosolic fraction appear reduced in expression following stimulation 
whereas there is increased detection of a range of proteins in the nuclear fraction 
following β-oestradiol stimulation (Figure 4.1a). Several of the proteins detected by C19 
in MDA-MB-231 cells were demonstrated by the ligand blot assay to bind progesterone 
(Figure 4.1b). Three proteins between 35kDa and 42kDa were detected by C19 and 
were able to bind progesterone; one in the nuclear fraction, one in the membrane 
fraction and one in the cytosolic fraction. These proteins correlate to the size of proteins 
knocked down by PR siRNA in MCF-7 cells in Section 3.3.6 of this thesis. The 
detection of three proteins rather than the two previously detected by C19 (Figure 3.13) 
could result from the fractionation of the cells enabling distinction between similarly 
sized proteins which may appear as a single band in Western immunoblots of whole cell 
lysates. The presence of progesterone binding proteins which are also detected by C19 
and may be knocked down by PR targeted siRNA supports the existence of PR proteins 
in the MDA-MB-231 cell line which is reported to be PR negative. 
 
MDA-MB-231 cells were separated into nuclear and cytoplasmic fractions and again a 
range of proteins were detected in each fraction by Western immunoblotting using C19. 
Bands corresponding to the size of proteins previously analysed by siRNA and Western 
immunoblotting in MCF-7 cells were again detected. In cells fractionated by this 
method a doublet of proteins at around 35kDa was evident in the nuclear fraction 
(Figure 4.2a) which was previously observed in whole cell lysates (Section 3.3.6) and in 
the nuclear fraction in Figure 4.1a as a single band. As described in Section 1.1 and 
demonstrated in Section 3.3.6, PR undergoes extensive phosphorylation so it is possible 
that the extra band is a phosphorylated version of the 35kDa protein and this differential 
phosphorylation may due to the different sample preparation methods used. The protein 
detected just above the 42kDa marker in the cytoplasmic fraction (Figure 4.2a) and as 
the lower band in the cytosolic doublet in Figure 4.1a (red box) may correlate to the 
upper protein of the doublet knocked down by PR siRNA in MCF-7 cells in Section 
3.3.6. Similarly to the pattern observed in Figure 3.9, expression of this 42kDa 
cytoplasmic protein is increased by β-oestradiol stimulation. The third protein detected 
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by C19 that was knocked down by PR siRNA in MCF-7 cells was approximately 50kDa 
and a protein of appropriate size (50-55kDa) is detected in both nuclear and cytoplasmic 
fractions of MDA-MB-231 cells, with cytosolic expression increasing in response to β-
oestradiol (Figure 4.2a). In the ligand blot assay a progesterone binding protein of this 
molecular weight was detected in the nuclear and cytosolic fractions which was also 
detected in these fractions by C19. The final protein described as PR following siRNA 
knockdown in MCF-7 cells was approximately 80kD and protein of this molecular 
weight was detected at a very low level in the nuclear fraction of MDA-MB-231 cells 
following fractionation by both methods (Figure 4.1a and Figure 4.2a). The 60kDa 
protein which was previously described as PR-C (Condon et al., 2006) but demonstrated 
to be non-specific binding by PR siRNA knockdown in this thesis was present in the 
cytoplasmic fraction of MDA-MB-231 cells (Figure 4.2a). 
 
Co-IP using the nuclear and cytoplasmic fractions of MDA-MB-231 cells with the C20 
antibody, targeted to an internal PR epitope, followed by Western immunoblotting using 
the C-terminal PR antibody C19 allowed comparison of proteins detected by these two  
non N-terminal PR antibodies and also assessment of the potential presence of 
multimeric PR complexes. A protein at approximately 100kDa was detected in both 
nuclear and cytoplasmic fractions (Figure 4.3a) which had not been identified as PR by 
siRNA knockdown in MCF-7 cells. It is possible that this protein is a cell type specific 
isoform and it may therefore still be a PR protein since it is detected by both antibodies 
and a progesterone binding protein was detected at approximately this size in MDA-
MB-231 cell cytosolic fractions (Figure 4.1b). Proteins at approximately 80kDa, 55kDa 
and 35kDa were also detected by C19 after immunoprecipitation with C20 ((Figure 
4.3a). These proteins were detected in both nuclear and cytoplasmic fractions whereas 
they were detected specifically in the nuclear fraction by Western immunoblotting of 
the nuclear and cytoplasmic fractions before Co-IP (Figure 4.2a). The protein 
concentrations of the individual fractions allowed loading of 30µg of nuclear or 
cytoplasmic extract for SDS-PAGE, whereas 50µg was used for Co-IPs. 
Immunoprecipitation using C20 would lead to an increased concentration of specific 
proteins being loaded for SDS-PAGE allowing detection of proteins expressed at a 
much lower level than were detectable by initial Western immunoblotting of cell 
fractions. All of these proteins detected by both C19 and C20 correspond to proteins 
previously described in this thesis as PR following siRNA knockdown in MCF-7 cells 
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and the 55kDa and 35kDa proteins correspond to the molecular weight of progesterone 
binding proteins identified in MDA-MB-231 cells by ligand blot experiments. 
 
High molecular weight protein bands (greater than 170kDa) were detected using C19 
following Co-IP by C20 (Figure 4.3b) and potentially represent PR dimers which may 
contain truncated PR proteins detected by C19 in complex with other PR proteins 
detected by C20. This supports the possibility that PR proteins detected by these 
antibodies may be able to function similarly to wild-type PR which dimerise following 
ligand binding. 
 
The nuclear protein PSF has previously been reported to interact with PR-A and PR-B 
(Tyson-Capper et al., 2009). Co-IP using a PSF antibody and MDA-MB-231 nuclear 
and cytoplasmic extracts demonstrated that the 80kDa and 35kDa PR proteins detected 
by C19 were capable of interacting with PSF in a similar manner to full length PR 
(Figure 4.4a). PSF is a nuclear protein (Shav-Tal and Zipori, 2002) and the interaction 
of these PR proteins with PSF was predominantly nuclear. PSF has been demonstrated 
to interact with the DBD of thyroid hormone receptors and retinoid X receptors (Shav-
Tal and Zipori, 2002). These receptors are members of the same receptor superfamily as 
PR so it is possible that PR also interacts with PSF via the DBD, meaning that the 
80kDa and 35kDa proteins reported herein to interact with PSF may require at least part 
of this domain. A 35kDa protein was previously demonstrated to be PR in MCF-7 cells 
in Section 3.3.6 of this thesis and a similarly sized protein is shown in Figure 3.1b to 
bind progesterone in MDA-MB-231 cells. Interestingly, a protein doublet at 35kDa was 
also detected by Western immunoblotting using the N-terminally targeted PR antibody 
NCL-PgR-AB following Co-IP of MCF-7 nuclear and cytoplasmic fractions using a 
PSF antibody (Figure 4.4b). The proteins detected in MCF-7 cells must therefore 
possess the normal PR-A/B N-terminal domain which would be predicted to be lacking 
from the proteins in MDA-MB-231 cells since NCL-PgR-AB fails to detect protein in 
this cell line. Therefore these results suggest that different 35kDa PR proteins may be 
expressed in the two cell lines. 
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This chapter has assessed the potential for interaction of low molecular weight PR 
proteins with PSF to investigate the potential for co-factor regulation. The choice of 
PSF as the co-regulator to be studied has been described in Section 4.1 and again in 
Section 4.3.4. Other co-factors such as the SRC family can also interact with PR, as 
described in Section 1.1.6, and the interaction of these proteins with low molecular 
weight PR is a potential area of study. However, the aim of this chapter was to make a 
preliminary assessment of several aspects of PR function; ligand binding, dimerisation, 
co-factor binding and DNA binding. Therefore only one potential co-factor of low 
molecular weight PR was studied. 
 
DNA affinity precipitation assays have demonstrated that a nuclear protein of 
approximately 100kDa which is specifically detected in MDA-MB-231 cells, and is 
neither PR-A nor PR-B, is capable of binding to PRE (Figure 4.5a). A protein of this 
size was also demonstrated to be able to bind to progesterone in the ligand blot assay 
(Figure 4.1b) and was detected by both C19 and C20 antibodies as demonstrated by Co-
IP experiments (Figure 4.3a). If the proteins identified in the three assays described are 
the same protein then a potentially functional protein may be expressed which must 
possess both the LBD and DBD. Based on the PR variant mRNAs detected by the PR 
gene walking assay in Section 3.3.1, PRΔ4 could generate a protein with these 
functional domains mostly intact. The previously reported PRΔp4126 (Marshburn et al., 
2005; Balleine et al., 1999b) with a deletion of 126bp from the start of exon 4 would 
generate a protein lacking the hinge region but which may still be able to function as a 
nuclear receptor. The predicted molecular weights of PRΔ4 and PRΔp4126 resulting 
from alternative splicing of PR-B mRNA are 87kDa and 94kDa respectively. Since 
post-translational modifications mean that full length PR-B with a theoretical molecular 
weight of 99kDa migrates close to 120kDa in SDS-PAGE, it is possible that these two 
exon 4 alternatively spliced variants may generate proteins which are detected at 
100kDa. However, if these proteins were expressed resulting from alternative splicing 
of PR-B mRNA then detection with N-terminal PR antibodies would be observed, 
suggesting that any proteins observed in MDA-MB-231 cells resulting from exon 
deleted mRNA must also have an altered N-terminal domain. Therefore whilst these 
results support the existence of functional truncated PR proteins in a reportedly PR 
negative breast cancer cell line, the identity of this protein remains undefined. 
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A 35kDa nuclear protein in MDA-MB-231 cells was demonstrated to bind PRE (Figure 
4.5b) in addition to binding progesterone. This protein which is likely to be different to 
the 35kDa protein knocked down by PR siRNA in MCF-7 cells, is likely to be a PR 
since it is capable of binding progesterone and PRE and interacting with the PR co-
factor PSF. Interaction of PSF with other nuclear receptors is mediated via the DBD 
(Shav-Tal and Zipori, 2002) however it is not known whether PR interacts with PSF in 
the same way, so the interaction of this protein with PSF may not require the DBD. 
Binding of this protein to PRE again suggests that the DBD must be present. However, 
if the protein was capable of dimerisation then it may be precipitated by PRE due to 
interaction with another DBD containing protein, such as the 100kDa protein described 
above, and the potential presence of PR dimers in MDA-MB-231 cells is demonstrated 
by Co-IP using C20. The 35kDa PR protein detected in MDA-MB-231 cells may 
therefore contain the C-terminal LBD and DD encoded by exons 4 to 6.  
 
A cytoplasmic protein of 50-55kDa was demonstrated by DAPA in MDA-MB-231 cells 
to be able to interact with PRE (Figure 4.5c). Whilst the cytoplasmic location of this 
protein suggests that it is unlikely to usually function as a genomic PR, DNA binding 
ability does indicate that the DBD may be present, so this protein could potentially 
function through DNA binding if nuclear localisation could be induced following ligand 
binding. Expression of a protein of this size was induced by β-oestradiol stimulation of 
MDA-MB-231 cells (Figure 4.2a) and expression of a similar sized protein was 
knocked down by PR targeted siRNA in MCF-7 cells previously in this thesis (Section 
3.3.6). A protein of this molecular weight was also demonstrated in MDA-MB-231 
nuclear and cytosolic fractions to bind progesterone in the ligand blot assay. The 
progesterone binding and DNA binding ability of this protein suggest that both LBD 
and DBD are present. However, as described above, DNA binding may be mediated 
through dimerisation with other functional proteins. The functions described for the 
55kDa PR protein, together with its detection specifically by non N-terminal PR 
antibodies in MDA-MB-231 cells, suggests that this protein may be an N-terminally 
truncated PR variant encoded by exons 2 to 8 or exons 4 to 8. Two truncated ER-α 
proteins, ERα46 and ERα36, have been identified resulting from the alternative splicing 
of non-coding leader exons from the 5′ UTR onto exon 2 resulting in use of promoters 
within exon 2 (Wang et al., 2005; Flouriot et al., 2000). ERα46 contains sequences 
encoded by the remainder of exons 2 to 8 (Flouriot et al., 2000), whereas ERα36 results 
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from alternative splicing of the 3′ end of exon 6 onto a novel exon 9 within the 3′ UTR 
(Wang et al., 2005). Alternative splicing of non-coding exons onto PR exon 4 has 
previously been reported (Hirata et al., 2002; Hirata et al., 2000) and if leader exons 
exist within the 5′ UTR of PR which are spliced onto exon 2 in a similar manner to that 
described for ERα then this could provide a mechanism of alternative splicing which 
could encode N-terminally truncated proteins which contain the exon 2 to 8 sequence. 
The exon 1 sequence encodes 56kDa of the full length PR-B protein predicted using 
ExPASy Compute pI/MW. Therefore the predicted molecular weight of a putative 
protein encoded by just exons 2 to 8 would be approximately 43kDa depending on the 
leader exon sequence and the translational initiation site used, and could potentially be 
the protein detected at 50-55kDa in MDA-MB-231 cells . 
 
The 42kDa cytoplasmic protein detected by C19 in MDA-MB-231 cells, which was 
demonstrated to bind progesterone in the cytosolic fraction was unable to interact with 
PSF or PRE and may therefore function through non-genomic pathways. PR-M mRNA 
is predicted to encode a 39kDa protein that localises in the cytoplasm (Price et al., 2005; 
Saner et al., 2003) and this mRNA was detected in MDA-MB-231 cells in Section 3.3.1 
of this thesis. As described above, PR-B has a theoretical molecular weight of 99kDa 
but migrates close to 120kDa in SDS-PAGE, so it is therefore possible that PR-M 
mRNA could encode a protein with a molecular weight greater than the predicted 
39kDa, possibly this 42kDa cytoplasmic protein or the 55kDa protein described above.  
 
A 60kDa protein detected by C19 has previously been described as the N-terminally 
truncated PR-C isoform, resulting from initiation of translation at Met595 (Condon et 
al., 2006; Wei et al., 1996). Detection of this protein in MCF-7 cells was demonstrated 
in Section 3.3.6 of this thesis to be the result of non-specific binding since expression 
was not reduced by siRNA knockdown of total PR expression. In MDA-MB-231 cells 
this protein was detected in the cytoplasmic fraction but was unable to bind 
progesterone, PSF or PRE in the assays described in this chapter. Therefore the results 
presented in this thesis support previous reports (Madsen et al., 2007) that the 60kDa 
protein detected by C19 is not a PR isoform. 
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In summary, siRNA knockdown of PR expression in MCF-7 cells reported earlier in 
this thesis has demonstrated that C19 detects PR proteins of approximately 80kDa, 
50kDa and two proteins between 30-40kDa (Section 3.3.6). Progesterone binding 
proteins of these sizes were detected by a ligand blot assay in MDA-MB-231 cell 
fractions. Whilst results described in this chapter suggest that differences may exist 
between proteins detected by C19 in MCF-7 and MDA-MB-231 cells, the functional 
data presented above suggests that the MDA-MB-231 cells do contain PR proteins. The 
35kDa nuclear progesterone binding protein detected in MDA-MB-231 cells was also 
able to interact with the nuclear co-factor PSF and with PRE. An 80kDa nuclear protein 
expressed at a low level in this cell line was able to bind progesterone and interact with 
PSF and so potentially function as a classical nuclear PR, although specific interaction 
of this protein with PRE was not observed. A third nuclear protein was detected 
specifically in MDA-MB-231 cells and was able to bind progesterone and interact with 
PRE. This protein of approximately 100kDa was a different size to either PR-A or PR-B. 
Exon deletion events characterised in Section 3.3.1 of this thesis could generate both the 
80kDa and 100kDa potential PR proteins in MDA-MB-231 cells. However, since 
neither protein is detected by N-terminal antibodies in MDA-MB-231 cells, the normal 
N-terminal region must be truncated or altered in these proteins in addition to any 
internal exon deletions. Deletions within PR exon 1 were identified in MDA-MB-231 
cells by the gene walking assay in Section 3.3.1 of this thesis. PR exon 1 is an 
extremely long exon (1637bp) and the PR gene walking assay used primers spanning 
exons and therefore only identified deletions towards the 3′ end of exon 1, in regions in 
which the primers could be paired with primers to downstream exons and generate PCR 
products of less than 1kbp. However exon 1 contains many putative 5′ and 3′ splice sites, 
suggesting that this extremely long exon may be alternatively spliced which could 
generate proteins lacking the N-terminal region such as those described in this chapter.  
 
A cytoplasmic protein of around 50-55kDa was able to bind progesterone and interact 
with PRE, suggesting that it may be able to function as a nuclear PR if it is able to 
dimerise and translocate. Alternatively the presence of this protein in breast cancer cells, 
along with other low molecular weight progesterone binding proteins such as the 
cytoplasmic 42kDa protein, could indicate the presence of non-genomic PR isoforms.  
This chapter has focussed on the potential of PR proteins in MDA-MB-231 cells to 
function through the classical genomic PR signalling pathway in which PR binds 
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progesterone, dimerises and translocates to the nucleus before interacting with co-
regulators and PREs within target genes. The presence of cytoplasmic proteins which 
are capable of binding progesterone suggests that PR proteins which function through 
non-genomic pathways may also exist in the reportedly PR negative MDA-MB-231 
breast cancer cell line. Future studies may focus on the potential for non-genomic 
signalling by low molecular weight PR proteins by assessing interaction with known PR 
non-genomic binding partners and activation of rapid progesterone response pathways 
in cells expressing these low molecular weight proteins. 
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5 Characterisation of PR alternative splicing events in 
breast tumours 
5.1 Introduction 
Current breast cancer PR screening uses N-terminally targeted antibodies which detect, 
but do not distinguish between, both PR-A and PR-B (Hanley et al., 2009). Alternative 
splicing of PR pre-mRNA may encode proteins which are undetectable by current breast 
cancer screening using these N-terminally targeted antibodies, or which are functionally 
distinct but indistinguishable from full length PR. An RT-PCR based gene walking 
assay in Section 3.3.1 of this thesis has demonstrated that alternatively spliced PR 
mRNA is expressed in the reportedly PR negative MDA-MB-231 breast cancer cell line. 
Furthermore PR proteins are detected in this cell line using a C-terminally targeted 
antibody, which are not detected using N-terminally targeted antibodies (Section 3.3.2). 
The proteins present in MDA-MB-231 cells which are detected by this C-terminal 
antibody, and may result from alternative splicing of PR pre-mRNA, have been 
demonstrated to have the potential to function as PR proteins (Chapter 4).  
 
To validate the results of the cell line studies presented in Chapters 3 and 4, primers 
from the PR gene walking assay were used to identify PR ASEs in a small cohort of 
frozen breast tumour tissue and predict the potential functionality of the proteins that 
may be encoded. RNA was extracted from fifteen frozen breast tumour tissue samples 
obtained from a Newcastle University/Gateshead Queen Elizabeth Hospital Breast 
Cancer Biomarkers tissue bank. The tissues used had been previously characterised for 
ER and PR status at the time of sample collection using N-terminal antibodies for both 
hormone receptors. RT-PCR was performed using the PR gene walking assay and DNA 
sequencing analysis was used to identify PR ASEs in the breast tumour tissue. 
Computational analysis was then performed to predict the functionality of the expected 
protein product of each alternatively spliced PR mRNA. 
 
The breast cancer cell line studies detailed in Section 3.3.6 demonstrated that the C-
terminal PR antibody C19, which detects PR proteins by Western immunoblotting 
(Section 3.3.6.) is unsuitable for immunofluorescent analysis and 
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immunohistochemistry. The potential expression of N-terminally truncated PR variants 
in breast cancer, resulting from alternative splicing (Saner et al., 2003; Hirata et al., 
2002; Hirata et al., 2000) or alternative promoter usage (Wei and Miner, 1994) suggests 
that non N-terminal antibodies should also be considered for use in breast cancer PR 
screening. The lack of specificity of commercially available non N-terminal PR 
antibodies has been previously reported (Samalecos and Gellersen, 2008; Madsen et al., 
2007) and makes them unsuitable for use in breast cancer screening, necessitating the 
development of novel non N-terminal PR antibodies. Therefore, the PR antibodies A3 
and A4 were developed, targeting an internal and a C-terminal epitope respectively. The 
specificity of the antibodies was assessed by Western immunoblotting, Co-IP and 
siRNA knockdown of PR expression. The PR status of the breast tumours used for the 
PR gene walking assay was then reassessed using the novel antibodies. Further 
information on the HER2 status, tumour grade, lymph node involvement and 
Nottingham prognostic index was also available from original histology reports for the 
tumours analysed. 
 
5.2 Aims 
The aims of this chapter were to: 
1. Analyse PR mRNA expression in a small cohort frozen breast tumour 
samples of previously characterised PR status and identify PR ASEs 
occurring in breast tumours. 
2. Purify novel PR antibodies PRA3 and PRA4 
3. Optimise PRA3 and PRA4 for use in: 
 Western immunoblotting 
 Immunohistochemical staining of FFPE breast tumour tissue 
4. Validate the specificity of PRA3 and PRA4 by Western immunoblotting 
following Co-IP or siRNA knockdown of PR expression in MCF-7 cells. 
5. Use PRA3 and PRA4 to characterise the PR status of FFPE breast tumours, 
and compare this to the reported PR status determined using N-terminal PR 
antibodies. 
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5.3 Results 
5.3.1 Characterisation of PR mRNA expression in breast tumour 
tissue 
Alternative splicing of PR has been shown in this thesis to generate mRNA which may 
encode truncated protein isoforms which are functionally distinct from wild-type PR-A 
and B in breast cancer cell lines. The presence of these isoforms in breast tumour tissue 
may have implications in understanding the role of PR in breast cancer development 
and in the use of PR as a predictive marker for assigning breast cancer therapies.  
 
The presence of alternatively spliced PR mRNA was examined in fifteen frozen breast 
tumour tissue samples. RNA was extracted from five ER+/PR+, one ER-/PR+, four 
ER+/PR- and five ER-/PR- breast tumours and used for RT-PCR using primer 
combinations from the PR gene walking assay which had previously been demonstrated 
in cell line studies to detect ASEs (Section 3.3). Initially, RT-PCR was performed using 
primers spanning long regions of the PR gene; sense primers to exon 2 (S7) or exon 1 
(SA) and antisense primers to exon 8 (A1), exon 7 (A2) or exon 6 (A3). The full length 
PCR product was seen in the positive control MCF-7 lane (Figure 5.1, lane 16). 
However, whilst full length PCR products were detected in some samples, primers 
spanning these long regions (PCR products >750bp) failed to consistently detect full 
length product, potentially demonstrating degradation of the RNA in the frozen breast 
tumour samples (Figure 5.1, lanes 1-15). 
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Figure 5.1: RNA degradation in frozen breast tumour samples may prevent detection of 
long PCR products. 
RT-PCR was performed for 45 cycles on RNA from frozen breast tumour samples using sense 
primers to exon 2 (S7) or exon 1 (SA) and antisense primers to exon 8 (A1), exon 7 (A2) or 
exon 6 (A3). 15 breast tumour samples were analysed with the following previously 
characterised hormone receptor status; lanes 1-5= ER+/PR+, lane 6= ER-/PR+, lanes 7-10= 
ER+/PR-, lanes 11-15= ER-/PR-. MCF-7 cDNA was used in a positive control reaction (lane 16) 
and a no-template control reaction was performed for each primer pair (NTC, lane 17). 
M=100bp DNA ladder. 
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Since primer pairs spanning long regions of the PR gene had failed to consistently 
detect PR mRNA, primer sets were used to focus specifically on the regions which were 
previously demonstrated by the PR gene walking assay to undergo ASEs in breast 
cancer cell lines. Firstly, primers spanning exon 1 (S4) to exon 3 (A6) were used to 
examine ASEs occurring within exons 1 and 2 (Figure 5.2). No full length PCR product 
was detected in any of the tumour samples. Two differently sized PCR products were 
detected between approximately 250 and 300bp suggesting that ASEs may be occurring 
in this region of PR in breast tumour samples. The larger product (~300bp) was detected 
specifically in PR+ tumours (Figure 5.2, lanes 1, 2, 4, 6). In two of these tumours the 
smaller product (~250bp) was also detected (Figure 5.2, lane 1 and 6). The larger 
product was not detected in PR- tumours but the smaller band was detected in some of 
these samples (Figure 5.2 lanes 9, 14 and 15). A smaller PCR product of approximately 
150bp was also detected using these primers in one PR+ and one PR- tumour, 
potentially representing mRNA with large deletions within exon 1 and exon 2 (Figure 
5.2, lanes 4 and 11). 
 
 
Figure 5.2: Different patterns of exon 1 and 2 alternative splicing exist between PR+ and 
PR- breast tumours. 
RT-PCR performed for 45 cycles using RNA from frozen breast tumour samples and primers 
spanning exon 1 (S4) to exon 3 (A6). PCR products were compared between 5 ER+/PR+ 
tumours (lanes 1-5), 1 ER-/PR+ tumour (lane 6), 4 ER+/PR- tumour (lanes 7-10), 5 ER-/PR- 
tumours (lanes 11-15) and a positive control (MCF-7 cells, lane 16). A no template control 
reaction (NTC, lane 17) was also included. M=100bp DNA ladder. 
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ASEs involving exon 3 were then examined using primers spanning exon 2 (S6) to exon 
4 (A5). The full length PCR product was detected in the positive control MCF-7 cells 
(Figure 5.3, lane 16) and in all PR+ tumours and the majority of PR- tumours (7 out of 9 
tumours examined, Figure 5.3). No truncated PCR product was detected, indicating that 
exon 3 does not appear to be alternatively spliced in breast tumours (Figure 5.3). 
 
 
Figure 5.3: PR exon 3 does not undergo alternative splicing in breast tumour tissue. 
RT-PCR performed for 45 cycles using RNA from frozen breast tumour samples and primers 
spanning exon 2 (S6) to exon 4 (A5). PCR products were compared between 5 ER+/PR+ 
tumours (lanes 1-5), 1 ER-/PR+ tumour (lane 6), 4 ER+/PR- tumour (lanes 7-10), 5 ER-/PR- 
tumours (lanes 11-15) and a positive control (MCF-7 cells, lane 16). A no template control 
reaction (NTC, lane 17) was also included. M=100bp DNA ladder. 
 
 
 
In breast cancer cell lines the PR gene walking assay detected extensive ASEs involving 
both whole exon (Δ4) and partial exon deletion (Δp4) of exon 4 (Section 3.3.1.4).  
Primers spanning exon 3 (S7) to exon 5 (A4) were used to detect Δ4 or Δp4 mRNA. 
Full length PCR product was detected in the positive control MCF-7 cells (Figure 5.4a, 
lane 16), and also in many PR+ and PR- tumours (Figure 5.4a). In most tumours in 
which PR mRNA was detected, a truncated PCR product, potentially representing Δ4 
mRNA was also detected (Figure 5.4a). In some tumours, both PR+ and PR-, only the 
truncated Δ4 PCR product was detected (Figure 5.4a, lanes 3, 10, 12, 14). The truncated 
PCR product was detected at higher levels in breast tumour samples compared to the 
positive control, suggesting that more Δ4 mRNA may be present in these tumours than 
in the MCF-7 breast cancer cell line (Figure 5.4a). The presence of a PCR product, 
potentially representing Δ4 mRNA was confirmed by two further PCR experiments; the 
first using primers spanning exon 1 (SA) to exon 4 (A5) in which only a full length PCR 
product was detected in breast tumours and the positive control (Figure 5.4b, lanes 1-6)), 
and the second using primers spanning exon 1 (SA) to exon 5 (A4) in which both a full 
length and truncated PCR product were detected in both breast tumours and MCF-7 
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cells (Figure 5.4b, lanes 7-12). Again, the Δ4 PCR product was more prevalent in breast 
tumours than MCF-7 cells, and was detected as the main product in one of the tumours 
examined (Figure 5.4b, lane 8). Primer sets S7/A4 and SA/A4 both detected, at a lower 
level, another PCR product with a smaller deletion, potentially indicating the presence 
of mRNA with a deletion of part of exon 4, such as Δp4 (Figure 5.4a and b). 
 
Figure 5.4: Exon 4 deleted mRNA is detected in breast tumours at a higher level than 
MCF-7 breast cancer cells. 
RT-PCR performed for 45 cycles using RNA from frozen breast tumour samples. a) PCR using 
primers spanning exon 3 (S7) to exon 5 (A4). PCR products were compared between 5 
ER+/PR+ tumours (lanes 1-5), 1 ER-/PR+ tumour (lane 6), 4 ER+/PR- tumour (lanes 7-10), 5 
ER-/PR- tumours (lanes 11-15) and a positive control (MCF-7 cells, lane 16). A no template 
control reaction (NTC, lane 17) was also included. M=100bp DNA ladder. b) PCR using 
primers spanning exon 1 (SA) to exon 4 (A5) (lanes 1-6); and primers spanning exon 1 (SA) to 
exon 5 (A4) (lanes 7-12. PCR products were compared between 2 PR+ tumours (lanes 1,2 and 7, 
8), 2 PR- tumours (lanes 3, 4 and 9, 10) and a positive control (MCF-7 cells, lanes 5 and 11). No 
template control reactions were included for each primer set (NTC, lanes 6 and 12). M=100bp 
DNA ladder. 
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Exon 6 deleted mRNA (Δ6) was not detected by the gene walking assay in MDA-MB-
231 cells, but has previously been reported (Balleine et al., 1999b; Richer et al., 1998). 
RT-PCR was performed using the primer set S9/A2, spanning exon 5 to exon 7, to 
examine the presence of Δ6 mRNA in the breast tumour samples. The full length PCR 
product was detected in the positive control (Figure 5.5, lane 16) and in all PR+ tumours 
(Figure 5.5, lanes 1-6). A truncated (Δ6) PCR product was also detected in half of the 
PR+ tumours (Figure 5.5, lanes 4-6). Full length PCR product was detected in some PR- 
tumours (Figure 5.5, lanes 7, 8, 11, 12, 13, 12 and 15), along with Δ6 PCR product in 
lanes 7, 8, 12 and 15. Δ6 was the only PCR product detected in one PR- tumour (Figure 
5.5, lane 9) and another PCR product, potentially representing an mRNA with a deletion 
of part of exon 6, was detected in addition to full length and Δ6 in one PR- tumour 
(Figure 5.5, lane 15).  
 
 
Figure 5.5: Exon 6 deleted mRNA was detected in breast tumours. 
RT-PCR performed for 45 cycles using RNA from frozen breast tumour samples and primers 
spanning exon 5 (S9) to exon 7 (A2). PCR products were compared between 5 ER+/PR+ 
tumours (lanes 1-5), 1 ER-/PR+ tumour (lane 6), 4 ER+/PR- tumour (lanes 7-10), 5 ER-/PR- 
tumours (lanes 11-15) and a positive control (MCF-7 cells, lane 16). A no template control 
reaction (NTC, lane 17) was also included. M=100bp DNA ladder. 
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PR-M is a previously reported potential PR isoform which is the result of retention of an 
intronic sequence between exons 3 and 4. PR-M mRNA would encode a protein lacking 
the normal N-terminal domain and DBD, with an N-terminal signal sequence of 
hydrophobic amino acids (Saner et al., 2003). PR-M mRNA was detected in the 
reportedly PR- MDA-MB-231 breast cancer cell line using a sense primer to the 
intronic exon M (M) and an antisense primer to exon 4 (A) (Section 3.3.1.3). Sense 
primer M was used in combination with an antisense primer directed to exon 5 (A4) to 
examine the presence of PR-M mRNA in breast tumour samples. A PCR product 
representing PR-M mRNA was detected infrequently in both PR+ and PR- tumours 
(Figure 5.6a). PCR was repeated to confirm the presence of PR-M mRNA using the 
tumour samples in which PR-M mRNA had previously been detected (Figure 5.6b). 
 
Figure 5.6: PR-M mRNA was detected in a small number of breast tumours. 
RT-PCR performed for 45 cycles using RNA extracted from frozen breast tumour samples and 
primers spanning intronic exon M (sense, M) to exon 5 (antisense, A4). a) PCR products were 
compared between 5 ER+/PR+ tumours (lanes 1-5), 1 ER-/PR+ tumour (lane 6), 4 ER+/PR- 
tumour (lanes 7-10) and 5 ER-/PR- tumours (lanes 11-15). A no template control reaction (NTC, 
lane 16) was also included. M=100bp DNA ladder. b) PCR was repeated using previously PR-
M positive samples. PR+ tumours (lanes 1 and 2), PR- tumours lanes 3, 4, and 5). M=100bp 
DNA ladder. 
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5.3.2 Identifying potential PR proteins resulting from ASEs in breast 
tumours 
Truncated PCR products detected in breast tumour samples were cloned and sequenced 
to validate the regions deleted in each mRNA. Figure 5.7 is a diagrammatic 
representation of the potential protein that would be generated by each of the truncated 
mRNAs which were identified by sequencing. Figure 5.7a shows the eight exon 
structure of the PR gene and the full length protein which is encoded, identifying the 
main functional domains associated with the role of PR-B as a ligand activated nuclear 
transcription factor. Deletions/retentions within the PR mRNA are indicated by the 
dashed lines in Figure 5.7a. A deletion of a large region at the end of exon 1, along with 
the start of exon 2 was identified by sequencing of a PCR product generated in a PR- 
tumour using primers spanning exon 1 to exon 3 (Figure 5.2, lane 9). A similar deletion 
was also seen in several other tumours, both PR+ and PR- (Figure 5.2). This deletion 
had previously been identified in Section 3.3.1 of this in MDA-MB-231 breast cancer 
cells and the protein product would lack all of the internal and C-terminal functional 
domains so is unlikely to have any function (Figure 5.7b, Δp1,p2). A deletion of part of 
exon 2, the whole of exon 3 and part of exon 4 was identified by sequencing of a PCR 
product generated using primers spanning exon 1 to exon 7 in a PR+ tumour (Figure 5.1, 
lane 3). This deletion (Δp2,3,p4) would lead to truncation of the protein in the region 
encoded by exon 4 so would lack most PR functional domains (Figure 5.7). 
 
Two deletions were sequenced from breast tumour samples which would not change the 
translational reading frame; a deletion of the whole of the cassette exon 4 (Δ4) and of 
the first 126 base pairs of exon 4 (Δp4126). Δ4 was generated using primers spanning 
exon 1 to exon 5 in a PR+ tumour (Figure 5.4b, lane 7). This deletion was also detected 
in MDA-MB-231 cells and in a number of other PR+ and PR- tumours and using 
primers spanning exon 1 to exon 6 and exon 3 to exon 5. The Δ4 protein would lack the 
hinge region and part of the LBD encoded by this exon but possess normal N-terminal 
and C-terminal functional domains (Figure 5.7c). Δp4126 was sequenced from a PCR 
product detected by primers spanning exon 3 to exon 4 in a PR- tumour (Figure 5.4a, 
lane 8) and by primers spanning exon 3 to exon 8 and exon 1 to exon 7 in both PR+ and 
PR- tumours. Δp4126 differed from the partial exon 4 deletion (Δ4) mRNA identified in 
MDA-MB-231 cells and would encode a protein lacking most of the hinge and NLS but 
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would possess completely undisrupted C-terminal domains along with normal N-
terminal functional domains (Figure 5.7c).  
 
Deletion of the entire sequences of exons 5 and 6 (Δ5,6) was sequenced from a PCR 
product generated by primers spanning exon 1 to exon 7 in a PR- tumour and would 
encode a protein lacking a functional LBD, but possessing the DBD, hinge region, NLS 
and N-terminal functional domains (Figure 5.7d). A deletion of a 52bp section at the 
start of exon 6 was detected using primers spanning exon 3 to exon 8 in a PR- tumour. 
This deletion (Δp6.2) differs from the deletion in exon 6 which was observed in MDA-
MB-231 cells (termed Δp6, Chapter 3). Δp6.2 would cause a shift in reading frame and 
truncation within the LBD encoded by exon 6 (Figure 5.7d). 
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Figure 5.7: Structures of potential truncated PR proteins in breast tumour tissue. 
RT-PCR products generated using primers from the PR gene walking assay and cDNA from 
breast tumour samples were cloned and sequenced. DNA sequences were compared to the 
published PR gene sequence (NCBI Accession: NM_000926.4) using the ALIGN database to 
identify the regions deleted from the mRNA represented by each PCR product. The protein 
sequence generated by each truncated mRNA was determined using the ExPASy Translate Tool. 
a) Eight exon PR gene sequence with the regions deleted from each sequenced mRNA indicated 
by dashed lines. The functional domains of the full length protein encoded by each exon are 
shown. b) Deletions of parts of multiple exons in the region exons 1 to 4 cause truncation of the 
protein. c) Deletions that do not cause a change in reading frame encode proteins lacking 
specific functional domains. d) A deletion at the start of exon 6 causes a change in reading 
frame and truncation of the LBD. 
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5.3.3 Affinity purification of novel PR antibodies 
MAPs consisting of individual peptides targeted to different non N-terminal PR 
epitopes were designed for PR specificity, to differ from the epitopes targeted by 
commercial antibodies and for maximum immunogenicity. MAP A3 targeted to an 
internal epitope within the DBD, encoded by exons 2 and 3, and MAP A4 targeted to a 
C-terminal epitope encoded by exon 7, were used to inoculate a rabbit and a sheep 
respectively and produce novel PR antibodies. Serum extracted from the animals 
thirteen weeks post-immunisation was used to affinity purify the novel PR antibodies 
which will be referred to as PRA3 and PRA4 in reference to the MAP used to immunise 
the animal. PRA3 was purified at a concentration of 1mg/ml in 20ml 1xPBS, whereas a 
much lower quantity of PRA4 was successfully purified, only 117µg/ml in 6ml 1xPBS. 
 
The presence of purified PRA3 antibody was assessed by adsorbing antibody onto an 
ELISA plate and comparing the levels present to two commercial non N-terminal PR 
antibodies, C19 and C20. The amount of antibody adsorbed was detected using an anti-
rabbit IgG secondary antibody and OPD, and determined by reading the absorbance at 
492nm. All three antibodies adsorbed at similar efficiencies, confirming successful 
PRA3 antibody purification, and no major differences were seen in the amount adsorbed 
when 1µg/ml and 10µg/ml of antibody were added to the plate (Figure 5.8). 
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Figure 5.8: PRA3 can be detected, bound to ELISA plates, at a similar level to commercial 
PR antibodies by an anti-rabbit IgG secondary antibody. 
PRA3, C19 and C20 were used to coat ELISA plates at concentrations of 1µg/ml and 10µg/ml. 
No antibody controls (0µg/ml) were included along with each antibody. Antibody bound to the 
plate was detected using an HRP-conjugated anti-rabbit IgG secondary antibody and developed 
using OPD. The average absorbance at 492nm from two experiments is plotted for each 
antibody concentration. 
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5.3.4 Optimisation of novel PR antibodies for Western 
immunoblotting 
Following affinity purification and quantification of novel PR antibodies, initial 
Western blotting experiments were performed using MCF-7 and MDA-MB-231 whole 
cell lysates to determine the optimal conditions for use. A range of dilutions of PRA3 
(1:500-1:2000) were used for Western immunoblotting to optimise conditions (Figure 
5.9). Best detection of low molecular weight proteins was seen at the highest 
concentration, 1:500, with minimal background. This dilution was selected for future 
Western immunoblotting experiments. These initial experiments demonstrated that 
PRA3 could detect high molecular weight proteins, of around 100kDa (PR-A/PR-B) 
and lower molecular weight proteins (Figure 5.9). The identity of these proteins requires 
further investigation. 
 
Figure 5.9: Optimisation of PRA3 for use in Western immunoblotting. 
Western immunoblotting of MCF-7 and MDA-MB-231 whole cell lysates using PRA3. A range 
of concentrations of PRA3 were used; 1:2000 - 1:500 in 1xPBS + 1% non-fat milk powder. 
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Similar Western immunoblotting experiments were performed to optimise the 
conditions for use of PRA4. A range of concentrations of PRA4 were used, with two 
concentrations of anti-sheep IgG secondary antibody. None of the concentrations of 
PRA4 detected any protein in either MCF-7 or MDA-MB-231 cells (Figure 5.10). Both 
concentrations of secondary antibody produced high levels of background; therefore 
further optimisation of the secondary antibody conditions was necessary. 
 
Figure 5.10: Optimisation of PRA4 for Western immunoblotting. 
Western immunoblotting of MCF-7 and MDA-MB-231 whole cell lysates using PRA4. A range 
of concentrations of PRA4 1:500-1:100 in 1xPBS + 1% non-fat milk powder. Two 
concentrations of anti-sheep IgG secondary antibody were used, 1:5000 and 1:3000 in 1xPBS. 
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Different concentrations of anti-sheep IgG secondary antibody were used for Western 
immunoblotting of MCF-7 whole cell lysates using PRA4 at a dilution of 1:100. The 
best conditions for use of PRA4 were with the secondary antibody diluted 1:5000 
adding Tween20 to the secondary antibody to reduce background. PRA4 detects a range 
of low molecular weight proteins under these conditions (Figure 5.11).  
 
 
Figure 5.11: Optimisation of rabbit anti-sheep IgG secondary antibody for use with PRA4 
for Western immunoblotting. 
Western immunoblotting of MCF-7 whole cell lysates using PRA4 (1:100 in 1x PBS+1% non-
fat milk powder) and anti-sheep IgG secondary antibody under different conditions. Milk= 1x 
PBS + 1% non-fat milk powder. Milk+T= 1x PBS + 1% non-fat milk powder + 0.1% Tween20. 
PBST= 1xPBS + 0.1% Tween20. BSA= 1% bovine serum albumin. 
 
5.3.5 PRA3 detects similar proteins to commercial PR antibodies C20 
and C19 
Whilst also detecting non-specific proteins, the commercial C-terminal PR antibody 
C19 has been demonstrated to detect some PR proteins. Therefore, to validate the 
specificity of the novel PR antibodies PRA3 and PRA4, they were used as detection 
antibodies for Western immunoblotting following Co-IP of MCF-7 whole cell lysates 
using C19 and C20. PRA3 and PRA4 were also used as the capture antibodies for Co-IP 
of MCF-7 whole cell lysates with detection using the other novel antibody. 
 
Western immunoblotting using PRA3 of co-immunoprecipitated proteins demonstrates 
that PRA3 is capable of detecting similar proteins to both of the commercially available 
antibodies studied, suggesting that these may be PR proteins. Proteins greater than 
100kDa and around 35-40kDa that were immunoprecipitated specifically by C20 and 
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C19, and not the IgG control, were detected by Western immunoblotting with PRA3 
(Figure 5.12a). However, using PRA4 as the capture antibody, PRA3 did not detect any 
immunoprecipitated proteins (Figure 5.12a). Western immunoblotting of proteins 
immunoprecipitated using C20, C19 or PRA3 using PRA4 did not detect any proteins 
(Figure 5.12b), demonstrating that PRA4 may not detect any PR proteins. 
 
 
Figure 5.12: PRA3 detects similar proteins to commercial PR antibodies but PRA4 fails to 
detect any proteins following co-immunoprecipitation. 
MCF-7 whole cell lysates were used for co-immunoprecipitation using C20, C19, PRA3 and 
PRA4. A Rabbit IgG control was also used. a) Western immunoblotting using PRA3 of proteins 
immunoprecipitated by C20, C19 a rabbit IgG control (RbIgG) or PRA4. b) Western 
immunoblotting using PRA4 of proteins immunoprecipitated by C20, C19, RbIgG or PRA3. 
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5.3.6 Validation of PRA3 and PRA4 by siRNA knockdown of PR 
expression 
The novel PR antibody PRA3 appears to behave as a specific PR antibody in Co-IP and 
Western immunoblotting. The second novel PR antibody, PRA4, fails to detect any 
protein following immunoprecipitation using PR antibodies. To validate the specificity 
of these antibodies for Western immunoblotting, siRNA knockdown of total PR 
expression was carried out to determine whether a reduction in the level of proteins 
detected by the novel antibodies could be observed. Using PRA3 for Western 
immunoblotting following siRNA knockdown of PR expression, a slight reduction in 
the levels of protein detected at 100kDa and 40kDa can be seen suggesting that this 
novel non N-terminal PR antibody is detecting truncated PR proteins (Figure 5.15a, 
lanes 1 and 2). No knockdown of any of the proteins detected by PRA4 was observed 
(Figure 5.15b), suggesting that this antibody may be detecting non-specific proteins by 
Western immunoblotting. To confirm that the siRNA knockdown of PR had been 
successful, lysates were used for Western immunoblotting using NCL-PgR-B, the 
specificity of which was demonstrated in Section 3.3.6 of this thesis. Knockdown of 
PR-B was observed in cells treated with PR siRNA (Figure 5.15c, lanes 1 and 2). 
Knockdown of GAPDH with the positive transfection control GAPDH siRNA was 
observed in each experiment (Figure 5.15a, b and c, lane 3 lower panels). 
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Figure 5.13: PR knockdown is not observed using PRA3 or PRA4. 
MCF-7 cells were treated in culture with siRNA for 72 hours prior to lysing for SDS-PAGE and 
Western immunoblotting. PR= PR targeted siRNA, G= GAPDH targeted siRNA (positive 
transfection control), N= negative control (untargeted siRNA), V= transfection reagent (vehicle) 
only control, U= untreated cells. Specific PR and GAPDH knockdown is highlighted in red 
boxes. a) Western immunoblotting using: Upper panel= PRA3, Lower panel= GAPDH. b) 
Western immunoblotting using: Upper panel= PRA4, Lower panel= GAPDH. c) Western 
immunoblotting using: Upper panel= NCL-PgR-B, Lower panel= GAPDH. 
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5.3.7 Clinicopathological screening of PR status in FFPE breast 
tumour sections using novel PR antibodies 
4µm sections from FFPE breast tumour blocks were stained using PRA3 and PRA4. 
Optimisation of immunohistochemical staining conditions demonstrated that PRA4 did 
not produce staining of sufficient quality for assessment of PR status as determined by 
the Histocytopathology Department, Gateshead Queen Elizabeth Hospital. Therefore, 
only PRA3 was used to stain the fifteen breast tumour samples analysed by RT-PCR 
(Section 5.3.1). Sections from each tumour block were initially analysed by H&E 
staining to assess the presence of tumour tissue (data not shown). This analysis revealed 
that insufficient tissue was present to reassess sample 15 (Table 5.1). 
 
The remaining fourteen samples were demonstrated by H&E staining to be tumour 
tissue and were therefore used for re-assessment of PR status by immunohistochemical 
staining with PRA3. The original PR status was determined by assessment of nuclear 
staining using an N-terminal PR antibody and the positive/negative tumour status, as 
well as the Quickscore (when available), is detailed in Table 5.1. The tumour PR status 
was re-assessed by immunohistochemistry using PRA3 and a modification of the 
Quickscore method at the Histocytopathology Department, Gateshead Queen Elizabeth 
Hospital where the original assessment of PR status had been performed. The modified 
Quickscore method is described in Section 2.18.3. A tumour was deemed PR positive 
if >10% of nuclei were stained. The positive or negative status determined using PRA3 
for each tumour is detailed in Table 5.1. 
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Table 5.1: Comparison of the original PR status of fifteen breast tumour samples with the 
status determined using PRA3. 
Original PR status was assessed by immunohistochemistry using an N-terminal antibody and 
the Quickscore method, as indicated by the number under ‘Original PR’. When Quickscore was 
not detailed in the histology report, a positive/negative status is indicated (+/-). FFPE breast 
tumour sections were analysed by H & E staining for the presence of cancer cells. Sample 15 
was discounted from re-assessment of PR status using PRA3 due to insufficient tissue being 
present. Re-screening by immunohistochemistry using PRA3 analysed the presence or absence 
of nuclear PR staining to determine positive (+) or negative (-) status. Sample 7 is from a patient 
with multiple tumours classed as grade 1 and grade 2; information detailing from which tumour 
the research tissue was taken is not available. 
 
Comparison of the nuclear PR status determined using PRA3 with the original PR status, 
determined using the N-terminal antibody, shows that PRA3 confirms the status as 
positive or negative for twelve of the fourteen tumours examined (Table 5.1). Original 
PR staining with the N-terminal antibody and PR staining using PRA3 is shown in 
Figure 5.14 for two samples for which PR positive status was confirmed; sample 3 
(Figure 5.14a and b) and sample 1 (Figure 5.14c and d). Nuclear PR staining is visible 
in both samples using both the N-terminal antibody (Figure 5.14a and c) and PRA3 
(Figure 5.15b and d). 
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Figure 5.14: Immunohistochemical staining of breast tumour sections using PRA3 
confirms the previously reported PR status. 
Breast tumour sections were analysed for PR expression by immunohistochemistry  using PRA3 
and compared to the PR expression detected using N-terminal antibodies during initial 
screening. Images at x40 magnification. a) and b) PR expression in a grade 2 invasive ductal 
carcinoma specimen. a) PR expression detected by the N-terminal antibody during original 
tumour screening; intense nuclear staining (brown) indicates PR expression. b) PR expression 
detected by PRA3; intense nuclear staining (brown) is visible in some cells confirming the PR 
status determined by original screening. c) and d) PR expression in a grade 2 invasive lobular 
carcinoma specimen. c) PR expression detected by the N-terminal antibody, intense nuclear PR 
staining (brown) is visible. d) PR expression detected by PRA3; nuclear PR staining (brown) 
can be seen in some cells confirming PR positive status. 
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Sample 6 was initially scored as PR positive with a Quickscore of 12, however staining 
with PRA3 characterised this tumour as PR negative (Table 5.1). It is therefore possible 
that the PR protein present in this tumour may lack the epitope to which PRA3 is 
targeted. Nuclear staining is clearly visible in analysis of PR expression in sample 6 
using the N-terminal antibody (Figure 5.15a), however no staining is observed using 
PRA3 (Figure 5.15b). 
 
 
Figure 5.15: Screening with PRA3 indicates a PR negative status in a tumour previously 
characterised as PR positive. 
Sections from a grade 3 invasive ductal carcinoma specimen were analysed for PR expression 
by immunohistochemistry using an N-terminal antibody and re-assessed using PRA3. Images at 
x40 magnification. a) Original PR staining using the N-terminal antibody demonstrates intense 
nuclear PR staining (brown). b) Staining using PRA3 does not detect nuclear PR expression 
(lack of brown staining). 
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Analysis with PRA3 characterised sample 10, a grade 3 invasive ductal carcinoma, as 
PR positive. However this tumour was originally characterised as PR negative using the 
N-terminal antibody (Table 5.1). No nuclear staining is visible using the N-terminal PR 
antibody (Figure 5.16a), however intense nuclear staining is visible using PRA3 (Figure 
5.16b). This observed difference in PR status, detected using the different antibodies, 
suggests that the PR protein expressed in this tumour may be N-terminally truncated. 
Some cytoplasmic PR staining can also be observed in this sample using PRA3. 
 
Traditional PR screening using N-terminal antibodies focussed on nuclear PR staining 
which was used to determine the Quickscores detailed in Table 5.1. For direct 
comparison with the original PR status, re-scoring following staining with PRA3 
therefore assessed only nuclear PR expression. However, as described previously in 
Section 1.1.9, PR can also signal via non-genomic pathways which do not require 
nuclear localisation. In addition to the nuclear staining detailed in Table 5.1, 
cytoplasmic PR staining was observed in some tumours. Sample 12 was characterised 
by both original screening and PRA3 as nuclear PR negative, however cytoplasmic 
brown staining is visible using PRA3 (Figure 5.17b). A similar pattern of cytoplasmic 
staining using PRA3 was seen in sample 11 (5.17d), which again was characterised as 
nuclear PR negative using both the N-terminal antibody and PRA3. This staining 
suggests that breast tumours may express cytoplasmic PR isoforms which are not 
detected by N-terminally targeted antibodies and may signal non-genomically. 
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Figure 5.16: Screening with PRA3 detects PR in a breast tumour originally characterised 
as PR negative. 
PR expression was assessed by immunohistochemistry in a DCIS sample. a) Original PR 
screening using the N-terminal antibody did not detect PR expression, indicated by the lack of 
brown staining (x20 magnification). b) and c) Nuclear staining (brown) with PRA3 indicates PR 
positive status. b) x20 magnification, c) x40 magnification. Cytoplasmic brown PR staining can 
also be seen in b) and c). 
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Figure 5.17: Screening with PRA3 indicates cytoplasmic PR expression in tumours 
characterised as PR negative. 
PR expression in breast tumour sections was analysed by immunohistochemistry using the N-
terminal screening antibody, and re-assessed using PRA3. a) and b) PR expression in a DCIS 
specimen. a) Original PR screening using the N-terminal PR antibody did not detect PR 
expression, indicated by the lack of brown staining (x20 magnification). b) Screening with 
PRA3 reveals cytoplasmic PR expression indicated by brown staining surrounding the nuclei 
(x40 magnification). c) and d) PR expression in a grade 3 invasive ductal carcinoma (x40 
magnification). c) Original PR screening with the N-terminal antibody did not detect PR 
expression. d) PRA3 detects cytoplasmic PR expression. 
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5.4 Discussion 
The analysis of PR mRNA expression in breast tumours presented in this chapter uses a 
small cohort of frozen breast tumour tissue. Whilst this number is too small to draw 
firm conclusions regarding differences in patterns of alternative splicing between 
different groups of tumours (e.g. tumours of different grade), it is sufficient to confirm 
that alternatively spliced PR mRNA is present in breast tumour tissue, including in 
samples characterised as PR negative. As described (Section 5.3.1) some RNA 
degradation may have occurred due to the freezing and storage of these tumour samples. 
RNA degradation may have affected analysis of long regions by PCR but did not 
prevent use of the samples in the PR gene walking assay. RNA quality was analysed by 
NanoDrop spectrophotometry and confirmed by an A260/280 ratio between 1.8 and 2.1. 
 
Fifteen breast tumours were analysed for PR mRNA expression using primers from the 
PR gene walking assay. For RT-PCR, tumours were ordered according to their hormone 
receptor status. Information on the individual tumours from the original histology 
reports from the time of sample collection can be seen in Appendix 2. FFPE sections for 
fourteen of the tumours used for mRNA analysis were assessed for PR expression by 
immunohistochemistry using the novel antibody PRA3. As described in Section 5.3.7, 
sample 15 was not re-assessed by immunohistochemistry due to insufficient tissue being 
present in the FFPE block. 
 
Analysis of PR alternative splicing in breast tumour tissue using the PR gene walking 
assay has identified several exon deletion ASEs which occur in breast tumours which 
are characterised as both PR positive and PR negative. mRNA resulting from retention 
of the intronic exon M, between exons 3 and 4, which encodes an N-terminally 
truncated protein was also detected breast tumour samples. Details of the deletions are 
shown in Table 5.2 and the potential functionality of the putative proteins encoded by 
each mRNA will be discussed. 
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Table 5.2: Predicted structures of potential PR proteins present in breast tumour tissue. 
The mRNA sequence of each sequenced PCR product was entered into the ExPASy Translate 
Tool to determine the encoded amino acid sequence and identify a change in translational 
reading frame. The molecular weight of each potential protein was predicted using the ExPASy 
Compute pI/Mw tool. Details of full length PR-A/B proteins, encoded by the full 8 exon PR 
mRNA,  are given for comparison. 
 
 
A deletion of 682bp from the end of exon 1 and 27bp from the start of exon 2 (Δp1,p2) 
was sequenced from sample 9, a grade 1 invasive ductal carcinoma. A PCR product of 
the same size was also detected in samples 1, 3, 14 and 15 (Figure 5.2) and was 
sequenced from MDA-MB-231 cells (Section 3.3.1). This mRNA would encode a 
protein with a truncated N-terminal domain lacking AF1, and lacking the DBD and C-
terminal functional domains. Δp2,3,p4 was sequenced from sample 3, a grade 3 invasive 
ductal carcinoma. This deletion has not previously been reported and would encode a 
protein lacking the DBD and hinge, and would cause a change in reading frame and 
truncation within the LBD. Therefore it is unlikely that this protein could function as a 
PR. The changes in reading frame caused by these deletions, encoding a PTC, may 
target the mRNA for degradation by NMD. 
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Exon 4 deleted PR mRNA has previously been reported (Richer et al., 1998; Leygue et 
al., 1996a) and was detected in the MDA-MB-231 cell line (Section 3.3.1). Deletion of 
exon 4 would delete the hinge region and the N-terminal portion of the LBD. This 
deletion was sequenced from sample 1 and sample 9, a grade 2 lobular and grade 1 
ductal carcinoma respectively. Δ4 mRNA was detected in the majority of tumour 
samples studied. Analysis of the relative levels of full length mRNA and Δ4 mRNA 
generated using an exon 3 sense primer and exon 5 antisense primer (Figure 5.4a) 
showed that DCIS, samples 10, 12 and 14, appear to express more Δ4 than full length 
mRNA. In tumours of higher grade, there appears to be a shift towards higher levels of 
full length mRNA relative to Δ4 (Figure 5.4a). Within the PR exon 4 sequence is a 
cryptic 3′ splice site which generates the previously reported Δ4126 mRNA (Marshburn 
et al., 2005; Balleine et al., 1999b). This deletion would truncate 42 amino acids from 
the hinge region, but the mRNA would remain in the original reading frame, so an 
encoded protein would possess the normal LBD, DD and AF2. Although the deleted 
region of exon 4 encodes protein domains essential for nuclear localisation, mutations 
affecting this region have been demonstrated to only delay, and not to prevent, nuclear 
localisation and transcriptional response to progestins (Daniel et al., 2010). Therefore, 
PR-AΔ4126 (77kDa) or PR-BΔ4126 (94kDa) may function as a normal PR protein. 
PRΔ4126 was sequenced from a PCR product generated using sample 8, sample 11 and 
sample 15 and similar sized PCR products are visible in a number of other samples 
(Figure 5.4a and b). 
 
Exon 5 and 6 deleted PR mRNA (Δ5,6) has previously been reported (Misao et al., 2000; 
Leygue et al., 1996a). This deletion was sequenced from a DCIS specimen, sample 14, 
from a PCR product generated using primers spanning exon 1 to exon 7. This deletion 
would change the reading frame and insert a PTC, potentially targeting the mRNA for 
degradation by NMD. Alternatively it may encode a protein lacking the functional LBD, 
but possessing DNA binding and phosphorylation domains, as well as the N-terminal 
Src binding domain, AF1 and AF3. Therefore this protein could function independently 
of ligand via non-genomic or transcriptional pathways. Similarly to exon 4, the cassette 
exon 6 contains a cryptic 3′ splice site, deleting 52 bp from the start of the exon. This 
deletion causes a change in reading frame and truncation within the LBD.  Therefore, 
similarly to Δ5,6 described above, this protein is unlikely to function in response to 
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hormone but may function through ligand independent pathways. Alternatively this 
mRNA may be a target for NMD. 
 
PR exon 6 is a cassette exon, meaning deletion does not cause a change in translational 
reading frame. Whilst an exon 6 deletion (Δ6) was not successfully sequenced from 
PCR products generated using breast tumour RNA, an appropriately sized deletion was 
observed in eight of the fifteen tumours using primers spanning exon 5 to exon 7 
(Figure 5.5). This deletion would remove a section of the LBD, potentially removing 
the ligand binding capacity, but would not target the mRNA for NMD. Therefore PRΔ6 
protein is more likely to be expressed than the other LBD deletions described above. 
 
PR-M mRNA was also detected in some tumours using primers spanning exon M to 
exon 5. Analysis of PR-M expression in MDA-MB-231 cells (Section 3.3.1) used 
primers spanning exon M to exon 4, however PCR using GAPDH primers (data not 
shown) demonstrated a small amount of gDNA contamination in tumour RNA which 
was not present in cell line RNA. Therefore a longer gene region was examined by PCR 
to exclude amplification of this gDNA instead of the cDNA template. PR-M mRNA 
was detected in tumours of different reported PR status and different tumour grade 
(Figure 5.6). As described previously, PR-M may be a non-genomic signalling 
cytoplasmic PR isoform, although thorough characterisation of protein expression and 
function has not been reported. 
 
Breast tumour tissue expresses alternatively spliced PR mRNA which may encode 
functionally distinct PR variant proteins, including PR-M. PR-M mRNA may encode a 
potentially functional N-terminally truncated protein detected in MDA-MB-231 breast 
cancer cells (discussed in Section 4.4). N-terminally truncated proteins such as PR-M 
would be undetectable by current breast cancer screening antibodies targeting N-
terminal epitopes, leading to ‘false negative’ tumour statuses. Conversely, non-
functional/differently functional PR isoforms may result from exon deletion which 
would be detected by breast cancer screening, leading to positive status tumours which 
may not express wild-type PR-A or PR-B. Analysis of the commercially available C-
terminal PR antibody C19 demonstrated that non-specific protein binding makes this 
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antibody unsuitable for immunofluorescent analysis of PR expression in cell lines. 
Therefore, for the detection of N-terminally truncated PR isoforms in breast cancer, new 
and more specific antibodies are required. Novel antibodies were therefore developed in 
this study, targeted to non N-terminal epitopes, and their specificity analysed for use in 
laboratory techniques and as potential breast cancer screening antibodies. MCF-7 breast 
cancer cells were used for validation of the novel antibodies since they are known to 
express high levels of PR protein. Western immunoblotting demonstrated that PRA3, 
targeted to an internal epitope, detects a range of proteins in MCF-7 breast cancer cells 
(Figure 5.9). Co-IP experiments further demonstrated that the proteins detected by 
PRA3 were also detected by the commercial non N-terminally targeted PR antibodies 
C19 and C20 (Figure 5.12a). Western immunoblotting and Co-IP experiments appeared 
to demonstrate that the novel antibody PRA4, targeted to a C-terminal epitope, did not 
detect PR proteins (Figures 5.11 and 5.12b).  
 
To validate that the novel antibody PRA3 was detecting PR protein, and to confirm that 
PRA4 was not, siRNA knockdown of total PR expression was performed in MCF-7 
cells and analysed by Western immunoblotting with each novel antibody (Figure 5.13a 
and b). Efficient PR knockdown was confirmed by Western immunoblotting using 
NCL-PgR-B (Figure 5.13c) which was demonstrated in Section 3.3.6 to specifically 
detect PR-B protein. No knockdown of any protein detected by PRA4 was observed 
(Figure 5.13b), which may indicate a lack of specificity or may be due to the low 
quantity of antibody purified being insufficient to adequately detect protein. 
Knockdown of a protein of approximately 100kDa and another of approximately 40kDa 
was observed in PR siRNA treated MCF-7 cells by Western immunoblotting using 
PRA3 (Figure 5.13a), confirming that this antibody detects PR proteins. However, no 
knockdown of other proteins detected by PRA3 was observed demonstrating some non-
specific binding by this antibody. 
 
The novel PR antibody PRA3, targeted to an epitope within the DBD was demonstrated 
to detect PR in the preliminary cell line validation studies described above. PRA4, 
targeted to a C-terminal epitope, appeared not to detect PR proteins. Both antibodies 
were optimised by the Histocytopathology Department, Gateshead Queen Elizabeth 
Hospital, for use in immunohistochemistry on FFPE breast tumour sections. Epitope 
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retrieval procedures were optimised for each antibody and optimal staining conditions 
determined by staining sections of tumours with different reported PR levels using 
different concentrations of each antibody (data not shown). This optimisation 
determined the best conditions for use of PRA3 and again demonstrated that PRA4 
failed to detect protein. 
 
PRA3 was subsequently used to assess PR expression in fourteen of the breast tumours 
analysed by RT-PCR. Of the samples analysed, three were DCIS, one grade 1 invasive 
ductal carcinoma, five grade 2 invasive ductal carcinoma, four grade 3 invasive ductal 
carcinoma and one grade 2 invasive lobular carcinoma. Sample 15, a grade 2 invasive 
ductal carcinoma, was not re-assessed due to insufficient tissue being present in the 
FFPE block as described above. Analysis of PR expression in the remaining fourteen 
samples using PRA3 was performed by the Histocytopathology Department, Gateshead 
Queen Elizabeth Hospital. The original PR status of the tumours was assessed using an 
N-terminal antibody and the Quickscore method at the time of sample collection, and 
assessed nuclear PR expression. The PR status determined following staining with 
PRA3, using a modified Quickscore method, was in agreement with the original status 
for twelve of the fourteen tumours assessed demonstrating that this novel antibody does 
detect PR (Table 5.1). The modification to the Quickscore method for analysis of PRA3 
staining was necessary since the staining was not as intense as commercial antibodies. 
The modified PRA3 Quickscore therefore considered only the proportion of positively 
stained nuclei and reported a positive/negative status as described in Section 2.18.3. 
 
The PR status of the other two tumours, sample 6 and sample 10, differed from that 
originally reported following assessment with the N-terminal antibody. Sample 6 is a 
grade 3 invasive ductal carcinoma which was originally characterised as PR positive 
with a Quickscore of 12. Staining with PRA3 did not detect PR and the tumour was 
scored as PR negative. Sample 10 is a DCIS which was originally characterised as PR 
negative, however following staining with PRA3 this sample was scored as PR positive. 
It is interesting to note that the tumour which was originally scored positive but rescored 
negative is a high grade invasive tumour, whereas the opposite rescoring was seen in a 
DCIS sample. Further analysis of a greater number of tumours of differing grade is 
necessary to identify if there is a correlation between tumour grade and the difference in 
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PR status following assessment with PRA3. As discussed above, PRΔ4 mRNA is more 
prevalent than full length PR mRNA in DCIS samples (samples 10, 12 and 14). Along 
with the rescoring of sample 10 as PR positive using PRA3, this data suggests that 
alternative splicing of PR may be occurring in the early stages of breast cancer 
development which may affect the PR status as determined using N-terminal antibodies. 
Whilst N-terminal PR antibodies would detect the protein encoded by an exon 4 deleted 
PR-A or PR-B variant, it is possible that an N-terminally truncated PR variant may also 
contain exon deletions. Previous reports studying other hormone receptors have 
demonstrated that use of differential 5′ exons can lead to differences in the pattern of 
downstream splicing (Russcher et al., 2007; Wang et al., 2005; Flouriot et al., 2000). 
For example, the GR 5′ UTR consists of at least nine alternative exons 1 and the first 
thirteen nucleotides of exon 2 (Bockmuhl et al., 2011; Russcher et al., 2007); alternative 
exon 1 usage has been linked to alternative 3′ end splicing in human GR (Russcher et al., 
2007), and tissue specific variation of mouse GR transcripts resulting from different 
exons 1 has been reported (Bockmuhl et al., 2011). ERα46 and ERα36 result from 
splicing of alternative exons from within the 5′ UTR onto exon 2, leading to skipping of 
exon 1 (Wang et al., 2005; Flouriot et al., 2000). Use of the ERα36 5′ exon results in 
alternative 3′ end splicing (Wang et al., 2005). If similar, currently unidentified, exons 
exist in the PR 5′ UTR or within intron 1, similar to exons S, T and M within intron 3, 
then splicing of these exons onto exon 2 may favour different patterns of downstream 
splicing including exon 4 skipping. This alternative splicing would encode an N-
terminally truncated PR protein with DNA and ligand binding capacity which could be 
detected by PRA3 but not the N-terminal antibody and may be expressed preferentially 
in different tissue types or disease states, such as DCIS. 
 
Cytoplasmic PR staining was detected in several breast tumour samples (Figure 5.17). 
Whilst no apparent correlation can be seen in this small cohort of samples between the 
presence of cytoplasmic staining and the ASEs detected by RT-PCR, this staining 
potentially indicates the expression of PR isoforms which may lack the NLS encoded by 
exon 4 and function by cross-talk with cytoplasmic signalling pathways. Interaction of 
cytoplasmic PR with c-Src, EGFR and Stat transcription factors have been previously 
reported (Faivre et al., 2008; Proietti et al., 2005; Boonyaratanakornkit et al., 2001). 
However, this staining is only evident using PRA3 so the cytoplasmic PR proteins 
detected may lack the NTD which contains the domain responsible for interaction with 
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c-Src (Boonyaratanakornkit et al., 2001). Alternatively, the cytoplasmic staining may be 
the result of non-specific binding, although it was not visible in all samples. 
 
PR status has traditionally been considered as a surrogate marker of a functional ER 
signalling pathway (Osborne, 1998), however tumours which are ER negative, but PR 
positive, such as sample 6 in this study, suggests that ER is not essential for PR 
expression. Furthermore, the value of PR status as both a predictor of endocrine 
therapeutic outcome and prognosis (Anderson et al., 2011; Cui et al., 2005; Bardou et 
al., 2003) highlight the importance of accurate assessment of PR status in breast cancer. 
A tumour characterised as PR negative would be considered less likely to respond to 
endocrine therapies. However, as exemplified by sample 10 (Table 5.1) assessment with 
N-terminal antibodies may be unable to detect all PR proteins. Therefore the original PR 
status may give an inaccurate impression of the likely response to endocrine therapies. 
Breast cancer therapeutics targeting PR, such as SPRMs, are being developed (Im and 
Appleman, 2010). In order to target these therapies to the correct patients, accurate 
assessment of PR status would be vital, including the detection of N-terminally 
truncated variants which are currently not detected by breast cancer PR screening. 
Further development of non N-terminal PR antibodies such as PRA3 and PRA4 could 
contribute to improved detection of PR variants in breast cancer, thus contributing to 
accurate therapeutic targeting. 
 
PRA3 appears in the Western immunoblotting, Co-IP, siRNA and 
immunohistochemistry presented in this chapter to detect PR proteins. However, 
Western immunoblotting following siRNA knockdown demonstrates that non PR 
proteins are also detected by PRA3. Binding to these proteins does not appear to occur 
in immunohistochemistry; if PRA3 bound ubiquitously expressed non PR proteins in 
the immunohistochemical screening, then all sections would stain positive. Despite this 
apparent non-specific binding observed in cell line studies, the PR status of the majority 
of tumours agreed with the original PR status, including PR negative. It is possible 
therefore that the non-specific binding requires protein linearisation or that the epitope 
retrieval conditions used prior to immunohistochemistry may not expose the epitope in 
non PR proteins, so PRA3 does not detect the protein in its native form by 
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immunohistochemistry. Alternatively, it is possible that the non-PR proteins detected by 
PRA3 are cell line specific and not expressed in breast tumour tissue. 
 
In summary, this study of a small cohort of frozen breast tumour data validates the 
hypothesis that alternatively spliced PR mRNA, including that encoding the N-
terminally truncated PR-M isoform, is present in breast tumour tissue. Novel antibodies 
PRA3 and PRA4 have been developed in an attempt to detect N-terminally truncated as 
well as full length PR proteins. PRA4 does not appear to detect PR protein and therefore 
re-purification and validation of this C-terminally targeted antibody is necessary. PRA3 
detects PR proteins and confirms the PR status of the majority of tumours examined. 
Two tumours were re-scored using PRA3, confirming that the expression of variant PR 
proteins may affect the PR status determined using PR antibodies targeting different 
epitopes. This data provides a foundation for further comprehensive analysis of PR 
expression in breast tumour tissue, comparison with non-tumour breast tissue and 
development of novel PR antibodies for breast cancer screening. 
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6 Regulation of PR alternative splicing events in 
MCF-7 breast cancer cells 
6.1 Introduction 
As described in Section 1.4.2, splicing involves the recognition of a 5′ splice site by U1 
snRNP, the branch point adenosine by U2 snRNP and assembly of the mature 
spliceosome by recruitment of the U4/U6-U5 tri-snRNP. The spliceosome then 
catalyses the trans-esterification of the 5′ GU by the branch point adenosine, and the 
trans-esterification of the 3′ AG by the 3′ hydroxyl group of the upstream exon (Staley 
and Guthrie, 1998). The recognition of the 5′ and 3′ splice sites is thought to usually 
occur across the relatively short distance of an exon, a theory termed ‘exon definition’ 
(Berget, 1995). Recruitment of snRNPs is regulated by interaction with trans-acting 
splicing factors bound to cis-acting splicing regulatory elements which can be either 
exonic or intronic and either enhance or silence splicing; i.e. exon splice 
enhancers/silencers (ESE/ESS) or intron splice enhancers/silencers (ISE/ISS) (Hertel, 
2008). 
 
SR proteins are a family of splicing factors which commonly bind to ESEs and enhance 
splicing (Long and Caceres, 2009). The structure and function of SR proteins is 
described in Section 1.4.3. SR proteins contain RRMs which mediate binding to specific 
RNA sequences and the function of SR proteins depends on the context in which they 
are bound, i.e. within an exon or within an intron, and the proximity of the SR protein 
binding site to other regulatory elements (Long and Caceres, 2009). Antagonistic 
functions have been described between different SR proteins as well as between SR 
proteins and hnRNP splicing factors (Graveley et al., 2001). 
 
Alternative splicing of PR pre-mRNA was characterised in this study in the reportedly 
PR negative MDA-MB-231 breast cancer cell line in Chapter 3 and in a small cohort of 
breast tumour samples in Chapter 5. Amongst the ASEs identified in both MDA-MB-
231 cells and breast tumour tissue was deletion of exon 4, which had previously been 
reported in breast tumour tissue and other human tissues (Hodges et al., 1999; Misao et 
al., 1998; Leygue et al., 1996a). Furthermore, two different deletions of parts of exon 4 
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were observed; a novel 76bp deletion was seen within exon 4 in MDA-MB-231 cells, 
whereas in breast tumour tissue a 126bp deletion was observed from the start of exon 4. 
This latter deletion had previously been detected in breast tumour and normal 
endometrial tissue (Marshburn et al., 2005; Balleine et al., 1999b) and is associated with 
a cryptic 3′ AG splice site within exon 4. Further analysis of the PR exon 4 sequence 
identifies a 5′ GU splice site with a poor match to the consensus GUA/GAGU sequence, 
a 3′AG, a short PPT and a consensus BPS of CTGAC containing the conserved 
adenosine in the correct position. PR exon 4 is 306bp long, a greater length than is 
necessary for efficient ‘exon definition’ (Berget, 1995). Therefore, PR exon 4 is an ideal 
exon for enhancer dependent alternative splicing and was examined for the presence of 
potential RBP binding sites and preliminary investigation of its splicing regulation was 
performed. 
 
Analysis of PR alternative splicing in MDA-MB-231 cells did not identify deletion of 
the whole of exon 6 which had previously been identified in breast tumour and other 
tissues as well as breast cancer cell lines including MCF-7 (Hodges et al., 1999; Misao 
et al., 1998; Leygue et al., 1996a). In MDA-MB-231 breast cancer cells an in-frame 
deletion of 96bp was detected within exon 6, and in breast tumour tissue a previously 
reported 52bp deletion from the start of exon 6 was observed. This mRNA had 
previously been reported at a greater frequency in breast tumour than normal breast 
tissue (Nagao et al., 2003) and is associated with a cryptic 3′ AG splice site within exon 
6. Because exon 6 alternative splicing had previously been reported, and a cryptic splice 
site exists within the exon, preliminary investigation of the regulation of exon 6 
alternative splicing was also undertaken. 
 
Consensus binding motifs for the SR proteins SRSF1, SRSF2, SRSF5 and SRSF6 have 
been identified using a functional systematic evolution of ligands by exponential 
enrichment (SELEX) method (Liu et al., 2000; Liu et al., 1998). Briefly, ESEs were 
identified by the ability of oligonucleotide sequences to promote efficient splicing of 
pre-mRNA from a mini-gene. Pre-mRNA splicing of sequences containing ESE 
oligonucleotides was then performed in the presence of individual splicing factors 
(SRSF1, SRSF2, SRSF5 or SRSF6). The oligonucleotide sequences which promote 
splicing in the presence of each splicing factor were analysed to determine consensus 
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binding motifs (Liu et al., 2000; Liu et al., 1998). The ESEfinder program analyses an 
input sequence for the presence of the binding motifs and provides a score for each 
putative binding site based on how closely it matches the consensus and how frequently 
a nucleotide was seen at a particular position in SELEX experiments (Cartegni et al., 
2003). The sequences of PR exons 4 and 6 were entered into ESEfinder to identify 
potential SR protein binding sites. 
 
Splicing Rainbow searches the input exon sequence for the presence of binding motifs 
for a range of splicing factors using information gathered from literature and stored in 
the Alternative Splicing Database AEdb Motif database (Stamm et al., 2006). Results 
are presented in colour coded form to indicate the consensus match for each splicing 
factor and have been tabulated for presentation in this thesis.  
 
Both Splicing Rainbow and ESEfinder use the traditional nomenclature for SR proteins 
which has recently been replaced by a new convention (Manley and Krainer, 2010) 
which is used throughout this thesis and described in Section 1.4.3. Briefly the old and 
new nomenclature are as follows for the genes/proteins studied herein; SF2/ASF refers 
to SRSF1, SC35 to SRSF2, SRp40 to SRSF5 and SRp55 to SRSF6. 
 
6.2 Aims 
The aims of this chapter were to: 
 Predict the potential binding sites for a range of splicing factors present within 
the PR exon 4 and exon 6 sequences. 
 Knockdown the expression of SRSF1, SRSF2, SRSF5 and SRSF6 in MCF-7 
cells. 
 Perform RT-PCR experiments for a preliminary examination into the effect of 
splicing factor knockdown on the alternative splicing events involving PR exons 
4 and 6. 
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6.3 Results 
6.3.1 Identifying SR protein binding sites in PR exons 4 and 6 
Analysis of PR exon 4 using ESEfinder demonstrated that this exon contains potential 
binding sites for SRSF1, SRSF2, SRSF5 and SRSF6. Eleven potential SRSF5 and six 
potential SRSF2 binding sites are seen throughout the exon 4 sequence. Interestingly, 
four of the six SRSF2 sites are located close to the 5′ end of the exon (Figure 6.1a) 
which is rich in potential RBP binding sites, with overlapping sites for SRSF1 and 
SRSF2, SRSF2 and SRSF5, and SRSF5 and SRSF6. Exon 6 contains far fewer potential 
binding sites; three potential SRSF5 binding sites are present, one of which overlapped 
with a high scoring potential SRSF1 sites. Two potential SRSF6 sites are present in 
exon 6, and no SRSF5 binding sites were detected (Figure 6.1b). 
 
Figure 6.1: Histograms representing the presence of potential SR protein binding sites 
within PR exons 4 and 6.  
PR exons 4 and 6 (x-axis) were screened for the presence of potential SR protein binding motifs 
by the ESEfinder database. Sequence similarity to a consensus matrix motif was identified by 
ESEfinder and the potential binding motif was scored to indicate binding probability (y-axis). a) 
Potential SR protein binding motifs within PR exon 4. b) Potential SR protein binding motifs 
present in PR exon 6. 
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The presence of potential binding sites for SR proteins within the alternatively spliced 
PR exons 4 and 6 was also analysed using Splicing Rainbow. The sequence of each 
exon was entered into the program and analysed for the presence of consensus binding 
sequences for each RBP. Binding sites for the SRSF1, SRSF2, SRSF5 and SRSF6 
proteins analysed by ESEfinder were again observed in exon 4 using Splicing Rainbow 
(Table 6.1). High scoring potential binding sequences for other SR proteins are also 
detected in PR exon 4, especially for SRSF3 (SRp20) towards the 3′ end of the sequence 
(Table 6.2). Binding sites for other RBPs known to have roles in activating constitutive 
or alternative splicing were also detected within exon 4 (Table 6.3). 
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Table 6.1: Confirmation of the presence SR protein binding sites within PR exon 4. 
The PR exon 4 sequence was screened for the presence of SRSF1 (SF2/ASF), SRSF2 (SC35), 
SRSF5 (SRp40) and SRSF6 (SRp55) binding sequences using Splicing Rainbow. The presence 
of binding sites previously detected by ESEfinder was confirmed. 
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Table 6.2: Binding motifs for other SR and SR related proteins are present within PR 
exon 4. 
Screening of PR exon 4 using splicing rainbow also revealed the presence of potential binding 
sites for other SR proteins not analysed by ESEfinder. 
 
 
Table 6.3: Binding sequences for RNA binding proteins within PR exon 4. 
Splicing rainbow revealed the presence of binding sites for a number of RBPs with known roles 
in splcing activation or silencing. 
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Within the sequence of PR exon 6 the presence of SRSF1, SRSF5 and SRSF6 binding 
sites detected by ESEfinder is confirmed by Splicing Rainbow (Table 6.4). In addition 
Splicing Rainbow identifies potential SRSF2 binding sites within PR exon 6 (Table 6.4) 
as well as high scoring binding sequences for SRSF3 and other SR proteins (Table 6.5). 
PR exon 6 also contains potential binding sites for a number of other RBPs which were 
not analysed by ESEfinder (Table 6.6). 
 
Table 6.4: SR protein binding sites within exon 6 are confirmed by Splicing Rainbow. 
Splicing Rainbow confirms the presence of SRSF1, SRSF5 and SRSF6 binding sites which had 
previously been identified by ESEfinder in PR exon 6. Additional SRSF2 motifs are identified. 
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Table 6.5: SR protein binding sites within PR exon 6. 
The presence of binding sequences for SR proteins not analysed by ESEfinder are detected by 
Splicing rainbow within PR exon 6. 
 
 
 
 
 
Table 6.6: RNA binding protein binding sequences within PR exon 6. 
Splicing Rainbow detected the presence of binding sites for RBPs with roles in splicing 
regulation within PR exon 6 which are not analysed by ESEfinder. 
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6.3.2 Knockdown of SR protein expression in MCF-7 cells 
Potential binding sites for SRSF1, SRSF2, SRSF5 and SRSF6 were identified within PR 
exons 4 and 6 by the ESEfinder and Splicing Rainbow databases. Therefore, the effect 
of knocking down expression of these splicing factors on ASEs involving PR exons 4 
and 6 was examined experimentally. MCF-7 breast cancer cells were treated with 
siRNA targeting each of these genes and cultured for 48 hours before harvesting and 
RNA extraction of RNA. RT-PCR was then performed using primers to detect each 
splicing factor mRNA and confirm successful knockdown (Figure 6.2). The siRNA 
transfections were performed, and protein knockdown confirmed by Western 
immunoblotting for each SR protein, by Dr H. Gautrey (unpublished data). Knockdown 
of SRSF mRNA and the effect on PR splicing are described below.  
 
A substantial reduction of each splicing factor was observed in siRNA treated cells 
(Figure 6.2). For each gene, cells were treated with 2 different siRNAs targeting 
different regions of the gene to ensure efficient knockdown. siRNA knockdown of each 
of the genes appears to give a reduction in the level of SRSF1 mRNA detected (Figure 
6.2a, lanes 1-8) compared to control samples; however the greatest effect was seen with 
the SRSF1 specific siRNA (Figure 6.2a, lanes 1 and 2). Only one of the SRSF2 siRNAs 
appears to give significant knockdown in the level of SRSF2 mRNA detected (Figure 
6.2b, lane 4). No off target knockdowns of SFRS2 were observed. A slight reduction in 
SRSF5 mRNA was observed after SRSF5 siRNA treatment (Figure 6.2c, lane 5), and a 
reduction of SRSF6 was seen after SRSF6 siRNA treatment (Figure 6.2d, lanes 7 and 8). 
However, detection of SRSF5 mRNA was also greatly reduced when cells were treated 
with SFRS1 siRNA (Figure 6.2d, lanes 1 and 2). No reduction of any of the splicing 
factor genes was observed in cells treated with siRNA to knockdown GAPDH, an 
untargeted negative control siRNA, a vehicle only control or in untreated cells. GAPDH 
knockdown was seen in cells treated with GAPDH siRNA (Figure 6.2e lane 9). 
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Figure 6.2: siRNA knockdown of splicing factor mRNA in MCF-7 cells. 
MCF-7 cells in 12 well culture plates were treated with siRNA to knockdown expression of the 
splicing factors SRSF1 (lanes 1 and 2), SRSF2 (lanes 3 and 4), SRSF5 (lanes 5 and 6) and 
SRSF6 (lanes 7 and 8). Cells were also treated with control siRNAs and a vehicle only control. 
Untreated cells were included for comparison. G= positive transfection control GAPDH siRNA 
(knockdown confirmed by PCR using GAPDH primers, highlighted by red underlining), lane 9; 
N= Negative control untargeted siRNA, lane 10; V= Vehicle (transfection agent) only control, 
lane 11; U= Untreated cells, lane 12.  The splicing factor targeted by the siRNA is indicated 
along the top and the mRNA detected by the PCR primers used is indicated beside each panel. 
Knockdown of each gene by the appropriate siRNA is highlighted by the red underlining of 
each panel. a) RT-PCR was performed using RNA from these cells and primers to detect SRSF1. 
b) RT-PCR to detect SRSF2. c) RT-PCR to detect SRSF5. d) RT-PCR to detect SRSF6. e) RT-
PCR to detect GAPDH. 
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6.3.3 The effect of SR protein knockdown on alternative splicing of PR 
exon 4 
The effect of depleting cells of SR proteins by siRNA knockdown on PR exon 4 ASEs 
was examined by PCR using primers spanning exons 3 to 5 and cDNA from MCF-7 
cells in which knockdown of the splicing factors SRSF1, SRSF2, SRSF5 and SRSF6 
had previously been demonstrated. 
 
RT-PCR was performed using RNA from cells 48 hours post siRNA treatment with 
primers spanning exons 3 to 5. Levels of full length PCR product (Figure 6.3a) and 
exon 4 deleted (Δ4) PCR product (Figure 6.3b) were examined in cells in which the SR 
proteins had been knocked down and compared to control siRNA treated or untreated 
cells. Knockdown of GAPDH was observed in the positive transfection control cells, 
treated with GAPDH siRNA (Figure 6.3c, lane 9). Knockdown of SRSF1 (Figure 6.3a, 
lane 2) or SRSF5 (Figure 6.3a, lane 5) appeared to give a slightly increased level of full 
length PCR product compared to control samples. No effects on the levels of PCR 
product detected were observed after SRSF2 or SRSF6 knockdown (Figure 6.3a and b, 
lanes 3, 4 and 7, 8). 
 
 
Figure 6.3: Effect of SR protein knockdown on PR exon 4 splicing after 48 hours. 
Expression of SRSF1 (lanes 1 and 2), SRSF2 (lanes 3 and 4), SRSF5 (lanes 5 and 6) and SRSF6 
(lanes 7 and 8) was knocked down by siRNA treatment in MCF-7 cells. Cells were harvested 48 
hours after siRNA treatments. The effect of knockdown on the alternative splicing of PR exon 4 
was examined by RT-PCR using primers spanning exons 3 to 5. The siRNA or control 
treatment is indicated along the top, and PCR product detected at the side of each panel. (a)  
Full length PCR product. (b) Exon 4 deleted PCR product. Levels of each PCR product in 
splicing factor knockdown cells were compared to control treated or untreated cells. G= 
GAPDH siRNA (knockdown confirmed by PCR using GAPDH primers (c), underlined red), 
lane 9; N= Negative control siRNA, lane 10; V= Vehicle (transfection agent) only treated cells, 
lane 11; U= Untreated cells, lane 12. 
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Since little effect of splicing factor knockdown on PR exon 4 alternative splicing was 
observed 48 hours post siRNA treatment, siRNA treatments were repeated and cells 
cultured for 72 hours to allow downstream effects of the loss of SR protein expression 
to be detected. SRSF1 and SRSF5 knockdown did not change the levels of PCR 
products detected after 72 hours in MCF-7 cells by this assay (Figure 6.4a and b, lanes 1, 
2 and 5, 6). In cells treated with the second SRSF2 siRNA, which produced the greatest 
reduction of SRSF2 mRNA after 48 hours (Figure 6.2b, lane 4), a reduced level of full 
length PR PCR product (Figure 6.4a, lane 4), and an increased level of PRΔ4 PCR 
product are detected (Figure 6.4b, lane 4). This indicates that SRSF2 may promote the 
inclusion of PR exon 4. Knockdown of SRSF6 appears to reduce the level of full length 
PR mRNA (Figure 6.4a, lanes 7 and 8), but no effect on PRΔ4 mRNA is observed in 
this assay (Figure 6.4b, lanes 7 and 8). 
 
 
Figure 6.4: Effect of SR protein knockdown on PR exon 4 splicing after 72 hours. 
Expression of SRSF1 (lanes 1 and 2), SRSF2 (lanes 3 and 4), SRSF5 (lanes 5 and 6) and SRSF6 
(lanes 7 and 8) was knocked down by siRNA treatment in MCF-7 cells. Cells were harvested 72 
hours after siRNA treatments. The effect of knockdown on the alternative splicing of PR exon 4 
was examined by RT-PCR using primers spanning exons 3 to 5. The siRNA or control 
treatment is indicated along the top, and PCR product detected at the side of each panel. (a)  
Full length PCR product. (b) Exon 4 deleted PCR product. Levels of each PCR product in 
splicing factor knockdown cells were compared to control treated or untreated cells. G= 
GAPDH siRNA (knockdown confirmed by PCR using GAPDH primers (c), underlined red), 
lane 9; N= Negative control siRNA, lane 10; V= Vehicle (transfection agent) only treated cells, 
lane 11; U= Untreated cells, lane 12. 
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6.3.4 The effect of SR protein knockdown on alternative splicing of PR 
exon 6 
The effect of SR protein knockdown on PR exon 6 alternative splicing was examined by 
PCR using primers spanning exons 5 to 7 and MCF-7 cell cDNA 48 hours after siRNA 
treatments. SRSF1 knockdown appeared to slightly reduce the level of exon 6 deleted 
mRNA (PRΔ6) detected in this system (Figure 6.5b, lanes 1 and 2). SRSF2 knockdown 
with the second siRNA reduced full length PR mRNA (Figure 6.5a, lane 4). SRSF6 
knockdown appeared to slightly increase the level of PRΔ6 mRNA (Figure 6.5b, lanes 7 
and 8). Similarly to exon 4 splicing, no effect was seen with SRSF5 knockdown relative 
to control samples. 
 
Figure 6.5: Effect of SR protein knockdown on PR exon 6 splicing after 48 hours. 
Expression of SRSF1 (lanes 1 and 2), SRSF2 (lanes 3 and 4), SRSF5 (lanes 5 and 6) and SRSF6 
(lanes 7 and 8) was knocked down by siRNA treatment in MCF-7 cells. Cells were harvested 48 
hours after siRNA treatments. The effect of knockdown on the alternative splicing of PR exon 6 
was examined by RT-PCR using primers spanning exons 5 to 7. The siRNA or control 
treatment is indicated along the top, and PCR product detected at the side of each panel. (a)  
Full length PCR product. (b) Exon 6 deleted PCR product. Levels of each PCR product in 
splicing factor knockdown cells were compared to control treated or untreated cells. G= 
GAPDH siRNA (knockdown confirmed by PCR using GAPDH primers (c), underlined red), 
lane 9; N= Negative control siRNA, lane 10; V= Vehicle (transfection agent) only treated cells, 
lane 11; U= Untreated cells, lane 12. 
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Since a greater effect of splicing factor knockdown on PR exon 4 splicing was observed 
after 72 hours, PCR was performed to further examine the effect of SR protein 
knockdown on exon 6 splicing using the primers spanning exons 5 to 7 and MCF-7 
cDNA from cells cultured for 72 hours post siRNA treatment. Reduced levels of Δ6 
PCR product were detected in MCF-7 cells after SRSF1 knockdown (Figure 6.6b, lanes 
1 and 2). Knockdown of SRSF2, SRSF5 and SRSF6 appeared to lead to increased 
detection of Δ6 PCR product (Figure 6.6b lanes 3-8) relative to control samples. This 
increase was particularly evident after SRSF6 knockdown (Figure 6.6b, lane 7) and this 
SRSF6 knockdown also appeared to reduce detection of full length PCR product 
(Figure 6.6a, lane 7) compared to control samples and samples treated with other SRSF 
siRNAs. 
 
 
Figure 6.6: Effect of SR protein knockdown on PR exon 6 splicing after 72 hours. 
Expression of SRSF1 (lanes 1 and 2), SRSF2 (lanes 3 and 4), SRSF5 (lanes 5 and 6) and SRSF6 
(lanes 7 and 8) was knocked down by siRNA treatment in MCF-7 cells. Cells were harvested 48 
hours after siRNA treatments. The effect of knockdown on the alternative splicing of PR exon 6 
was examined by RT-PCR using primers spanning exons 5 to 7. The siRNA or control 
treatment is indicated along the top, and PCR product detected at the side of each panel. (a)  
Full length PCR product. (b) Exon 6 deleted PCR product. Levels of each PCR product in 
splicing factor knockdown cells were compared to control treated or untreated cells. G= 
GAPDH siRNA (knockdown confirmed by PCR using GAPDH primers (c), underlined red), 
lane 9; N= Negative control siRNA, lane 10; V= Vehicle (transfection agent) only treated cells, 
lane 11; U= Untreated cells, lane 12. 
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6.4 Discussion 
Analysis of the PR exon 4 sequence identified a putative 5′ splice site GU, 3′ AG, weak 
PPT and a consensus BP in addition to a cryptic 3′ AG within the exon, 126 nucleotides 
upstream of the 3′ splice site of intron 3 (Figure 6.7). Binding motifs for SRSF1, SRSF2, 
SRSF5 and SRSF6 were identified within PR exon 4. A high number of putative ESE 
sequences were identified using ESEfinder close to the 5′ end of exon 4, potentially 
promoting alternative splicing of this exon (Figure 6.1a). Potential binding motifs for 
SRSF2 and to a lesser extent SRSF1 were particularly prevalent at the 5′ end of exon 4. 
Potential SRSF6 binding motifs were located throughout the sequence and were 
prevalent in proximity to the 3′ end of the exon. Additional motifs for these SR proteins 
were identified using Splicing Rainbow (Table 6.1). Discrepancies between the two 
analyses may be attributed to the different methods used by the two programs to 
identify motifs and also to the different thresholds for reporting a sequence match to a 
binding motif. The threshold in ESEfinder was set to report only strong consensus 
matches whereas Splicing Rainbow reports all potential motifs. 
 
 
Figure 6.7: PR exon 4 cDNA sequence with potential splice site sequences identified. 
5′ splice site GT and 3′ splice site AG are highlighted in red, cryptic 3′ splice site highlighted by 
the yellow background. PPT highlighted in blue font. BPS underlined with conserved adenosine 
in bold font. 
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Exon 4 deleted PR mRNA was detected in MDA-MB-231 cells (Section 3.3.1) and in 
MCF-7 cells (data not shown). Expression of SR proteins in MCF-7 and MDA-MB-231 
cells has previously been profiled in our laboratory: SRSF1, SRSF5 and SRSF6 were all 
expressed in both cell lines (E. Hong unpublished data). Since both cell lines exhibited a 
similar profile of SR protein expression and both express PRΔ4 mRNA, MCF-7 cells 
which also express PRΔ6 mRNA were used for analysing the effect of splicing factor 
knockdown on PR alternative splicing. MCF-7 cells also express a higher level of PR 
mRNA and have been demonstrated in this thesis to be easily manipulated by 
transfection with siRNA (Section 3.3.6). 
 
siRNA knockdown of SRSF1, SRSF2, SRSF5 and SRSF6 was achieved in the MCF-7 
breast cancer cell line (Figure 6.2). Knockdown was assessed after 48 hours 
demonstrating reduced levels of each SRSF gene following targeted siRNA treatment. 
In addition to the specific knockdown targeted to each SRSF gene, each siRNA, 
especially that which targeted SRSF5, appeared to reduce expression of SRSF1 mRNA. 
Knockdown of SRSF1 additionally appeared to reduce levels of SRSF6 mRNA. The 
sequence identity between different SR proteins (Shepard and Hertel, 2009), and thus 
the similarity in gene sequence may explain the off target effects of siRNAs targeted to 
individual SRSF genes. 
 
The effect of SR protein knockdown on PR exon 4 alternative splicing was assessed 
after 48 hours (Figure 6.3) and 72 hours (Figure 6.4) by RT-PCR using primers 
spanning exons 3 to 5. A greater effect of SRSF knockdown was observed after 72 
hours, attributable to the need for degradation of existing proteins to see an effect from 
reduced gene expression. After 48 hours SRSF1 and SRSF5 siRNA appeared to result 
in a slight increase in full length PR mRNA (Figure 6.3). SRSF5 siRNA appeared to 
give the smallest specific knockdown and resulted in a much greater level of SRSF1 
knockdown than SRSF5 relative to controls (Figure 6.2). Therefore the effects of both 
sets of siRNA could be due to the reduction in SRSF1 expression.  
 
After 72 hours, knockdown of SRSF2 using the second siRNA appeared to reduce 
levels of full length PR (Figure 6.4a, lane 4) and increase levels of exon 4 deleted 
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(PRΔ4) mRNA (Figure 6.4b, lane 4). Figure 4.2b demonstrates that efficient 
knockdown of SRSF2 was only achieved using the second siRNA (lane 4). Therefore, 
this preliminary data suggests that SRSF2 may promote the inclusion of PR exon 4. A 
high number of potential SRSF2 binding motifs were identified by ESEfinder and 
Splicing Rainbow at the 5′ end of exon 4, suggesting that SRSF2 binding in this region 
may promote the use of the 3′ splice site of intron 3 upstream of exon 4. Similarly 
SRSF6 knockdown reduced full length PR mRNA levels, implicating this splicing 
factor in exon 4 inclusion and again numerous potential binding motifs for this splicing 
factor were identified by ESEfinder or Splicing Rainbow at the 5′ end of exon 4. 
 
The majority of the high scoring SR protein binding motifs detected by ESEfinder in PR 
exon 6 were for SRSF6 (Figure 6.1) and knockdown of this splicing factor appeared to 
both decrease levels of full length mRNA detected by RT-PCR using primers spanning 
exons 5 to 7, and increase the levels of the truncated exon 6 deleted (PRΔ6) mRNA 
(Figure 4.6). High scoring potential binding motifs for SRSF1 or SRSF2 were identified 
by either ESEfinder or Splicing Rainbow (Figure 6.1 and Table 6.4). SRSF1 
knockdown appeared to slightly decrease the level of PRΔ6 mRNA detected suggesting 
that this splicing factor promotes exon skipping, while SRSF2 knockdown decreased 
full length PR mRNA levels suggesting a role in promoting exon inclusion (Figure 6.6).  
 
The knockdown of SRSF mRNA was assessed by semi-quantitative RT-PCR whereby 
PCR reactions are performed for a cycle number which is optimised to allow 
comparison of PCR products in the logarithmic phase of amplification. This method 
allows identification of a reduction in mRNA levels following siRNA treatment 
compared to controls, although absolute quantification is not possible. Absolute 
quantification of the level of knockdown could be achieved by qRT-PCR but is not 
necessary in this instance. Analysis of the effect of SRSF knockdown on PR mRNA and 
alternative splicing was again assessed by semi-quantitative RT-PCR. Whilst the cycle 
numbers used for this PCR appear high, the relatively low level of PR mRNA in MDA-
MB-231 cells means that the amplifications are still in the logarithmic phase. The use of 
RT-PCR rather than alternative methods for analysis of exon skipping is described in 
Section 3.4. Splice specific primers to detect just the Δ4 or Δ6 mRNA could be used to 
quantify the changes in expression following SRSF knockdown and is an experiment 
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which could be performed when this preliminary study is expanded. However, SR 
proteins other roles in addition to functioning as splicing factors, including an 
involvement in preventing RNA polymerase stalling and promoting transcriptional 
elongation (Long and Caceres, 2009; Moore and Proudfoot, 2009). Knockdown of 
SRSF6 led to a reduction in full length mRNA detected using primers spanning exon 3- 
exon 5 (Figure 6.4a, lanes 7 and 8). However, no parallel increase in Δ4 mRNA was 
detected (Figure 6.4b, lanes 7 and 8) suggesting that this could be a transcriptional 
effect, rather than the splicing effect discussed above. This effect would not have been 
identified using splice specific primers for qRT-PCR, further justifying the use of RT-
PCR and agarose gel electrophoresis in this chapter. 
 
Potentially antagonistic roles for SR proteins in the regulation of the alternatively 
spliced cassette exons 4 and 6 of PR have been described. SRSF1 appears to promote 
exon 4 skipping whereas SRSF2 may promote exon 4 inclusion, and SRSF1 appears to 
promote exon 6 skipping whereas SRSF2 and SRSF6 may promote exon inclusion. 
Antagonistic functions of SR proteins have previously been reported (Solis et al., 2008; 
Gallego et al., 1997) and thus the balance of SRSF1 and SRSF2 expression, as well as 
SRSF6 may influence the alternative splicing of PR exon 6. Whilst SR proteins are 
usually associated with exon inclusion, roles for this family of proteins in exon skipping 
have been reported; for example, SRSF1 promotes the skipping of SRSF3 exon 4 
(Jumaa and Nielsen, 1997). Furthermore, the presence of overlapping binding sites for 
antagonistic SR proteins and other splicing factors in both exons (Figure 6.1 and Tables 
6.1-6.6) suggests that the balance of expression levels of different splicing factors 
competing for the same sites could regulate PR exon inclusion. Splicing regulatory 
elements consisting of overlapping and competing binding motifs have also previously 
been described. For example composite exonic regulatory elements of splicing (CERES) 
have been reported, consisting of overlapping enhancer and silencer elements which 
bind different splicing factors (Pagani et al., 2003b). The CERES element within CFTR 
exon 12 is capable of binding both SR proteins and hnRNPs, and mutations of the 
element alter the pattern of exon inclusion depending on the splicing factor binding 
which is disrupted (Haque et al., 2010). 
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The potential impact of the off target knockdown of SRSF1 by SRSF5 siRNA has been 
discussed above. The differing effect on PR exon 4 and exon 6 alternative splicing of  
other siRNAs targeting individual SR proteins suggests that the off target knockdown 
may not be sufficient to affect the overall pattern of splicing. For example knockdown 
of SRSF1 also appeared to reduce SRSF6 mRNA levels, however knockdown of SRSF1 
appears to have the opposite effect on PR exon 6 splicing to knockdown of SRSF6 
(Figure 6.6). Off target knockdown may reduce the effect observed with each siRNA 
but does not appear to completely mask the effects in most cases. 
 
The results presented in this chapter represent a preliminary investigation into the 
regulation of alternative splicing of the cassette exons 4 and 6 of PR, implicating 
different combinations of SR proteins in the regulation of each ASE. A more 
comprehensive study of the splicing regulation will also investigate the roles of other 
splicing factors, such as hnRNPs which are known to exhibit functions antagonistic to 
SR proteins (Caceres et al., 1994). The presence of splicing regulatory elements within 
the intronic regions flanking the exons, as well as the ability of SR proteins and other 
splicing factors to bind to specific regulatory sequences identified within the 
alternatively spliced PR exons, must also be considered. Details of future investigations 
into the regulation of PR alternative splicing will be described in Section 7.2. 
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7 Summary and future work 
7.1 Summary 
In Chapter 3 of this thesis an RT-PCR based PR gene walking assay was used to 
characterise PR expression in breast cancer cell lines. PR mRNA was detected both in 
MCF-7 cells and in reportedly PR negative MDA-MB-231 cells. In MDA-MB-231 cells 
PR alternative splicing events were detected which result in deletions from within exon 
1 and spanning exon 1 to exon 2, leading to a change in translational reading frame. A 
variant mRNA, termed Δp1c, was detected with an in frame deletion within exon 1, 
deleting AF1 encoded by this region from a potential protein. Deletions of exon 2 or 
exon 3 were also detected; each of these exons encodes one zinc finger of the DBD and 
deletion of exon 3 would encode a protein lacking just this portion of the DBD, whilst 
exon 2 deletion would cause a change in reading frame, generating a PTC within exon 3. 
A deletion of part of exon 4, encoding the hinge and part of the LBD was observed in 
MDA-MB-231 cells which would cause a change in reading frame and truncation 
within the LBD. A deletion of the entire cassette exon 4 was also observed which would 
generate a protein with DNA binding ability but lacking the NLS and part of the LBD. 
Several deletions affecting regions within exons 4 to 6 were also observed which would 
cause a change in reading frame and disruption of the LBD. mRNA containing the 
intronic exon M was also detected in MDA-MB-231 cells, which potentially encodes an 
N-terminally truncated protein also lacking the DBD. mRNA for the putative N-
terminally truncated isoforms PR-S and PR-T were additionally detected in MCF-7 cells, 
along with PR-i45 mRNA resulting from retention of intronic exons between exons 4 
and 5 which truncate the C-terminal end of the protein. 
 
MDA-MB-231 cells appear PR negative by Western immunoblotting using N-terminal 
PR antibodies. However, using the C-terminal antibody C19 a range of proteins are 
detected in this cell line by Western immunoblotting, suggesting expression of N-
terminally truncated alternatively spliced variants in this cell line. siRNA knockdown of 
PR expression in MCF-7 cells, followed by Western immunoblotting using C19 
confirms that this antibody does detect truncated PR proteins; reduced expression of 
proteins of 80kDa, 55kDa and a doublet between 35-40kDa were seen following siRNA 
transfection. It was further demonstrated that these proteins are not the products of 
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proteolytic degradation of full length PR and that the range of protein sizes detected is 
not due to differential phosphorylation of a single isoform. However, due to non-
specific binding by C19, this antibody does not appear suitable for analysis of PR 
protein expression by immunofluorescent staining. Therefore, novel and more specific 
PR antibodies which detect N-terminally truncated PR spliced variants are required. 
 
In Chapter 4, a series of functional assays were used to investigate the potential of 
truncated proteins detected by C19 to function as PR. Progesterone binding, 
dimerisation, interaction with the PR nuclear co-factor PSF and DNA binding were 
investigated. Potentially functional proteins were detected in MDA-MB-231 cells; a 
35kDa nuclear protein could bind progesterone, PSF and PRE, an 80kDa protein could 
bind progesterone and PSF, and a 100kDa protein could bind progesterone and PRE. 
Cytoplasmic proteins were also detected in MDA-MB-231 cells with functional 
capabilities similar to PR-A/PR-B; a protein of approximately 50-55kDa could bind 
progesterone and PRE, whilst an approximately 42kDa progesterone binding protein 
was also detected by C19. High molecular weight protein bands were detected by C19 
following Co-IP with the PR antibody C20, representing potential denaturation resistant 
PR heterodimers, suggesting that the truncated proteins detected by C19 may be capable 
of dimerisation. The detection of N-terminally truncated proteins by these assays 
suggest that the ASEs characterised in MDA-MB-231 cells may encode functional 
proteins. The molecular weights of the functional PR proteins identified in this chapter 
correspond to the molecular weights of PR proteins identified by C19 following siRNA 
knockdown of total PR expression in MCF-7 cells in Chapter 3. 
 
Chapter 5 provides preliminary validation of the detection of alternatively spliced PR 
mRNA in breast tumour tissue using the PR gene walking assay. Fifteen frozen breast 
tumour samples were analysed by RT-PCR and alternatively spliced PR mRNA was 
detected in breast tumours which were originally characterised as both PR positive and 
PR negative. A deletion of the end of exon 1 and the beginning of exon 2, Δp1,p2 which 
was observed in MDA-MB-231 cells, was seen in a number of breast tumours. Exon 4 
deleted PR mRNA was also detected in several breast tumours with an apparent 
correlation between the level of Δ4 mRNA relative to full length mRNA and tumour 
grade; in DCIS more Δ4 was present than full length, whereas in high grade invasive 
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tumours less Δ4 mRNA was present relative to full length. Two partial exon deletions 
were seen in breast tumour tissue which were not detected in MDA-MB-231 cells, 
resulting from use of cryptic 3′ splice sites within exon 4 (Δp4126) and exon 6 (Δp6.2). 
Δp4126 would lead to deletion of the hinge and NLS but leave the LBD intact, whilst 
Δp6.2 would change the translational reading frame and truncate the LBD. Deletion of 
the whole of exon 6 was also observed in breast tumour tissue, a deletion which would 
remove part of the LBD but not change the reading frame. 
 
The data presented in Chapter 3 of this thesis supports existing literature (Samalecos 
and Gellersen, 2008; Madsen et al., 2007) and validates the hypothesis that commercial 
non N-terminal PR antibodies detect non-PR proteins and are therefore unsuitable for 
PR screening by immunohistochemistry. Therefore, novel PR antibodies PRA3, 
targeted to the DBD, and PRA4, targeted to the C-terminal end of the LBD, were 
generated and validated in Chapter 5 of this study. PRA3 appeared in preliminary 
Western immunoblotting, Co-IP and siRNA experiments to detect PR proteins whereas 
in these initial experiments PRA4 did not. Further purification and validation of PRA4 
is therefore necessary. The novel antibodies were optimised for immunohistochemical 
analysis of PR expression in FFPE breast tumour sections; again PRA4 did not 
satisfactorily detect PR. PRA3 was used to re-score nuclear PR expression in fourteen 
breast tumour samples which had been assessed using an N-terminal antibody, 
confirming the original PR status in twelve of the fourteen samples analysed, 
confirming the specificity of this novel antibody. One sample originally scored PR 
negative but appeared PR positive after staining using PRA3, validating the hypothesis 
that N-terminal antibodies may be unable to detect some PR proteins expressed in breast 
tumour tissue. The final tumour was originally scored PR positive but appeared PR 
negative using PRA3, demonstrating that whilst non N-terminal PR antibodies may 
detect additional proteins, internal exon deletions may make it difficult to target an 
epitope which is present in all isoforms. Further analysis of PR alternative splicing in a 
large cohort of breast tumour specimens would be necessary to identify cancer specific 
alternative splicing events which could be used to target antibodies to specific isoforms. 
 
Chapter 6 of this thesis presents a preliminary investigation into the regulation of PR 
alternative splicing, focussing on exon 4 which was alternatively spliced in both MDA-
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MB-231 cells and in breast tumour tissue, and exon 6, alternative splicing of which was 
observed specifically in breast tumour tissue in this study. siRNA targeting genes 
encoding the SR proteins SRSF1, SRSF2, SRSF5 and SRSF6 were used to investigate 
the role of these splicing factors in PR exon 4 and exon 6 inclusion. SRSF1 appears to 
promote the skipping of both exon 4 and exon 6, whereas SRSF2 which is known to 
function antagonistically to SRSF1 appears to promote inclusion of both exons. 
Similarly SRSF6 may promote the inclusion of PR exon 6. 
 
7.2 Future work 
Future work based on the findings from this study will focus on: 
 Investigating a role for truncated PR proteins in rapid signalling pathways. 
 Defining the structure of the functional low molecular weight PR proteins 
detected in this study. 
 Re-purification and further validation of novel PR antisera generated in this 
study with the aim of developing novel monoclonal antibodies for laboratory use 
and clinical PR screening. 
 Analysis of PR expression in a large cohort of breast tumour and normal breast 
tissue specimens to identify any cancer specific PR ASEs which may provide 
targets for novel antibodies to detect cancer specific protein isoforms. 
 
The investigation into PR alternative splicing regulation will be extended to examine 
other ASEs identified in this study. Future work will include: 
 An investigation into the role of splicing factors in regulating the PR ASEs 
identified in this study using gene knockdown, protein:RNA binding studies and 
mutation analyses. 
 Analysis of the function of exon deleted PR proteins overexpressed in a PR 
negative cell line, investigating the effects on gene expression and rapid 
signalling. 
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Appendix 1 
Examples of DNA sequence analysis using ALIGN. Examples shown illustrate ASEs 
identified in both MDA-MB-231 cells and in breast tumour tissue. 
Δp1,p2 S4/A6 
>_                                                  950 nt vs. 
>_                                                  241 nt 
scoring matrix: , gap penalties: -12/-2 
25.4% identity; Global alignment score: -464 
 
               10        20        30        40        50        60 
581745 ACGGTGATGGATTTCATCCACGTGCCTATCCTGCCTCTCAATCACGCCTTATTGGCAGCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      ACGGTGATGGATTTCATCCACGTGCCTATCCTGCCTCTCAATCACGCCTTATTGGCAGCC 
               10        20        30        40        50        60 
 
               70        80        90       100       110       120 
581745 CGCACTCGGCAGCTGCTGGAAGACGAAAGTTACGACGGCGGGGCCGGGGCTGCCAGCGCC 
       :                                                            
_      C----------------------------------------------------------- 
                                                                    
 
              130       140       150       160       170       180 
581745 TTTGCCCCGCCGCGGAGTTCACCCTGTGCCTCGTCCACCCCGGTCGCTGTAGGCGACTTC 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              190       200       210       220       230       240 
581745 CCCGACTGCGCGTACCCGCCCGACGCCGAGCCCAAGGACGACGCGTACCCTCTCTATAGC 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              250       260       270       280       290       300 
581745 GACTTCCAGCCGCCCGCTCTAAAGATAAAGGAGGAGGAGGAAGGCGCGGAGGCCTCCGCG 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              310       320       330       340       350       360 
581745 CGCTCCCCGCGTTCCTACCTTGTGGCCGGTGCCAACCCCGCAGCCTTCCCGGATTTCCCG 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
 
              370       380       390       400       410       420 
581745 TTGGGGCCACCGCCCCCGCTGCCGCCGCGAGCGACCCCATCCAGACCCGGGGAAGCGGCG 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
 
              430       440       450       460       470       480 
581745 GTGACGGCCGCACCCGCCAGTGCCTCAGTCTCGTCTGCGTCCTCCTCGGGGTCGACCCTG 
                                                                    
_      ------------------------------------------------------------                                                              
251 
              490       500       510       520       530       540 
581745 GAGTGCATCCTGTACAAAGCGGAGGGCGCGCCGCCCCAGCAGGGCCCGTTCGCGCCGCCG 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              550       560       570       580       590       600 
581745 CCCTGCAAGGCGCCGGGCGCGAGCGGCTGCCTGCTCCCGCGGGACGGCCTGCCCTCCACC 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              610       620       630       640       650       660 
581745 TCCGCCTCTGCCGCCGCCGCCGGGGCGGCCCCCGCGCTCTACCCTGCACTCGGCCTCAAC 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              670       680       690       700       710       720 
581745 GGGCTCCCGCAGCTCGGCTACCAGGCCGCCGTGCTCAAGGAGGGCCTGCCGCAGGTCTAC 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              730       740       750       760       770       780 
581745 CCGCCCTATCTCAACTACCTGAGGCCGGATTCAGAAGCCAGCCAGAGCCCACAATACAGC 
                                                         :::::::::: 
_      --------------------------------------------------ACAATACAGC 
                                                                70  
 
              790       800       810       820       830       840 
581745 TTCGAGTCATTACCTCAGAAGATTTGTTTAATCTGTGGGGATGAAGCATCAGGCTGTCAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      TTCGAGTCATTACCTCAGAAGATTTGTTTAATCTGTGGGGATGAAGCATCAGGCTGTCAT 
              80        90       100       110       120       130  
 
              850       860       870       880       890       900 
581745 TATGGTGTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      TATGGTGTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAG 
             140       150       160       170       180       190  
 
              910       920       930       940       950 
581745 CACAACTACTTATGTGCTGGAAGAAATGACTGCATCGTTGATAAAATCCG 
       :::::::::::::::::::::::::::::::::::::::::::::::::: 
_      CACAACTACTTATGTGCTGGAAGAAATGACTGCATCGTTGATAAAATCCG 
             200       210       220       230       240 
 
Primer sequences shaded grey, deleted region in bold font; 682bp 3′ end of exon 1 and 
27bp 5′ end of exon 2 deleted. Exon 1/2 and 2/3 boundaries indicated (   ). 
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Δ4 SA/A2 
>            891 nt vs. 
>_                                                  585 nt 
scoring matrix: , gap penalties: -12/-2 
65.3% identity; Global alignment score: 1697 
 
               10        20        30        40        50        60 
294897 CCCTATCTCAACTACCTGAGGCCGGATTCAGAAGCCAGCCAGAGCCCACAATACAGCTTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::: ::::: 
_      CCCTATCTCAACTACCTGAGGCCGGATTCAGAAGCCAGCCAGAGCCCACAATACGGCTTC 
               10        20        30        40        50        60 
 
               70        80        90       100       110       120 
294897 GAGTCATTACCTCAGAAGATTTGTTTAATCTGTGGGGATGAAGCATCAGGCTGTCATTAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      GAGTCATTACCTCAGAAGATTTGTTTAATCTGTGGGGATGAAGCATCAGGCTGTCATTAT 
               70        80        90       100       110       120 
 
              130       140       150       160       170       180 
294897 GGTGTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAGCAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      GGTGTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAGCAC 
              130       140       150       160       170       180 
 
              190       200       210       220       230       240 
294897 AACTACTTATGTGCTGGAAGAAATGACTGCATCGTTGATAAAATCCGCAGAAAAAACTGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      AACTACTTATGTGCTGGAAGAAATGACTGCATCGTTGATAAAATCCGCAGAAAAAACTGC 
              190       200       210       220       230       240 
 
              250       260       270       280       290       300 
294897 CCAGCATGTCGCCTTAGAAAGTGCTGTCAGGCTGGCATGGTCCTTGGAGGTCGAAAATTT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::          
_      CCAGCATGTCGCCTTAGAAAGTGCTGTCAGGCTGGCATGGTCCTTGGAGGT--------- 
              250       260       270       280       290           
 
              310       320       330       340       350       360 
294897 AAAAAGTTCAATAAAGTCAGAGTTGTGAGAGCACTGGATGCTGTTGCTCTCCCACAGCCA 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              370       380       390       400       410       420 
294897 GTGGGCGTTCCAAATGAAAGCCAAGCCCTAAGCCAGAGATTCACTTTTTCACCAGGTCAA 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              430       440       450       460       470       480 
294897 GACATACAGTTGATTCCACCACTGATCAACCTGTTAATGAGCATTGAACCAGATGTGATC 
                                                                    
_      ------------------------------------------------------------ 
                                                                    
 
              490       500       510       520       530       540 
294897 TATGCAGGACATGACAACACAAAACCTGACACCTCCAGTTCTTTGCTGACAAGTCTTAAT 
                                                                    
_      ------------------------------------------------------------ 
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              550       560       570       580       590       600 
294897 CAACTAGGCGAGAGGCAACTTCTTTCAGTAGTCAAGTGGTCTAAATCATTGCCAGGTTTT 
                                                                ::: 
_      ---------------------------------------------------------TTT 
                                                                    
 
              610       620       630       640       650       660 
294897 CGAAACTTACATATTGATGACCAGATAACTCTCATTCAGTATTCTTGGATGAGCTTAATG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      CGAAACTTACATATTGATGACCAGATAACTCTCATTCAGTATTCTTGGATGAGCTTAATG 
          300       310       320       330       340       350     
 
              670       680       690       700       710       720 
294897 GTGTTTGGTCTAGGATGGAGATCCTACAAACACGTCAGTGGGCAGATGCTGTATTTTGCA 
       :::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::: 
_      GTGTTTGGTCTAGGATGGAGATCCTACAAACATGTCAGTGGGCAGATGCTGTATTTTGCA 
          360       370       380       390       400       410     
 
              730       740       750       760       770       780 
294897 CCTGATCTAATACTAAATGAACAGCGGATGAAAGAATCATCATTCTATTCATTATGCCTT 
       :::::::::::::::::::::::::: ::::::::::::::::::::::::::::::::: 
_      CCTGATCTAATACTAAATGAACAGCGAATGAAAGAATCATCATTCTATTCATTATGCCTT 
          420       430       440       450       460       470     
 
              790       800       810       820       830       840 
294897 ACCATGTGGCAGATCCCACAGGAGTTTGTCAAGCTTCAAGTTAGCCAAGAAGAGTTCCTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      ACCATGTGGCAGATCCCACAGGAGTTTGTCAAGCTTCAAGTTAGCCAAGAAGAGTTCCTC 
          480       490       500       510       520       530     
 
              850       860       870       880       890  
294897 TGTATGAAAGTATTGTTACTTCTTAATACAATTCCTTTGGAAGGGCTACGA 
       ::::::::::::::::::::::::::::::::::::::::::::::::::: 
_      TGTATGAAAGTATTGTTACTTCTTAATACAATTCCTTTGGAAGGGCTACGA 
          540       550       560       570       580      
 
Primer sequences shaded grey, deleted region in bold font; entire 306bp exon 4 
sequence. Exon 1/2, 2/3, 3/4, 4/5, 5/6 and 6/7 boundaries indicated (  ). 
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Information extracted from histology reports for clinical material used in this study. 
+/- status indicated when PR Quickscore not recorded. n/a= not available; HER2 not assessed for all samples, node involvement and NPI not routinely recorded.
2
5
4
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NPI = Nottingham prognostic index  
 NPI = [0.2 x S] + N + G  
 
S = size of the index lesion in cm 
N = number of lymph nodes involved: 0 nodes =1, 1-3 nodes = 2, >3 nodes = 3  
G = grade of tumour: Grade I =1, Grade II =2, Grade III =3  
 
≥2.0 to ≤2.4, 5yr survival 93%;  
>2.4 to ≤3.4, 5yr survival 85%;  
>3.4 to ≤5.4, 5yr survival 70%;  
≥5.4, 5yr survival 50%. 
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Appendix 3 
Publications, presentations and prizes arising from this study 
Publications 
Cork, D.M., Lennard, T.W. and Tyson-Capper, A.J. ‘Alternative splicing generates 
functional truncated progesterone receptor proteins in breast cancer cells’ (Submitted). 
Cork, D.M., Lennard, T.W. and Tyson-Capper, A.J. (2010) ‘Alternatively spliced 
progesterone receptor expression in breast cancer’ (http://www.isge2010.com.)   
Cork, D.M., Lennard, T.W. and Tyson-Capper, A.J. (2009) ‘Progesterone Receptor 
Variants in Breast Cancer’, Reproductive Sciences, 16, (3) (Supplement) A268. 
Cork, D. M., Lennard, T. W. and Tyson-Capper, A. J. (2008) 'Alternative splicing and 
the progesterone receptor in breast cancer', Breast Cancer Res, 10, (3), pp. 207 
(Included at the end of Appendix 3). 
 
Presentations 
23/06/2010 Non-genomic progesterone receptor expression in breast cancer.              
(Oral presentation, ICM Research Day, Newcastle University) 
05/03/2010 Alternatively spliced progesterone receptor expression in breast 
cancer. (Oral presentation, 14th World Congress of Gynecological 
Endocrinology, Florence, Italy) 
11/01/2010 Alternative splicing and the progesterone receptor in breast cancer.       
(Oral presentation, ICM Science Forum, Newcastle University) 
12/05/2009  Progesterone Receptor Variants in Breast Cancer.                                   
(Oral presentation, RNA Interest Group, Newcastle University) 
17/03/2009 Progesterone Receptor Variants in Breast Cancer.                                    
(Poster presentation, SGI, 56th Annual Meeting, Glasgow) 
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23/01/2009 Progesterone Receptor Variants in Breast Cancer Cell Lines.                  
(Oral presentation, EURASNET UK RNA Splicing Workshop, Rydal 
Hall, Cumbria) 
28/07/2008 Alternative Splicing and the Progesterone Receptor in Breast Cancer. 
(Poster presentation, RNA2008, The RNA Society (USA) Annual 
Congress, Berlin) 
30/06/2008 Characterisation of Progesterone Receptors in Breast Cancer: 
Potential for Novel Diagnostic and Prognostic Markers.                                               
(Oral presentation, School of Surgical & Reproductive Sciences 
'Science Forum', Newcastle University).  
 
Prizes 
23/06/2010 ‘Speaker’s Prize’ for best student oral presentation at the ICM 
Research Day, Newcastle University. 
04/03/2010 Young Scientist Travel and Conference Registration Award, 
International  Society for Gynecological Endocrinology Abstract 
Competition for the 14
th
 World Congress of Gynecological 
Endocrinology. 
27/11/2008 2
nd
 Prize, ICM Poster Competition, Newcastle University. 
